,label,eligibility_criteria,interventionname
0,0,fulfilling all the following criteria,Hydroxychloroquine
1,0,fulfilling all the following criteria,Hydroxychloroquine
2,0,"aged between 18 and 60 years, male or female.",Hydroxychloroquine
3,0,"aged between 18 and 60 years, male or female.",Hydroxychloroquine
4,0,hospitalized participants with diagnosis of covid 19 by real time - polymerase chain reaction.,Hydroxychloroquine
5,0,hospitalized participants with diagnosis of covid 19 by real time - polymerase chain reaction.,Hydroxychloroquine
6,0,"moderate cases according to the official guideline ""pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 6)"".",Hydroxychloroquine
7,0,"moderate cases according to the official guideline ""pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 6)"".",Hydroxychloroquine
8,0,"confusion, urea, respiratory rate, blood pressure-65 (curb-65) >= 2.",Hydroxychloroquine
9,0,"confusion, urea, respiratory rate, blood pressure-65 (curb-65) >= 2.",Hydroxychloroquine
10,0,sequential organ failure assessment score (sofa) < 6.,Hydroxychloroquine
11,0,sequential organ failure assessment score (sofa) < 6.,Hydroxychloroquine
12,0,ability to understand and the willingness to sign a written informed consent document.,Hydroxychloroquine
13,0,ability to understand and the willingness to sign a written informed consent document.,Hydroxychloroquine
14,0,participant is willing and able to provide informed consent.,Hydroxychloroquine - Daily Dosing
15,0,participant is willing and able to provide informed consent.,Hydroxychloroquine - Weekly Dosing
16,0,participant is willing and able to provide informed consent.,Hydroxychloroquine - Daily Dosing
17,0,participant is willing and able to provide informed consent.,Hydroxychloroquine - Weekly Dosing
18,0,participant is 18-75 years of age.,Hydroxychloroquine - Daily Dosing
19,0,participant is 18-75 years of age.,Hydroxychloroquine - Weekly Dosing
20,0,participant is 18-75 years of age.,Hydroxychloroquine - Daily Dosing
21,0,participant is 18-75 years of age.,Hydroxychloroquine - Weekly Dosing
22,0,"participant does not have symptoms of respiratory infection, including cough, fevers (temperature >38.0c), difficulty breathing, shortness of breath, chest pains, malaise, myalgia, headaches, nausea or vomiting, or other symptoms associated with covid-19.",Hydroxychloroquine - Daily Dosing
23,0,"participant does not have symptoms of respiratory infection, including cough, fevers (temperature >38.0c), difficulty breathing, shortness of breath, chest pains, malaise, myalgia, headaches, nausea or vomiting, or other symptoms associated with covid-19.",Hydroxychloroquine - Weekly Dosing
24,0,"participant does not have symptoms of respiratory infection, including cough, fevers (temperature >38.0c), difficulty breathing, shortness of breath, chest pains, malaise, myalgia, headaches, nausea or vomiting, or other symptoms associated with covid-19.",Hydroxychloroquine - Daily Dosing
25,0,"participant does not have symptoms of respiratory infection, including cough, fevers (temperature >38.0c), difficulty breathing, shortness of breath, chest pains, malaise, myalgia, headaches, nausea or vomiting, or other symptoms associated with covid-19.",Hydroxychloroquine - Weekly Dosing
26,0,participant is willing to provide blood samples for the study.,Hydroxychloroquine - Daily Dosing
27,0,participant is willing to provide blood samples for the study.,Hydroxychloroquine - Weekly Dosing
28,0,participant is willing to provide blood samples for the study.,Hydroxychloroquine - Daily Dosing
29,0,participant is willing to provide blood samples for the study.,Hydroxychloroquine - Weekly Dosing
30,0,subject agrees to all aspects of the study.,Hydroxychloroquine - Daily Dosing
31,0,subject agrees to all aspects of the study.,Hydroxychloroquine - Weekly Dosing
32,0,subject agrees to all aspects of the study.,Hydroxychloroquine - Daily Dosing
33,0,subject agrees to all aspects of the study.,Hydroxychloroquine - Weekly Dosing
34,0,the participant has no known allergies or contraindications (as stated in the consent form) to the use of hydroxychloroquine (hcq) as noted in the exclusion criteria and pharmacy sections.,Hydroxychloroquine - Daily Dosing
35,0,the participant has no known allergies or contraindications (as stated in the consent form) to the use of hydroxychloroquine (hcq) as noted in the exclusion criteria and pharmacy sections.,Hydroxychloroquine - Weekly Dosing
36,0,the participant has no known allergies or contraindications (as stated in the consent form) to the use of hydroxychloroquine (hcq) as noted in the exclusion criteria and pharmacy sections.,Hydroxychloroquine - Daily Dosing
37,0,the participant has no known allergies or contraindications (as stated in the consent form) to the use of hydroxychloroquine (hcq) as noted in the exclusion criteria and pharmacy sections.,Hydroxychloroquine - Weekly Dosing
38,0,18 years of age or older,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
39,0,respiratory failure requiring mechanical ventilation due to covid-19 induced pneumonia with confirmation via sars-cov-2 rt-pcr testing,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
40,0,pao2/fio2 ratio < 300 (or spo2/fio2 < 315),Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
41,0,bilateral pulmonary infiltrates,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
42,0,adult ≥18 years of age,COVID-19 Convalescent Plasma
43,0,laboratory-confirmed sars-cov-2 infection as determined by pcr or other authorized or approved assay in any specimen collected within 72 hours prior to enrollment.,COVID-19 Convalescent Plasma
44,0,note - an exception must be requested to the sponsor if ≥72 hours since positive test.,COVID-19 Convalescent Plasma
45,0,hospitalized in participating facility.,COVID-19 Convalescent Plasma
46,0,"documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g., chest x-ray or ct scan).",COVID-19 Convalescent Plasma
47,0,"abnormal respiratory status that is judged worse than baseline by the investigator and as documented at any point within 24 hours prior to randomization, consistent with ordinal scale levels 5, 6 or 7, specifically defined as:",COVID-19 Convalescent Plasma
48,0,"room air saturation of oxygen (sao2) < 93%, or",COVID-19 Convalescent Plasma
49,0,"requiring supplemental oxygen, or",COVID-19 Convalescent Plasma
50,0,tachypnea with respiratory rate ≥30,COVID-19 Convalescent Plasma
51,0,patient or proxy is willing and able to provide written informed consent and comply with all protocol requirements,COVID-19 Convalescent Plasma
52,0,> 18 years of age,Hydroxychloroquine
53,0,> 18 years of age,Hydroxychloroquine
54,0,willing and able to provide written informed consent prior to performing study procedures,Hydroxychloroquine
55,0,willing and able to provide written informed consent prior to performing study procedures,Hydroxychloroquine
56,0,confirmed sars-cov2 infection by pcr,Hydroxychloroquine
57,0,confirmed sars-cov2 infection by pcr,Hydroxychloroquine
58,0,have mild symptoms of sars-cov2,Hydroxychloroquine
59,0,have mild symptoms of sars-cov2,Hydroxychloroquine
60,0,must show documentation of sars-cov2 to screening visit,Hydroxychloroquine
61,0,must show documentation of sars-cov2 to screening visit,Hydroxychloroquine
62,0,must have had recent hematology and chemistry results,Hydroxychloroquine
63,0,must have had recent hematology and chemistry results,Hydroxychloroquine
64,0,must be able to take heart rate daily,Hydroxychloroquine
65,0,must be able to take heart rate daily,Hydroxychloroquine
66,0,must agree to skype/facetime daily,Hydroxychloroquine
67,0,must agree to skype/facetime daily,Hydroxychloroquine
68,0,must agree to take temperature daily,Hydroxychloroquine
69,0,must agree to take temperature daily,Hydroxychloroquine
70,0,must agree not to enroll in another study of an investigational agent prior to completion of day 14 of treatment.,Hydroxychloroquine
71,0,must agree not to enroll in another study of an investigational agent prior to completion of day 14 of treatment.,Hydroxychloroquine
72,0,for all patients:,Convalescent Plasma from COVID-19 donors
73,0,a. patient must sign an informed consent to participate in this trial,Convalescent Plasma from COVID-19 donors
74,0,b. signed consent to participate in this trial must be given not after 14 days from the first day of symptoms covid-19 related,Convalescent Plasma from COVID-19 donors
75,0,patients with severity criteria must have any of the following: dyspnea and or respiratory rate >=30 per min and or saturation <= 93% with fraction of inspired oxygen 21% and or ratio of partial pressure arterial oxygen and fraction of inspired oxygen (pafi )<300 and or lung images showing worsening in 24-48 hours,Convalescent Plasma from COVID-19 donors
76,0,or,Convalescent Plasma from COVID-19 donors
77,0,patients without severity criteria but with 2 or more factor risks:,Convalescent Plasma from COVID-19 donors
78,0,a. 50 years or older,Convalescent Plasma from COVID-19 donors
79,0,"b. any of the following comorbidities: diabetes mellitus, hypertension, chronic obstructive pulmonary disease, chronic kidney failure, non-oncological related chronic immunosuppression",Convalescent Plasma from COVID-19 donors
80,0,"c. total bilirubin>1,2 mg/dl or blood urea nitrogen> 20 mg/dl or lactate dehydrogenase>245 u/l",Convalescent Plasma from COVID-19 donors
81,0,d. d-dimer > 1mg/l,Convalescent Plasma from COVID-19 donors
82,0,"e. neutrophils 7.3 x 10³ or greater and or lymphocytes lesser than 0,8 x 10³ µl",Convalescent Plasma from COVID-19 donors
83,0,"f. c reactive protein >9,5 mg/dl and ferritin > 300 ug/ml",Convalescent Plasma from COVID-19 donors
84,0,g. interleukin-6 >7 pg/ml,Convalescent Plasma from COVID-19 donors
85,0,h. antineoplastic treatment such as radiotherapy- cytotoxic chemotherapy- immunotherapy- molecular therapy- oncological surgery during the last 8 weeks,Convalescent Plasma from COVID-19 donors
86,0,age ≥ 65,COVID-19 Convalescent Plasma
87,0,pneumonia at ct scan,COVID-19 Convalescent Plasma
88,0,pao2/fio2 ≥300 mmhg,COVID-19 Convalescent Plasma
89,0,presence of one or more comorbidities (consider the list provided in appendix a),COVID-19 Convalescent Plasma
90,0,signed informed consent,COVID-19 Convalescent Plasma
91,0,adult ≥18 years of age,COVID-19 Convalescent Plasma
92,0,laboratory-confirmed sars-cov-2 infection as determined by pcr or other authorized or approved assay in any specimen collected within 72 hours prior to enrollment. note - an exception must be requested to the sponsor if≥72 hours since positive test.,COVID-19 Convalescent Plasma
93,0,"hospitalized, on invasive mechanical ventilation or ecmo, consistent with a clinical status assessment 8-point ordinal scale severity score of 7.",COVID-19 Convalescent Plasma
94,0,"documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g., chest x-ray or ct scan).",COVID-19 Convalescent Plasma
95,0,patient or proxy is willing and able to provide written informed consent and comply with all protocol requirements.,COVID-19 Convalescent Plasma
96,0,age ≥ 18 years or older,anti-SARS-CoV-2 convalescent plasma
97,0,hospitalized as an in-patient with positive covid-19 test by pcr,anti-SARS-CoV-2 convalescent plasma
98,0,presence of respiratory symptoms with any of severe features as below:,anti-SARS-CoV-2 convalescent plasma
99,0,respiratory rate ≥ 24/min,anti-SARS-CoV-2 convalescent plasma
100,0,oxygen support >3l/min by nasal cannula,anti-SARS-CoV-2 convalescent plasma
101,0,new onset or worsening of respiratory symptoms with radiologic confirmation of bilateral ground glass opacities that cannot be attributed to another cause,anti-SARS-CoV-2 convalescent plasma
102,0,patient / hcpoa must agree to storage of blood specimens for future testing.,anti-SARS-CoV-2 convalescent plasma
103,0,"patient / hcpoa is willing and able to provide electronic informed consent and comply with all protocol requirements. if patient is unable to consent due to incapacity, health care poa should be defined and able to consent for the patient.",anti-SARS-CoV-2 convalescent plasma
104,0,patients are allowed to receive all standard of care. co enrollment in other clinical trials is permitted.,anti-SARS-CoV-2 convalescent plasma
105,0,i. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.,Hydroxychloroquine
106,0,i. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.,Hydroxychloroquine
107,0,ii. understands and agrees to comply with planned study procedures. iii. male or female adult ≥18 - 95 years of age at time of enrolment. iv. laboratory-confirmed sars-cov-2 infection in any specimen < 5 days prior to randomization.,Hydroxychloroquine
108,0,ii. understands and agrees to comply with planned study procedures. iii. male or female adult ≥18 - 95 years of age at time of enrolment. iv. laboratory-confirmed sars-cov-2 infection in any specimen < 5 days prior to randomization.,Hydroxychloroquine
109,0,v. at least one of the following:,Hydroxychloroquine
110,0,v. at least one of the following:,Hydroxychloroquine
111,0,"radiographic infiltrates by imaging (chest x-ray, ct scan, etc.) or",Hydroxychloroquine
112,0,"radiographic infiltrates by imaging (chest x-ray, ct scan, etc.) or",Hydroxychloroquine
113,0,clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air vi. women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study.,Hydroxychloroquine
114,0,clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air vi. women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study.,Hydroxychloroquine
115,0,age 18 or older,SARS-CoV-2 convalescent plasma
116,0,admitted to a study hospital,SARS-CoV-2 convalescent plasma
117,0,active covid-19 defined as symptoms + sars cov-2 identified from upper or lower airway samples,SARS-CoV-2 convalescent plasma
118,0,negative pregnancy test taken before inclusion and use of an acceptable effective method of contraception until treatment discontinuation if the participant is a woman of childbearing potential,SARS-CoV-2 convalescent plasma
119,0,written informed consent after meeting with a study physician and ability and willingness to complete follow up,SARS-CoV-2 convalescent plasma
120,0,age ≥ 18 years,Hydroxychloroquine
121,0,age ≥ 18 years,Hydroxychloroquine
122,0,healthcare or hospital worker who has direct patient contact,Hydroxychloroquine
123,0,healthcare or hospital worker who has direct patient contact,Hydroxychloroquine
124,0,willing to participate in the research.,Hydroxychloroquine
125,0,willing to participate in the research.,Hydroxychloroquine
126,0,able to understand and sign the informed consent form,Hydroxychloroquine
127,0,able to understand and sign the informed consent form,Hydroxychloroquine
128,0,age 18 years and older,Convalescent Plasma
129,0,laboratory confirmed diagnosis of sars-cov-2,Convalescent Plasma
130,0,admitted to an acute care facility for the treatment of covid-19 complications,Convalescent Plasma
131,0,informed consent provided by patient or legally authorized representative,Convalescent Plasma
132,0,"severe or life threatening covid-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease",Convalescent Plasma
133,0,severe disease defined as any of the following,Convalescent Plasma
134,0,dyspnea,Convalescent Plasma
135,0,respiratory rate > 30/minute,Convalescent Plasma
136,0,oxygen saturation <94%,Convalescent Plasma
137,0,partial pressure of arterial oxygen to fraction of inspired oxygen ratio <300,Convalescent Plasma
138,0,lung infiltrates >50% within 24 to 48 hours,Convalescent Plasma
139,0,life-threatening disease defined as any of the following,Convalescent Plasma
140,0,respiratory failure,Convalescent Plasma
141,0,septic shock,Convalescent Plasma
142,0,multiple organ dysfunction or failure • informed consent provided by patient or healthcare proxy,Convalescent Plasma
143,0,age ≥18 years,pathogen reduced SARS-CoV-2 convalescent plasma
144,0,currently hospitalized or in an emergency department with anticipated hospitalization.,pathogen reduced SARS-CoV-2 convalescent plasma
145,0,"symptoms of acute respiratory infection, defined as one or more of the following: cough, fever (> 37.5° c / 99.5° f), shortness of breath",pathogen reduced SARS-CoV-2 convalescent plasma
146,0,laboratory-confirmed sars-cov-2 infection within the past 10 days,pathogen reduced SARS-CoV-2 convalescent plasma
147,0,group b: sars-cov-2 pcr positive but asymptomatic or mild symptoms at screening,Convalescent Plasma (anti-SARS-CoV-2 plasma)
148,0,subjects must be 18 years of age or older,Convalescent Plasma (anti-SARS-CoV-2 plasma)
149,0,close contact* of a person with covid-19 within the last 7 days. it is anticipated that most contacts will be household contacts with extensive interaction. all must meet the cdc criteria for close contacts.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
150,0,evidence of infection by nasopharyngeal swab pcr that is positive for sars-cov-2,Convalescent Plasma (anti-SARS-CoV-2 plasma)
151,0,no symptoms or no more than 5 days of mild symptoms at the time of screening. mild symptoms+ may include:,Convalescent Plasma (anti-SARS-CoV-2 plasma)
152,0,mild rhinorrhea,Convalescent Plasma (anti-SARS-CoV-2 plasma)
153,0,mild sore throat or throat irritation,Convalescent Plasma (anti-SARS-CoV-2 plasma)
154,0,mild nonproductive cough,Convalescent Plasma (anti-SARS-CoV-2 plasma)
155,0,mild fatigue (able to perform activities of daily living (adls)),Convalescent Plasma (anti-SARS-CoV-2 plasma)
156,0,"high risk for severe covid-19 based on a risk score of ≥ 2 calculated risk score of ≥ 2 points, with risk factors based on center for disease control and prevention (cdc) description",Convalescent Plasma (anti-SARS-CoV-2 plasma)
157,0,age 65-74: 1 point,Convalescent Plasma (anti-SARS-CoV-2 plasma)
158,0,age ≥ 75: 2 points,Convalescent Plasma (anti-SARS-CoV-2 plasma)
159,0,known cardiovascular disease (including hypertension): 1 point,Convalescent Plasma (anti-SARS-CoV-2 plasma)
160,0,diabetes mellitus: 1 point,Convalescent Plasma (anti-SARS-CoV-2 plasma)
161,0,"pulmonary disease (copd, moderate to severe asthma, current smoking or other): 1 point",Convalescent Plasma (anti-SARS-CoV-2 plasma)
162,0,morbid obesity: 1 point,Convalescent Plasma (anti-SARS-CoV-2 plasma)
163,0,"immunocompromised state: 1 point received a bone marrow or solid organ transplant at any time, received chemotherapy for a malignancy within the past 6 months, has an acquired or congenital immunodeficiency, currently receiving immunosuppressive or immune modulating medications, hiv with non-suppressed viral load and/or cluster of differentiation 4 (cd4+) t cell count <200 cells/ml).",Convalescent Plasma (anti-SARS-CoV-2 plasma)
164,0,mild symptoms are rated by participant as mild and not interfering with normal daily activities,Convalescent Plasma (anti-SARS-CoV-2 plasma)
165,0,group c: sars-cov-2 pcr negative (uninfected) at time of screening but asymptomatic or mildly symptomatic at screening,Convalescent Plasma (anti-SARS-CoV-2 plasma)
166,0,subjects must be 18 years of age or older,Convalescent Plasma (anti-SARS-CoV-2 plasma)
167,0,close contact* of a person with covid-19 within the last 7 days. it is anticipated that most contacts will be household contacts with extensive interaction. all must meet the cdc criteria for close contacts.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
168,0,nasopharyngeal swab negative for sars-cov-2 at screening,Convalescent Plasma (anti-SARS-CoV-2 plasma)
169,0,no symptoms or no more than 5 days of mild symptoms at the time of screening. mild symptoms+ may include:,Convalescent Plasma (anti-SARS-CoV-2 plasma)
170,0,mild rhinorrhea,Convalescent Plasma (anti-SARS-CoV-2 plasma)
171,0,mild sore throat or throat irritation,Convalescent Plasma (anti-SARS-CoV-2 plasma)
172,0,mild nonproductive cough,Convalescent Plasma (anti-SARS-CoV-2 plasma)
173,0,mild fatigue (able to perform adls),Convalescent Plasma (anti-SARS-CoV-2 plasma)
174,0,"high risk for severe covid-19 based on a risk score of ≥ 2, as above.*",Convalescent Plasma (anti-SARS-CoV-2 plasma)
175,0,"close contact is defined by cdc as being within approximately 6 feet (2 meters) of a covid-19 case for a prolonged period of time (without ppe); close contact can occur while caring for, living with, visiting, or sharing a healthcare waiting area or room with a covid-19 case.",Convalescent Plasma (anti-SARS-CoV-2 plasma)
176,0,mild symptoms are rated by participant as mild and not interfering with normal daily activities,Convalescent Plasma (anti-SARS-CoV-2 plasma)
177,0,"confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation.",Hydroxychloroquine
178,0,"confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation.",Hydroxychloroquine
179,0,"self-reported symptoms of sars-cov-2 infection including any of the following: fever ≥37.5°c, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza",Hydroxychloroquine
180,0,"self-reported symptoms of sars-cov-2 infection including any of the following: fever ≥37.5°c, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza",Hydroxychloroquine
181,0,time from a positive test result to day 1 of treatment within 4 days,Hydroxychloroquine
182,0,time from a positive test result to day 1 of treatment within 4 days,Hydroxychloroquine
183,0,time from patient reported first symptoms to day 1 of treatment within 12 days,Hydroxychloroquine
184,0,time from patient reported first symptoms to day 1 of treatment within 12 days,Hydroxychloroquine
185,0,"adults, age 18 and over, with any risk factor for severe disease",Hydroxychloroquine
186,0,"adults, age 18 and over, with any risk factor for severe disease",Hydroxychloroquine
187,0,resident of alberta or if not a resident of alberta able to provide complete follow-up data,Hydroxychloroquine
188,0,resident of alberta or if not a resident of alberta able to provide complete follow-up data,Hydroxychloroquine
189,0,agrees to use adequate contraception for the duration of the study,Hydroxychloroquine
190,0,agrees to use adequate contraception for the duration of the study,Hydroxychloroquine
191,0,informed consent,Hydroxychloroquine
192,0,informed consent,Hydroxychloroquine
193,0,for donors:,convalescent plasma
194,0,volunteer enrolment (informed consent will be obtained; annexures-2a & 2b).,convalescent plasma
195,0,all the regulations related to ich-gcp and blood transfusion authority (bta) pakistan will be followed.,convalescent plasma
196,0,should fulfill all the criteria of a healthy blood donor (with the exception of history of covid-19 during last 4-8 weeks.,convalescent plasma
197,0,history of covid-19 during last 4-8 weeks,convalescent plasma
198,0,rt-pcr negative for sars-cov-2 rna (carried out on nasopharyngeal or oropharyngeal specimen),convalescent plasma
199,0,age cutoff: 18-55years,convalescent plasma
200,0,body weight cut off: >50 kg for men and > 45kg for women,convalescent plasma
201,0,for recipients:,convalescent plasma
202,0,volunteer enrolment (informed consent will be obtained; annexures-3a & 3b).,convalescent plasma
203,0,confirmed covid-19 cases confirmed by rt-pcr laboratory tests,convalescent plasma
204,0,severe or critical covid-19 related features (8):,convalescent plasma
205,0,"a. severe covid-19, defined by the presence of any of the following features: i. shortness of breath ii. respiratory rate ≥ 30/min, iii. arterial blood oxygen saturation ≤ 93%, iv. lung infiltrates > 50% within 24 to 48 hours b. criticalcovid-19, defined by the presence of any of the following features: i. respiratory failure, ii. shock iii. multiple organ dysfunction",convalescent plasma
206,0,pregnant,Hydroxychloroquine and azithromycin treatment
207,0,pregnant,Hydroxychloroquine and azithromycin treatment
208,0,18 and over,Hydroxychloroquine and azithromycin treatment
209,0,18 and over,Hydroxychloroquine and azithromycin treatment
210,0,monofetal pregnancy between 22+0 and 41+0 weeks of gestation,Hydroxychloroquine and azithromycin treatment
211,0,monofetal pregnancy between 22+0 and 41+0 weeks of gestation,Hydroxychloroquine and azithromycin treatment
212,0,"presenting a positive covid-19 rt-pcr test result after nasopharyngeal swab for one or more minor symptoms: cough, body temperature >37,3 °c, shortness of breath, diarrhea, asthenia, anosmia, taste loss, myalgia",Hydroxychloroquine and azithromycin treatment
213,0,"presenting a positive covid-19 rt-pcr test result after nasopharyngeal swab for one or more minor symptoms: cough, body temperature >37,3 °c, shortness of breath, diarrhea, asthenia, anosmia, taste loss, myalgia",Hydroxychloroquine and azithromycin treatment
214,0,presenting no contraindication to hydroxychloroquine and azithromycin,Hydroxychloroquine and azithromycin treatment
215,0,presenting no contraindication to hydroxychloroquine and azithromycin,Hydroxychloroquine and azithromycin treatment
216,0,informed consent signature,Hydroxychloroquine and azithromycin treatment
217,0,informed consent signature,Hydroxychloroquine and azithromycin treatment
218,0,affiliated to social security scheme,Hydroxychloroquine and azithromycin treatment
219,0,affiliated to social security scheme,Hydroxychloroquine and azithromycin treatment
220,0,age ≥ 18,Hydroxychloroquine
221,0,age ≥ 18,Hydroxychloroquine
222,0,ecog 0-3,Hydroxychloroquine
223,0,ecog 0-3,Hydroxychloroquine
224,0,for patients who have not started radiation at the time of screening: patients are required to have a plan in place for a minimum of 10 radiation treatments with or without concurrent systemic therapy,Hydroxychloroquine
225,0,for patients who have not started radiation at the time of screening: patients are required to have a plan in place for a minimum of 10 radiation treatments with or without concurrent systemic therapy,Hydroxychloroquine
226,0,for patients who have already started radiation at the time of screening: patients must complete enrollment such that they are able to receive at least 10 radiation treatments with hydroxychloroquine.,Hydroxychloroquine
227,0,for patients who have already started radiation at the time of screening: patients must complete enrollment such that they are able to receive at least 10 radiation treatments with hydroxychloroquine.,Hydroxychloroquine
228,0,disease site,Hydroxychloroquine
229,0,disease site,Hydroxychloroquine
230,0,mandatory inclusion criteria:,Hydroxychloroquine
231,0,mandatory inclusion criteria:,Hydroxychloroquine
232,0,no covid-19 symptoms within 14 days of enrollment:,Hydroxychloroquine
233,0,no covid-19 symptoms within 14 days of enrollment:,Hydroxychloroquine
234,0,"(temp >38c in addition to sore throat, cough, wheezing, chest tightness, shortness of breath, body aches, chills, diarrhea, and anosmia)",Hydroxychloroquine
235,0,"(temp >38c in addition to sore throat, cough, wheezing, chest tightness, shortness of breath, body aches, chills, diarrhea, and anosmia)",Hydroxychloroquine
236,0,"if symptoms are present within 14 days of enrollment, patients with a negative covid-19 pcr or covid-19 serology assay are eligible for inclusion.",Hydroxychloroquine
237,0,"if symptoms are present within 14 days of enrollment, patients with a negative covid-19 pcr or covid-19 serology assay are eligible for inclusion.",Hydroxychloroquine
238,0,no close contact with confirmed covid-19 person,Hydroxychloroquine
239,0,no close contact with confirmed covid-19 person,Hydroxychloroquine
240,0,close contact defined as:,Hydroxychloroquine
241,0,close contact defined as:,Hydroxychloroquine
242,0,within 6 feet for prolonged period,Hydroxychloroquine
243,0,within 6 feet for prolonged period,Hydroxychloroquine
244,0,cohabitating,Hydroxychloroquine
245,0,cohabitating,Hydroxychloroquine
246,0,optional laboratory criteria (recommended if available),Hydroxychloroquine
247,0,optional laboratory criteria (recommended if available),Hydroxychloroquine
248,0,negative pre-treatment sars-cov-2 rapid antigen test result (within 1 week of enrollment),Hydroxychloroquine
249,0,negative pre-treatment sars-cov-2 rapid antigen test result (within 1 week of enrollment),Hydroxychloroquine
250,0,negative pre-treatment sars-cov-2 pcr test result (within 1 week of enrollment) using mskcc laboratory or outside laboratory assay,Hydroxychloroquine
251,0,negative pre-treatment sars-cov-2 pcr test result (within 1 week of enrollment) using mskcc laboratory or outside laboratory assay,Hydroxychloroquine
252,0,negative pre-treatment standard q covid-19 igm/igg rapid serology result (within 1 week of enrollment),Hydroxychloroquine
253,0,negative pre-treatment standard q covid-19 igm/igg rapid serology result (within 1 week of enrollment),Hydroxychloroquine
254,0,blood serum for sars-cov-2 serology tests (being validated by mskcc),Hydroxychloroquine
255,0,blood serum for sars-cov-2 serology tests (being validated by mskcc),Hydroxychloroquine
256,0,disease site meets following criteria:,Hydroxychloroquine
257,0,disease site meets following criteria:,Hydroxychloroquine
258,0,head and neck / high-risk skin cancer,Hydroxychloroquine
259,0,head and neck / high-risk skin cancer,Hydroxychloroquine
260,0,lung cancer,Hydroxychloroquine
261,0,lung cancer,Hydroxychloroquine
262,0,breast cancer,Hydroxychloroquine
263,0,breast cancer,Hydroxychloroquine
264,0,prostate cancer,Hydroxychloroquine
265,0,prostate cancer,Hydroxychloroquine
266,0,central nervous system tumors,Hydroxychloroquine
267,0,central nervous system tumors,Hydroxychloroquine
268,0,gastrointestinal system cancer,Hydroxychloroquine
269,0,gastrointestinal system cancer,Hydroxychloroquine
270,0,gynecologic cancer,Hydroxychloroquine
271,0,gynecologic cancer,Hydroxychloroquine
272,0,other disease sites permitted at pi discretion,Hydroxychloroquine
273,0,other disease sites permitted at pi discretion,Hydroxychloroquine
274,0,"household contact of index case: currently residing in the same household as an individual evaluated at nyp via outpatient, emergency department (ed), or inpatient services who (1) test positive for covid-19, or (2) are defined as suspected cases, or persons under investigations (pui), by the treating physician.",Hydroxychloroquine
275,0,"household contact of index case: currently residing in the same household as an individual evaluated at nyp via outpatient, emergency department (ed), or inpatient services who (1) test positive for covid-19, or (2) are defined as suspected cases, or persons under investigations (pui), by the treating physician.",Hydroxychloroquine
276,0,willing to take study drug as directed for 5 days.,Hydroxychloroquine
277,0,willing to take study drug as directed for 5 days.,Hydroxychloroquine
278,0,"health care worker (hcw) at the hospital who work on a ""full time"" basis during the study period. for the purposes of the study, ""health care workers"" are physicians, nurses, nurse practitioners, physician assistants, respiratory therapists, x-ray technicians, social workers and support staff (including but not limited to house-keeping, and porters).",Hydroxychloroquine Pre-Exposure Prophylaxis
279,0,"health care worker (hcw) at the hospital who work on a ""full time"" basis during the study period. for the purposes of the study, ""health care workers"" are physicians, nurses, nurse practitioners, physician assistants, respiratory therapists, x-ray technicians, social workers and support staff (including but not limited to house-keeping, and porters).",Hydroxychloroquine Pre-Exposure Prophylaxis
280,0,age ≥18 years.,Hydroxychloroquine Pre-Exposure Prophylaxis
281,0,age ≥18 years.,Hydroxychloroquine Pre-Exposure Prophylaxis
282,0,ability to communicate with study staff in english,Hydroxychloroquine Pre-Exposure Prophylaxis
283,0,ability to communicate with study staff in english,Hydroxychloroquine Pre-Exposure Prophylaxis
284,0,willing and able to provide written informed consent prior to performing study procedures or have a legally authorized representative available to do so.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
285,0,willing and able to provide written informed consent prior to performing study procedures or have a legally authorized representative available to do so.,Non-convalescent Plasma (control plasma)
286,0,age ≥18 years,Convalescent Plasma (anti-SARS-CoV-2 plasma)
287,0,age ≥18 years,Non-convalescent Plasma (control plasma)
288,0,evidence of sars-cov-2 infection by pcr test of nasopharyngeal swab sample within 7 days of randomization,Convalescent Plasma (anti-SARS-CoV-2 plasma)
289,0,evidence of sars-cov-2 infection by pcr test of nasopharyngeal swab sample within 7 days of randomization,Non-convalescent Plasma (control plasma)
290,0,"peripheral capillary oxygen saturation (spo2) ≤ 94% on room air or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation at screening",Convalescent Plasma (anti-SARS-CoV-2 plasma)
291,0,"peripheral capillary oxygen saturation (spo2) ≤ 94% on room air or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation at screening",Non-convalescent Plasma (control plasma)
292,0,evidence of infiltrates on chest radiography,Convalescent Plasma (anti-SARS-CoV-2 plasma)
293,0,evidence of infiltrates on chest radiography,Non-convalescent Plasma (control plasma)
294,0,"females of childbearing age and males, must be willing to practice an effective contraceptive method or remain abstinent during the study period.",Convalescent Plasma (anti-SARS-CoV-2 plasma)
295,0,"females of childbearing age and males, must be willing to practice an effective contraceptive method or remain abstinent during the study period.",Non-convalescent Plasma (control plasma)
296,0,adult (age ≥ 18 years),Hydroxychloroquine
297,0,adult (age ≥ 18 years),Hydroxychloroquine
298,0,"confirmed or suspected covid-19,",Hydroxychloroquine
299,0,"confirmed or suspected covid-19,",Hydroxychloroquine
300,0,confirmed: positive assay for covid-19 within the last 10 days,Hydroxychloroquine
301,0,confirmed: positive assay for covid-19 within the last 10 days,Hydroxychloroquine
302,0,suspected: pending assay for covid-19 with high clinical suspicion,Hydroxychloroquine
303,0,suspected: pending assay for covid-19 with high clinical suspicion,Hydroxychloroquine
304,0,scheduled for admission or already admitted to an inpatient bed,Hydroxychloroquine
305,0,scheduled for admission or already admitted to an inpatient bed,Hydroxychloroquine
306,0,patients must be enrolled within 48 hours of hospital admission,Hydroxychloroquine
307,0,patients must be enrolled within 48 hours of hospital admission,Hydroxychloroquine
308,0,"men or women 18 to 80 years of age inclusive, at the time of signing the informed consent",Hydroxychloroquine Sulfate
309,0,"men or women 18 to 80 years of age inclusive, at the time of signing the informed consent",Hydroxychloroquine Sulfate
310,0,willing and able to provide informed consent,Hydroxychloroquine Sulfate
311,0,willing and able to provide informed consent,Hydroxychloroquine Sulfate
312,0,had a close contact of a person (index) with known pcr-confirmed sars-cov-2 infection or who is currently being assessed for covid-19. close contact defined as:,Hydroxychloroquine Sulfate
313,0,had a close contact of a person (index) with known pcr-confirmed sars-cov-2 infection or who is currently being assessed for covid-19. close contact defined as:,Hydroxychloroquine Sulfate
314,0,"household contact (i.e., residing with the index case in the 14 days prior to index diagnosis)",Hydroxychloroquine Sulfate
315,0,"household contact (i.e., residing with the index case in the 14 days prior to index diagnosis)",Hydroxychloroquine Sulfate
316,0,"medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)",Hydroxychloroquine Sulfate
317,0,"medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)",Hydroxychloroquine Sulfate
318,0,less than 4 days since last exposure (close contact with a person with sars-cov-2 infection) to the index case,Hydroxychloroquine Sulfate
319,0,less than 4 days since last exposure (close contact with a person with sars-cov-2 infection) to the index case,Hydroxychloroquine Sulfate
320,0,body weight < 100 kg (self-reported),Hydroxychloroquine Sulfate
321,0,body weight < 100 kg (self-reported),Hydroxychloroquine Sulfate
322,0,access to device and internet for telehealth visits,Hydroxychloroquine Sulfate
323,0,access to device and internet for telehealth visits,Hydroxychloroquine Sulfate
324,0,≥16 years old,Convalescent plasma
325,0,admitted to hospital with confirmed covid-19 respiratory illness,Convalescent plasma
326,0,receiving supplemental oxygen,Convalescent plasma
327,0,500 ml of abo compatible convalescent plasma is available,Convalescent plasma
328,0,"informed consent, provided electronically via the edc, demonstrating the subject understands the procedures required for the study and the purpose of the study",Hydroxychloroquine
329,0,"informed consent, provided electronically via the edc, demonstrating the subject understands the procedures required for the study and the purpose of the study",Hydroxychloroquine
330,0,male or female patients 18 years of age or older that are considered to be high-risk individuals.,Hydroxychloroquine
331,0,male or female patients 18 years of age or older that are considered to be high-risk individuals.,Hydroxychloroquine
332,0,"a. high-risk individuals are defined as all health care workers in hospitals, clinics, and emergency rooms, and medical facilities.",Hydroxychloroquine
333,0,"a. high-risk individuals are defined as all health care workers in hospitals, clinics, and emergency rooms, and medical facilities.",Hydroxychloroquine
334,0,"subjects must agree to practice at least two highly effective methods of birth control for the duration of the study this includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. at least one of these must be a barrier method. subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized)",Hydroxychloroquine
335,0,"subjects must agree to practice at least two highly effective methods of birth control for the duration of the study this includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. at least one of these must be a barrier method. subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized)",Hydroxychloroquine
336,0,patients must be 18 years of age or older,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
337,0,"patients hospitalized with covid-19 respiratory symptoms within 72 hours of admission to a""floor"" bed (non-icu bed) and confirmation via sars-cov-2 rt-pcr testing.",High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
338,0,patient and/or surrogate is willing and able to provide written informed consent and comply with all protocol requirements.,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
339,0,patients with hematologic malignancies or solid tumors are eligible.,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
340,0,patients with autoimmune disorders are eligible.,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
341,0,patients with immunodeficiency and organ or stem cell transplant recipients are eligible.,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
342,0,patients who have received or are receiving hydroxychloroquine or chloroquine are eligible (but will be taken off the drug),High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
343,0,prior use of ivig is allowed but the investigator should consider the potential for a hypercoagulable state.,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
344,0,"being tested positive for sars-cov-2 in outpatient setting in drive-thru, ed, or ambulatory clinics at the university of chicago within 72 hours of enrollment.",Hydroxychloroquine
345,0,"being tested positive for sars-cov-2 in outpatient setting in drive-thru, ed, or ambulatory clinics at the university of chicago within 72 hours of enrollment.",Hydroxychloroquine
346,0,age >18,Hydroxychloroquine
347,0,age >18,Hydroxychloroquine
348,0,"fever >100.4 f by any conventional clinical method (forehead, tympanic, oral, axillary, rectal) within 48h prior to enrollment",Hydroxychloroquine
349,0,"fever >100.4 f by any conventional clinical method (forehead, tympanic, oral, axillary, rectal) within 48h prior to enrollment",Hydroxychloroquine
350,0,"mild covid-19, defined as the presence of any symptom consistent with an upper respiratory tract infection, including dry cough, sore throat, nasal congestion, fatigue, myalgia, headaches.",Hydroxychloroquine
351,0,"mild covid-19, defined as the presence of any symptom consistent with an upper respiratory tract infection, including dry cough, sore throat, nasal congestion, fatigue, myalgia, headaches.",Hydroxychloroquine
352,0,"subjects must meet all the above-mentioned criteria, in addition to at least one of the following criteria:",Hydroxychloroquine
353,0,"subjects must meet all the above-mentioned criteria, in addition to at least one of the following criteria:",Hydroxychloroquine
354,0,age > 55,Hydroxychloroquine
355,0,age > 55,Hydroxychloroquine
356,0,"pre-existing pulmonary disease: airway diseases (asthma, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis), history of active or treated lung cancer, history of pneumectomy, interstitial lung diseases, pulmonary hypertension, sleep apnea.",Hydroxychloroquine
357,0,"pre-existing pulmonary disease: airway diseases (asthma, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis), history of active or treated lung cancer, history of pneumectomy, interstitial lung diseases, pulmonary hypertension, sleep apnea.",Hydroxychloroquine
358,0,diabetes: uncontrolled or controlled diabetes,Hydroxychloroquine
359,0,diabetes: uncontrolled or controlled diabetes,Hydroxychloroquine
360,0,hypertension,Hydroxychloroquine
361,0,hypertension,Hydroxychloroquine
362,0,chronic kidney disease stage 1-3,Hydroxychloroquine
363,0,chronic kidney disease stage 1-3,Hydroxychloroquine
364,0,history of cardiovascular disease with an electrocardiogram available to the physician-investigator through the subject's electronical medical record within the past thirty days showing a normal qt interval (qt < 500 ms).,Hydroxychloroquine
365,0,history of cardiovascular disease with an electrocardiogram available to the physician-investigator through the subject's electronical medical record within the past thirty days showing a normal qt interval (qt < 500 ms).,Hydroxychloroquine
366,0,history of immunosuppression,Hydroxychloroquine
367,0,history of immunosuppression,Hydroxychloroquine
368,0,"active cancer diagnosis, on palliative treatment or requiring current therapy with antimetabolic agents, immunotherapy or radiotherapy.",Hydroxychloroquine
369,0,"active cancer diagnosis, on palliative treatment or requiring current therapy with antimetabolic agents, immunotherapy or radiotherapy.",Hydroxychloroquine
370,0,at least one fever every 24 hours for > 72h,Hydroxychloroquine
371,0,at least one fever every 24 hours for > 72h,Hydroxychloroquine
372,0,18 years or older,Hydroxychloroquine sulfate
373,0,18 years or older,Hydroxychloroquine sulfate
374,0,moderate to severe covid-19 associated disease as defined by the who,Hydroxychloroquine sulfate
375,0,moderate to severe covid-19 associated disease as defined by the who,Hydroxychloroquine sulfate
376,0,hospitalized patient,Hydroxychloroquine sulfate
377,0,hospitalized patient,Hydroxychloroquine sulfate
378,0,willing and able to provide written informed consent prior to performing study procedures,Hydroxychloroquine sulfate
379,0,willing and able to provide written informed consent prior to performing study procedures,Hydroxychloroquine sulfate
380,0,"has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay",Hydroxychloroquine sulfate
381,0,"has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay",Hydroxychloroquine sulfate
382,0,"illness of any duration, and at least one of the following: radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air, or require mechanical ventilation and/or supplemental oxygen.",Hydroxychloroquine sulfate
383,0,"illness of any duration, and at least one of the following: radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air, or require mechanical ventilation and/or supplemental oxygen.",Hydroxychloroquine sulfate
384,0,"febrile defined as temperature ≥ 36.6 °c armpit, ≥ 37.2 °c oral, or ≥ 37.8 °c rectal documented within 48 hours of consent",Hydroxychloroquine sulfate
385,0,"febrile defined as temperature ≥ 36.6 °c armpit, ≥ 37.2 °c oral, or ≥ 37.8 °c rectal documented within 48 hours of consent",Hydroxychloroquine sulfate
386,0,provision of informed consent,Hydroxychloroquine
387,0,provision of informed consent,Hydroxychloroquine
388,0,"exposure to a covid19 case within 4 days as either a household contact or occupational exposure, or",Hydroxychloroquine
389,0,"exposure to a covid19 case within 4 days as either a household contact or occupational exposure, or",Hydroxychloroquine
390,0,symptomatic covid19 case with confirmed diagnosis within 4 days of symptom onset or symptomatic high risk exposure with known covid19 contact and within 4 days of symptom onset;,Hydroxychloroquine
391,0,symptomatic covid19 case with confirmed diagnosis within 4 days of symptom onset or symptomatic high risk exposure with known covid19 contact and within 4 days of symptom onset;,Hydroxychloroquine
392,0,ability to understand and the willingness to sign a written informed consent document.,Hydroxychloroquine
393,0,ability to understand and the willingness to sign a written informed consent document.,Hydroxychloroquine
394,0,individuals aged ≥ 18 years of all races and ethnic groups.,Hydroxychloroquine
395,0,individuals aged ≥ 18 years of all races and ethnic groups.,Hydroxychloroquine
396,0,"must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov-2 infection within the past 14 days",Hydroxychloroquine
397,0,"must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov-2 infection within the past 14 days",Hydroxychloroquine
398,0,"not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s).",Hydroxychloroquine
399,0,"not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s).",Hydroxychloroquine
400,0,must meet at least one of the following clinical stratifications:,Hydroxychloroquine
401,0,must meet at least one of the following clinical stratifications:,Hydroxychloroquine
402,0,"have at least 1 minor criterion per ats criteria (refer to appendix a), or",Hydroxychloroquine
403,0,"have at least 1 minor criterion per ats criteria (refer to appendix a), or",Hydroxychloroquine
404,0,"have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography [ct]), or",Hydroxychloroquine
405,0,"have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography [ct]), or",Hydroxychloroquine
406,0,"high risk for poor outcome, as defined by any one of the following:",Hydroxychloroquine
407,0,"high risk for poor outcome, as defined by any one of the following:",Hydroxychloroquine
408,0,i. age ≥ 60 years old,Hydroxychloroquine
409,0,i. age ≥ 60 years old,Hydroxychloroquine
410,0,"ii. underlying medical comorbidities, defined as:",Hydroxychloroquine
411,0,"ii. underlying medical comorbidities, defined as:",Hydroxychloroquine
412,0,cardiovascular disease,Hydroxychloroquine
413,0,cardiovascular disease,Hydroxychloroquine
414,0,diabetes,Hydroxychloroquine
415,0,diabetes,Hydroxychloroquine
416,0,"chronic respiratory disease (e.g., copd)",Hydroxychloroquine
417,0,"chronic respiratory disease (e.g., copd)",Hydroxychloroquine
418,0,"hypertension, defined as blood pressure ≥ 140 / 90 mmhg",Hydroxychloroquine
419,0,"hypertension, defined as blood pressure ≥ 140 / 90 mmhg",Hydroxychloroquine
420,0,iii. solid organ or stem cell transplant recipient,Hydroxychloroquine
421,0,iii. solid organ or stem cell transplant recipient,Hydroxychloroquine
422,0,iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy,Hydroxychloroquine
423,0,iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy,Hydroxychloroquine
424,0,v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent),Hydroxychloroquine
425,0,v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent),Hydroxychloroquine
426,0,participants with preexisting auditory damage are allowed.,Hydroxychloroquine
427,0,participants with preexisting auditory damage are allowed.,Hydroxychloroquine
428,0,participants with a history of epilepsy are allowed.,Hydroxychloroquine
429,0,participants with a history of epilepsy are allowed.,Hydroxychloroquine
430,0,female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug.,Hydroxychloroquine
431,0,female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug.,Hydroxychloroquine
432,0,focbp must agree to use highly-effective method(s) of contraception during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause.,Hydroxychloroquine
433,0,focbp must agree to use highly-effective method(s) of contraception during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause.,Hydroxychloroquine
434,0,male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through at least 1 months after the last dose of study drug.,Hydroxychloroquine
435,0,male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through at least 1 months after the last dose of study drug.,Hydroxychloroquine
436,0,participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.,Hydroxychloroquine
437,0,participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.,Hydroxychloroquine
438,0,admitted to a hospital with symptoms suggestive of covid-19 infection.,Remdesivir
439,0,subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.,Remdesivir
440,0,subject (or legally authorized representative) understands and agrees to comply with planned study procedures.,Remdesivir
441,0,male or non-pregnant female adult > / = 18 years of age at time of enrollment.,Remdesivir
442,0,"has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any specimen, as documented by either or the following:",Remdesivir
443,0,pcr positive in sample collected < 72 hours prior to randomization; or,Remdesivir
444,0,"pcr positive in sample collected >/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection.",Remdesivir
445,0,"illness of any duration, and at least one of the following:",Remdesivir
446,0,"radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or",Remdesivir
447,0,"spo2 < / = 94% on room air, or",Remdesivir
448,0,"requiring supplemental oxygen, or",Remdesivir
449,0,requiring mechanical ventilation.,Remdesivir
450,0,women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29.,Remdesivir
451,0,agrees to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 through day 29.,Remdesivir
452,0,"adult, age>44 years, competent to provide consent",Hydroxychloroquine
453,0,"adult, age>44 years, competent to provide consent",Hydroxychloroquine
454,0,"confirmed covid-19, via a positive nucleic acid assay for covid-19 within the last 7 days",Hydroxychloroquine
455,0,"confirmed covid-19, via a positive nucleic acid assay for covid-19 within the last 7 days",Hydroxychloroquine
456,0,positive polymerase chain reaction (pcr) for severe acute respiratory syndrome coronavirus 2 (sars-cov2) in a respiratory tract sample or positive anti-sars cov2 igm antibody test that is approved by food and drug administration (fda) or allowed under an emergency use authorization; either result obtained within 5 days prior to study entry,Hydroxychloroquine
457,0,positive polymerase chain reaction (pcr) for severe acute respiratory syndrome coronavirus 2 (sars-cov2) in a respiratory tract sample or positive anti-sars cov2 igm antibody test that is approved by food and drug administration (fda) or allowed under an emergency use authorization; either result obtained within 5 days prior to study entry,Hydroxychloroquine
458,0,cough and/or pneumonia on chest imaging,Hydroxychloroquine
459,0,cough and/or pneumonia on chest imaging,Hydroxychloroquine
460,0,"moderate disease with risk factor(s): peripheral capillary oxygen saturation (spo2) >= 92% on room air with one of the following risk factors for development of severe disease: age >= 60 years, receiving medication for hypertension, diagnosed diabetes mellitus, known cardiac disease, chronic lung disease, obesity (body mass index [bmi] >= 35 kg/m^2), active malignancy, immunosuppression (receiving biologics or glucocorticoids >= 20 mg/d prednisone equivalent for > 2 weeks)",Hydroxychloroquine
461,0,"moderate disease with risk factor(s): peripheral capillary oxygen saturation (spo2) >= 92% on room air with one of the following risk factors for development of severe disease: age >= 60 years, receiving medication for hypertension, diagnosed diabetes mellitus, known cardiac disease, chronic lung disease, obesity (body mass index [bmi] >= 35 kg/m^2), active malignancy, immunosuppression (receiving biologics or glucocorticoids >= 20 mg/d prednisone equivalent for > 2 weeks)",Hydroxychloroquine
462,0,severe disease: spo2 =< 92% on room air,Hydroxychloroquine
463,0,severe disease: spo2 =< 92% on room air,Hydroxychloroquine
464,0,"ability to understand and the willingness to sign a written informed consent. adults not competent to consent will be enrolled with the use of an appropriate legally authorized representative (per california code, health and safety code - hsc)",Hydroxychloroquine
465,0,"ability to understand and the willingness to sign a written informed consent. adults not competent to consent will be enrolled with the use of an appropriate legally authorized representative (per california code, health and safety code - hsc)",Hydroxychloroquine
466,0,"fda regulations generally require that the informed consent of a participant be documented by the use of a written consent form approved by the irb and signed and dated by the participant or the participant's legally authorized representative at the time of consent (21 case form report [cfr] 50.27[a]). in light of covid-19 infection control measures, the following procedure would satisfy documentation of this requirement if the participant signing the informed consent is in covid-19 isolation. if the technology is available, electronic methods of obtaining informed consent will be taken. the electronic consent and health insurance portability and accountability act (hipaa) forms will be uploaded and available through redcap",Hydroxychloroquine
467,0,"fda regulations generally require that the informed consent of a participant be documented by the use of a written consent form approved by the irb and signed and dated by the participant or the participant's legally authorized representative at the time of consent (21 case form report [cfr] 50.27[a]). in light of covid-19 infection control measures, the following procedure would satisfy documentation of this requirement if the participant signing the informed consent is in covid-19 isolation. if the technology is available, electronic methods of obtaining informed consent will be taken. the electronic consent and health insurance portability and accountability act (hipaa) forms will be uploaded and available through redcap",Hydroxychloroquine
468,0,"women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. note: should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. women of child-bearing potential should use highly effective methods of birth control. these are those methods of contraception, alone or in combination, that result in a low failure rate (i.e, less than 1% per year) when used consistently and correctly",Hydroxychloroquine
469,0,"women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. note: should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. women of child-bearing potential should use highly effective methods of birth control. these are those methods of contraception, alone or in combination, that result in a low failure rate (i.e, less than 1% per year) when used consistently and correctly",Hydroxychloroquine
470,0,age > 18 years of age,Hydroxychloroquine
471,0,age > 18 years of age,Hydroxychloroquine
472,0,sars-cov-2 positive per fda approved rt-pcr (reverse transcription-polymerase chain reaction),Hydroxychloroquine
473,0,sars-cov-2 positive per fda approved rt-pcr (reverse transcription-polymerase chain reaction),Hydroxychloroquine
474,0,"acute hypoxia (o2 sat < 90 % or pao2 < 60 on room air), or above baseline chronic o2 requirement",Hydroxychloroquine
475,0,"acute hypoxia (o2 sat < 90 % or pao2 < 60 on room air), or above baseline chronic o2 requirement",Hydroxychloroquine
476,0,inpatient admission,Hydroxychloroquine
477,0,inpatient admission,Hydroxychloroquine
478,0,1. patients admitted with rt-pcr confirmed covid-19 illness. 2. age > 18 years 3. written informed consent 4. has any of the two,Convalescent Plasma
479,0,pao2/ fio2 <300,Convalescent Plasma
480,0,respiratory rate > 24/min and sao2 < 93% on room air,Convalescent Plasma
481,0,"or in case of severe or immediately life-threatening covid-19, for example:",Convalescent Plasma
482,0,"a. severe disease is defined as: i. dyspnea, ii. respiratory frequency ≥ 30/min, iii. blood oxygen saturation ≤ 93%, iv. partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or v. lung infiltrates > 50% within 24 to 48 hours b. life-threatening disease is defined as: i. respiratory failure, ii. septic shock, and/or iii. multiple organ dysfunction or failure",Convalescent Plasma
483,0,aged 18 - 70 years;,Hydroxychloroquine
484,0,aged 18 - 70 years;,Hydroxychloroquine
485,0,healthcare workers in a healthcare facility delivering direct care to patients with either proven or suspected covid-19;,Hydroxychloroquine
486,0,healthcare workers in a healthcare facility delivering direct care to patients with either proven or suspected covid-19;,Hydroxychloroquine
487,0,understands and agrees to comply with planned study procedures;,Hydroxychloroquine
488,0,understands and agrees to comply with planned study procedures;,Hydroxychloroquine
489,0,signed informed consent for participation in the study.,Hydroxychloroquine
490,0,signed informed consent for participation in the study.,Hydroxychloroquine
491,0,≥ 18 years of age,Hydroxychloroquine
492,0,≥ 18 years of age,Hydroxychloroquine
493,0,≥ 18 years of age,remdesivir
494,0,"has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen prior to randomization.",Hydroxychloroquine
495,0,"has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen prior to randomization.",Hydroxychloroquine
496,0,"has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen prior to randomization.",remdesivir
497,0,hospitalized at a participating centre,Hydroxychloroquine
498,0,hospitalized at a participating centre,Hydroxychloroquine
499,0,hospitalized at a participating centre,remdesivir
500,0,"willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under international conference on harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age ≥18), or willing and able to provide assent (age ≥12 to <18, where locally and nationally approved) prior to performing study procedures",Remdesivir
501,0,"aged ≥ 18 years (at all sites), or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg (where permitted according to local law and approved nationally and by the relevant institutional review board [irb] or independent ethics committee [iec])",Remdesivir
502,0,severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 4 days before randomization,Remdesivir
503,0,currently hospitalized,Remdesivir
504,0,peripheral capillary oxygen saturation (spo2) ≤ 94% or requiring supplemental oxygen at screening,Remdesivir
505,0,key,Remdesivir
506,0,able to read and understand informed consent.,Hydroxychloroquine
507,0,able to read and understand informed consent.,Hydroxychloroquine
508,0,"high initial clinical suspicion by physician based on signs and symptoms (fever, cough, myalgias, fatigue, shortness of breath) followed by rt-pcr for confirmation of covid-19 diagnosis",Hydroxychloroquine
509,0,"high initial clinical suspicion by physician based on signs and symptoms (fever, cough, myalgias, fatigue, shortness of breath) followed by rt-pcr for confirmation of covid-19 diagnosis",Hydroxychloroquine
510,0,any gender,Hydroxychloroquine
511,0,any gender,Hydroxychloroquine
512,0,age 60 years and older,Hydroxychloroquine
513,0,age 60 years and older,Hydroxychloroquine
514,0,age 30-59 years with one or more of the following:,Hydroxychloroquine
515,0,age 30-59 years with one or more of the following:,Hydroxychloroquine
516,0,abnormal lung exam,Hydroxychloroquine
517,0,abnormal lung exam,Hydroxychloroquine
518,0,abnormal oxygen staturation <95%,Hydroxychloroquine
519,0,abnormal oxygen staturation <95%,Hydroxychloroquine
520,0,abnormal chest x-ray or chest ct,Hydroxychloroquine
521,0,abnormal chest x-ray or chest ct,Hydroxychloroquine
522,0,persistent fever >100.4 degrees fahrenheit upon arrival to emergency department (ed),Hydroxychloroquine
523,0,persistent fever >100.4 degrees fahrenheit upon arrival to emergency department (ed),Hydroxychloroquine
524,0,"one of the following co-morbidities: hypertension, diabetes mellitus, history of coronary artery disease, chronic kidney disease (ckd), asthma, chronic obstructive pulmonary disease, current or former smoker, or morbid obesity (body mass index ≥35)",Hydroxychloroquine
525,0,"one of the following co-morbidities: hypertension, diabetes mellitus, history of coronary artery disease, chronic kidney disease (ckd), asthma, chronic obstructive pulmonary disease, current or former smoker, or morbid obesity (body mass index ≥35)",Hydroxychloroquine
526,0,"willing and able to provide written informed consent prior to performing study procedures (participants ≥ 18 years of age) or assent (participants ≥ 12 and < 18 years of age) prior to performing study procedures. for participants ≥ 12 and < 18 years of age, a parent or legal guardian willing and able to provide written informed consent prior to performing study procedures",Remdesivir
527,0,severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 4 days before randomization,Remdesivir
528,0,currently hospitalized and requiring medical care for covid-19,Remdesivir
529,0,peripheral capillary oxygen saturation (spo2) > 94% on room air at screening,Remdesivir
530,0,radiographic evidence of pulmonary infiltrates,Remdesivir
531,0,key,Remdesivir
532,0,age > 18 with one or more of the following: dyspnea respiratory rate >= 30 breaths/min oxygen saturation <=93% pao2/fio2 <300 bilateral airspace opacities on chest radiograph at 24 to 48 hours,Convalescent plasma
533,0,age 0 to <19 years old,Convalescent plasma (CP)
534,0,hospitalized with symptoms compatible with covid-19 illness,Convalescent plasma (CP)
535,0,"laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen prior to randomization.",Convalescent plasma (CP)
536,0,abo compatible convalescent plasma available,Convalescent plasma (CP)
537,0,patients with proven sars-cov-2 infection by an accepted assay with symptoms consistent with covid-19,Hydroxychloroquine Sulfate + Azithromycin
538,0,patients with proven sars-cov-2 infection by an accepted assay with symptoms consistent with covid-19,Hydroxychloroquine Sulfate
539,0,patients with proven sars-cov-2 infection by an accepted assay with symptoms consistent with covid-19,Hydroxychloroquine Sulfate + Azithromycin
540,0,patients with proven sars-cov-2 infection by an accepted assay with symptoms consistent with covid-19,Hydroxychloroquine Sulfate
541,0,ability to measure and quantify viral load by quantitative pcr,Hydroxychloroquine Sulfate + Azithromycin
542,0,ability to measure and quantify viral load by quantitative pcr,Hydroxychloroquine Sulfate
543,0,ability to measure and quantify viral load by quantitative pcr,Hydroxychloroquine Sulfate + Azithromycin
544,0,ability to measure and quantify viral load by quantitative pcr,Hydroxychloroquine Sulfate
545,0,age 18 to 89,Hydroxychloroquine Sulfate + Azithromycin
546,0,age 18 to 89,Hydroxychloroquine Sulfate
547,0,age 18 to 89,Hydroxychloroquine Sulfate + Azithromycin
548,0,age 18 to 89,Hydroxychloroquine Sulfate
549,0,ability to swallow oral medications,Hydroxychloroquine Sulfate + Azithromycin
550,0,ability to swallow oral medications,Hydroxychloroquine Sulfate
551,0,ability to swallow oral medications,Hydroxychloroquine Sulfate + Azithromycin
552,0,ability to swallow oral medications,Hydroxychloroquine Sulfate
553,0,"patients must read, understand and sign irb approved informed consent",Hydroxychloroquine Sulfate + Azithromycin
554,0,"patients must read, understand and sign irb approved informed consent",Hydroxychloroquine Sulfate
555,0,"patients must read, understand and sign irb approved informed consent",Hydroxychloroquine Sulfate + Azithromycin
556,0,"patients must read, understand and sign irb approved informed consent",Hydroxychloroquine Sulfate
557,0,patients with pcr confirmed covid disease,Convalescent plasma
558,0,admitted to the hospital,Convalescent plasma
559,0,the most recent pcr positive sample is <96hrs old,Convalescent plasma
560,0,written informed consent by patient or legal patient representative,Convalescent plasma
561,0,age at least 18 years,Convalescent plasma
562,0,age greater than 18 years,Hydroxychloroquine
563,0,age greater than 18 years,Hydroxychloroquine
564,0,"positive sars-cov-2 testing or consistent clinical syndrome (based on clinical picture e.g. characteristic infiltrates on chest x-ray, laboratory findings, and with agreement by two physicians) in patients under investigation (puis).",Hydroxychloroquine
565,0,"positive sars-cov-2 testing or consistent clinical syndrome (based on clinical picture e.g. characteristic infiltrates on chest x-ray, laboratory findings, and with agreement by two physicians) in patients under investigation (puis).",Hydroxychloroquine
566,0,onset of symptoms < 7 days from date of enrollment,Hydroxychloroquine
567,0,onset of symptoms < 7 days from date of enrollment,Hydroxychloroquine
568,0,oxygen saturation of >94% on room air with defined risk factors (table 1) consistent with moderate disease or oxygen saturation of < 94% on room air consistent with severe disease,Hydroxychloroquine
569,0,oxygen saturation of >94% on room air with defined risk factors (table 1) consistent with moderate disease or oxygen saturation of < 94% on room air consistent with severe disease,Hydroxychloroquine
570,0,ability and willingness to comply with study procedures,Hydroxychloroquine
571,0,ability and willingness to comply with study procedures,Hydroxychloroquine
572,0,age ≥18 years,Hydroxychloroquine
573,0,age ≥18 years,Hydroxychloroquine
574,0,currently hospitalized or in an emergency department with anticipated hospitalization.,Hydroxychloroquine
575,0,currently hospitalized or in an emergency department with anticipated hospitalization.,Hydroxychloroquine
576,0,"symptoms of acute respiratory infection, defined as one or more of the following:",Hydroxychloroquine
577,0,"symptoms of acute respiratory infection, defined as one or more of the following:",Hydroxychloroquine
578,0,cough,Hydroxychloroquine
579,0,cough,Hydroxychloroquine
580,0,fever (> 37.5° c / 99.5° f),Hydroxychloroquine
581,0,fever (> 37.5° c / 99.5° f),Hydroxychloroquine
582,0,shortness of breath,Hydroxychloroquine
583,0,shortness of breath,Hydroxychloroquine
584,0,sore throat,Hydroxychloroquine
585,0,sore throat,Hydroxychloroquine
586,0,laboratory-confirmed sars-cov-2 infection within the past 10 days prior to randomization.,Hydroxychloroquine
587,0,laboratory-confirmed sars-cov-2 infection within the past 10 days prior to randomization.,Hydroxychloroquine
588,0,laboratory confirmed infection with sars-cov-2 ≤72 hours before randomization,Chloroquine or Hydroxychloroquine
589,0,laboratory confirmed infection with sars-cov-2 ≤72 hours before randomization,Chloroquine or Hydroxychloroquine
590,0,hospitalisation due to sars-cov-2 infection (for anti-viral treatment arms),Chloroquine or Hydroxychloroquine
591,0,hospitalisation due to sars-cov-2 infection (for anti-viral treatment arms),Chloroquine or Hydroxychloroquine
592,0,"for ""antiviral"" therapy because of limited drug supplies: oxygen saturation <94% when breathing room air or >3% drop in case of chronic obstructive lung disease",Chloroquine or Hydroxychloroquine
593,0,"for ""antiviral"" therapy because of limited drug supplies: oxygen saturation <94% when breathing room air or >3% drop in case of chronic obstructive lung disease",Chloroquine or Hydroxychloroquine
594,0,"informed consent obtained, the patient understands and agrees to comply with the planned study procedures, except for substudy c: obtaining informed consent may be impossible due to the severe condition of the patient and may be waived",Chloroquine or Hydroxychloroquine
595,0,"informed consent obtained, the patient understands and agrees to comply with the planned study procedures, except for substudy c: obtaining informed consent may be impossible due to the severe condition of the patient and may be waived",Chloroquine or Hydroxychloroquine
596,0,≥18 years of age,Chloroquine or Hydroxychloroquine
597,0,≥18 years of age,Chloroquine or Hydroxychloroquine
598,0,for female patients with childbearing potential: willingness to perform effective measures of contraception during the study.,Chloroquine or Hydroxychloroquine
599,0,for female patients with childbearing potential: willingness to perform effective measures of contraception during the study.,Chloroquine or Hydroxychloroquine
600,0,sub-study a: egfr of >20 ml/min,Chloroquine or Hydroxychloroquine
601,0,sub-study a: egfr of >20 ml/min,Chloroquine or Hydroxychloroquine
602,0,sub-study b: outpatients with covid-19 may be included,Chloroquine or Hydroxychloroquine
603,0,sub-study b: outpatients with covid-19 may be included,Chloroquine or Hydroxychloroquine
604,0,sub-study b: blood pressure ≥120/80mmhg in 2 consecutive measurements,Chloroquine or Hydroxychloroquine
605,0,sub-study b: blood pressure ≥120/80mmhg in 2 consecutive measurements,Chloroquine or Hydroxychloroquine
606,0,sub-study b: control group 1: patients with suspicion of but negative tests for covid-19. this group may consist of hospitalized and non-hospitalized patients.,Chloroquine or Hydroxychloroquine
607,0,sub-study b: control group 1: patients with suspicion of but negative tests for covid-19. this group may consist of hospitalized and non-hospitalized patients.,Chloroquine or Hydroxychloroquine
608,0,sub-study b: control group 2: healthy volunteers,Chloroquine or Hydroxychloroquine
609,0,sub-study b: control group 2: healthy volunteers,Chloroquine or Hydroxychloroquine
610,0,"sub-study c: signs of respiratory deterioration and progressing inflammation such as need for oxygen supplementation to achieve satisfactory blood oxygen saturation (spo2>90% at room air) as well as the need for mechanical ventilation, novel onset of uni- or bilateral lung infiltrates in cxr/ct scan, crp levels >5mg/dl",Chloroquine or Hydroxychloroquine
611,0,"sub-study c: signs of respiratory deterioration and progressing inflammation such as need for oxygen supplementation to achieve satisfactory blood oxygen saturation (spo2>90% at room air) as well as the need for mechanical ventilation, novel onset of uni- or bilateral lung infiltrates in cxr/ct scan, crp levels >5mg/dl",Chloroquine or Hydroxychloroquine
612,0,tested for covid-19 at a trial recruitment site as an outpatient;,Chloroquine or hydroxychloroquine
613,0,tested for covid-19 at a trial recruitment site as an outpatient;,Chloroquine or hydroxychloroquine
614,0,age 18 years or older;,Chloroquine or hydroxychloroquine
615,0,age 18 years or older;,Chloroquine or hydroxychloroquine
616,0,not requiring immediate hospitalisation;,Chloroquine or hydroxychloroquine
617,0,not requiring immediate hospitalisation;,Chloroquine or hydroxychloroquine
618,0,"mild disease, defined as respiratory rate <25/min, pulse rate <120/min, spo2 >94%;",Chloroquine or hydroxychloroquine
619,0,"mild disease, defined as respiratory rate <25/min, pulse rate <120/min, spo2 >94%;",Chloroquine or hydroxychloroquine
620,0,hiv-positive by rapid test or documented history;,Chloroquine or hydroxychloroquine
621,0,hiv-positive by rapid test or documented history;,Chloroquine or hydroxychloroquine
622,0,suspected or confirmed covid-19;,Chloroquine or hydroxychloroquine
623,0,suspected or confirmed covid-19;,Chloroquine or hydroxychloroquine
624,0,signed informed consent.,Chloroquine or hydroxychloroquine
625,0,signed informed consent.,Chloroquine or hydroxychloroquine
626,0,admitted to a hospital with symptoms suggestive of covid-19.,Remdesivir
627,0,subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.,Remdesivir
628,0,subject (or legally authorized representative) understands and agrees to comply with planned study procedures.,Remdesivir
629,0,male or non-pregnant female adult > / = 18 years of age at time of enrollment.,Remdesivir
630,0,"has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any specimen, as documented by either of the following:",Remdesivir
631,0,pcr positive in sample collected < 72 hours prior to randomization; or,Remdesivir
632,0,"pcr positive in sample collected >/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection.",Remdesivir
633,0,"illness of any duration, and at least one of the following:",Remdesivir
634,0,"radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or",Remdesivir
635,0,"spo2 < / = 94% on room air, or",Remdesivir
636,0,"requiring supplemental oxygen, or",Remdesivir
637,0,requiring mechanical ventilation or extracorporeal membrane oxygenation (ecmo).,Remdesivir
638,0,women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29.,Remdesivir
639,0,agrees to not participate in another clinical trial for the treatment of covid-19 through day 29.,Remdesivir
640,0,all types of locally advanced and metastatic malignancy,Hydroxychloroquine
641,0,all types of locally advanced and metastatic malignancy,Hydroxychloroquine
642,0,male/female participants,Hydroxychloroquine
643,0,male/female participants,Hydroxychloroquine
644,0,age>18 y.o.,Hydroxychloroquine
645,0,age>18 y.o.,Hydroxychloroquine
646,0,signed informed consent for participation in the study,Hydroxychloroquine
647,0,signed informed consent for participation in the study,Hydroxychloroquine
648,0,no restriction on eastern cooperative oncology group (ecog)/world health organization (who) performance status,Hydroxychloroquine
649,0,no restriction on eastern cooperative oncology group (ecog)/world health organization (who) performance status,Hydroxychloroquine
650,0,subject should not have received a prior systemic anti-viral treatment for covid19 disease.,Hydroxychloroquine
651,0,subject should not have received a prior systemic anti-viral treatment for covid19 disease.,Hydroxychloroquine
652,0,admitted to participating hospital with symptoms suggestive of covid-19 infection or develop symptoms of covid-19 during hospitalization,Hydroxychloroquine
653,0,admitted to participating hospital with symptoms suggestive of covid-19 infection or develop symptoms of covid-19 during hospitalization,Hydroxychloroquine
654,0,subject (or legally authorized representative) can provide written informed consent (in english or spanish) affirming intention to comply with planned study procedures prior to enrollment,Hydroxychloroquine
655,0,subject (or legally authorized representative) can provide written informed consent (in english or spanish) affirming intention to comply with planned study procedures prior to enrollment,Hydroxychloroquine
656,0,male or female adult aged 12 years or older at the time of enrollment,Hydroxychloroquine
657,0,male or female adult aged 12 years or older at the time of enrollment,Hydroxychloroquine
658,0,has laboratory-confirmed sars-cov-2 infection determined by a validated nucleic acid amplification assay (public health or commercial) in any respiratory specimen collected within 14 days of randomization,Hydroxychloroquine
659,0,has laboratory-confirmed sars-cov-2 infection determined by a validated nucleic acid amplification assay (public health or commercial) in any respiratory specimen collected within 14 days of randomization,Hydroxychloroquine
660,0,illness of any duration that includes,Hydroxychloroquine
661,0,illness of any duration that includes,Hydroxychloroquine
662,0,radiographic evidence of pulmonary infiltrates (chest x-ray or ct scan) or,Hydroxychloroquine
663,0,radiographic evidence of pulmonary infiltrates (chest x-ray or ct scan) or,Hydroxychloroquine
664,0,"clinical documentation of lower respiratory symptoms (cough, shortness of breath, wheezing) or",Hydroxychloroquine
665,0,"clinical documentation of lower respiratory symptoms (cough, shortness of breath, wheezing) or",Hydroxychloroquine
666,0,any documented spo2 ≤ 94% on room air or,Hydroxychloroquine
667,0,any documented spo2 ≤ 94% on room air or,Hydroxychloroquine
668,0,any inpatient initiation or supplemental oxygen regardless of documented cause,Hydroxychloroquine
669,0,any inpatient initiation or supplemental oxygen regardless of documented cause,Hydroxychloroquine
670,0,documented sars-cov-2 infection by qpcr assay without symptoms consistent with covid-19 within 1 week of enrollment,Hydroxychloroquine sulfate &Azithromycin
671,0,documented sars-cov-2 infection by qpcr assay without symptoms consistent with covid-19 within 1 week of enrollment,Hydroxychloroquine sulfate &Azithromycin
672,0,age ≥20,Hydroxychloroquine sulfate &Azithromycin
673,0,age ≥20,Hydroxychloroquine sulfate &Azithromycin
674,0,age >1 year.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
675,0,active covid-19 infection confirmed by positive sars-cov-2 pcr.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
676,0,meets institutional criteria for admission to hospital for covid-19.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
677,0,admitted to icu or non-icu floor within 5 days of enrollment.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
678,0,pao2/fio2 >200 mmhg if intubated.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
679,0,patient or lar able to provide informed consent.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
680,0,all patients with covid-19 test positive and... severe ill patient,convalescent plasma
681,0,respiratory difficulty,convalescent plasma
682,0,sat o2 <93% without o2 but improves with the use of supplemental oxygen,convalescent plasma
683,0,ct scan image: covid-19 compatible pneumonia,convalescent plasma
684,0,"one or more of at least: sofa = 0 d-dimer ≥500 age ≥ 65 years comorbidities such as high blood pressure, diabetes mellitus type i and ii, chronic kidney failure, controlled or cured cancer, ≥ 1 degree of obesity",convalescent plasma
685,0,very severe ill:,convalescent plasma
686,0,"respiratory difficulty that does not improve with supplemental oxygen, requiring intubation and connecting to ventilatory support of no more than 72hrs or 3 days.",convalescent plasma
687,0,ct image: covid-19 compatible pneumonia,convalescent plasma
688,0,"one or more of at least: sofa ≥1 dimer d ≥ 750 age ≥ 65 years comorbidities such as hypertension, diabetes mellitus type i and ii, chronic kidney failure, controlled or cured cancer, ≥ 1 degree of obesity.",convalescent plasma
689,0,survival over 5 days.,convalescent plasma
690,0,other inclusion criteria:,convalescent plasma
691,0,a) pregnant women are accepted,convalescent plasma
692,0,over 18 years old,Inactivated convalescent plasma
693,0,confirmed laboratory diagnosis for qrt-pcr to sars-cov-2,Inactivated convalescent plasma
694,0,"meet any of the following medical criteria (defined by who): be currently hospitalized with: pneumonia, severe pneumonia, acute respiratory distress syndrome (moderate or severe), sepsis or septic shock",Inactivated convalescent plasma
695,0,"the patient, or his representative, must sign an informed consent",Inactivated convalescent plasma
696,0,age >=18 years old,Hydroxychloroquine Sulfate
697,0,age >=18 years old,Hydroxychloroquine Sulfate
698,0,moderate to severe covid-19 pneumonia with fewer than 8 days of symptom onset and currently receiving standard medication for covid-19 at appropriate doses,Hydroxychloroquine Sulfate
699,0,moderate to severe covid-19 pneumonia with fewer than 8 days of symptom onset and currently receiving standard medication for covid-19 at appropriate doses,Hydroxychloroquine Sulfate
700,0,pafio2 of less than 300 mmhg or safi02 <315 mmhg,Hydroxychloroquine Sulfate
701,0,pafio2 of less than 300 mmhg or safi02 <315 mmhg,Hydroxychloroquine Sulfate
702,0,"patients who are not candidates for admission to the intensive care unit due to age, concomitant diseases or general condition.",Hydroxychloroquine Sulfate
703,0,"patients who are not candidates for admission to the intensive care unit due to age, concomitant diseases or general condition.",Hydroxychloroquine Sulfate
704,0,one of the following conditions:,Hydroxychloroquine Sulfate
705,0,one of the following conditions:,Hydroxychloroquine Sulfate
706,0,or il6 greater than 40,Hydroxychloroquine Sulfate
707,0,or il6 greater than 40,Hydroxychloroquine Sulfate
708,0,or pcr> 100mg / l,Hydroxychloroquine Sulfate
709,0,or pcr> 100mg / l,Hydroxychloroquine Sulfate
710,0,d-dimer greater than 1500ng / ml,Hydroxychloroquine Sulfate
711,0,d-dimer greater than 1500ng / ml,Hydroxychloroquine Sulfate
712,0,suspected cytokine release syndrome,Hydroxychloroquine Sulfate
713,0,suspected cytokine release syndrome,Hydroxychloroquine Sulfate
714,0,have read the information sheet and signed the informed consent,Hydroxychloroquine Sulfate
715,0,have read the information sheet and signed the informed consent,Hydroxychloroquine Sulfate
716,0,age 18 years and older,Hydroxychloroquine
717,0,age 18 years and older,Hydroxychloroquine
718,0,subjects must have a documented positive test for the sars-cov-2 infection within 7 days of randomization,Hydroxychloroquine
719,0,subjects must have a documented positive test for the sars-cov-2 infection within 7 days of randomization,Hydroxychloroquine
720,0,subject must be hospitalized within 72 hours of randomization,Hydroxychloroquine
721,0,subject must be hospitalized within 72 hours of randomization,Hydroxychloroquine
722,0,subjects must be receiving standard of care for sars-cov-2,Hydroxychloroquine
723,0,subjects must be receiving standard of care for sars-cov-2,Hydroxychloroquine
724,0,subject/legally authorized representative (lar) must have the ability to understand and give informed consent,Hydroxychloroquine
725,0,subject/legally authorized representative (lar) must have the ability to understand and give informed consent,Hydroxychloroquine
726,0,subject must be able to take and absorb hydroxychloroquine at the discretion of the investigator,Hydroxychloroquine
727,0,subject must be able to take and absorb hydroxychloroquine at the discretion of the investigator,Hydroxychloroquine
728,0,18 years of age or older to participate.,Apo-Hydroxychloroquine
729,0,18 years of age or older to participate.,Apo-Hydroxychloroquine
730,0,"healthcare workers with primary practice in intensive care unit, general internal medicine,",Apo-Hydroxychloroquine
731,0,"healthcare workers with primary practice in intensive care unit, general internal medicine,",Apo-Hydroxychloroquine
732,0,"covid-19 testing centres, emergency rooms, and nursing homes.",Apo-Hydroxychloroquine
733,0,"covid-19 testing centres, emergency rooms, and nursing homes.",Apo-Hydroxychloroquine
734,0,covid_19 symptom free at the time of randomization and have a negative diagnostic swab.,Apo-Hydroxychloroquine
735,0,covid_19 symptom free at the time of randomization and have a negative diagnostic swab.,Apo-Hydroxychloroquine
736,0,"patient age ≥18 years, competent to provide consent",Hydroxychloroquine
737,0,"patient age ≥18 years, competent to provide consent",Hydroxychloroquine
738,0,within 48 hours of positive nucleic acid test for sars-cov-2,Hydroxychloroquine
739,0,within 48 hours of positive nucleic acid test for sars-cov-2,Hydroxychloroquine
740,0,patients ≥18 years of age,Convalescent Plasma
741,0,hospitalized for covid-19 respiratory symptoms,Convalescent Plasma
742,0,hospitalized for less than 72 hours or within day 3 to 7 days from first signs of illness,Convalescent Plasma
743,0,laboratory confirmed covid-19,Convalescent Plasma
744,0,"on supplemental oxygen, non-invasive ventilation or high-flow oxygen",Convalescent Plasma
745,0,patients may be on other randomized controlled trials of pharmaceuticals for covid -19 and patients who meet eligibility criteria will not be excluded on this basis.,Convalescent Plasma
746,0,"-1. patients with age above 18 years and any gender with definite dx of covid19 and pneumonia in the ward according to the clinical, laboratory, and imaging criteria.",Hydroxychloroquine Sulfate
747,0,"-1. patients with age above 18 years and any gender with definite dx of covid19 and pneumonia in the ward according to the clinical, laboratory, and imaging criteria.",Hydroxychloroquine Sulfate
748,0,2. understands and agrees to comply with planned study procedures.,Hydroxychloroquine Sulfate
749,0,2. understands and agrees to comply with planned study procedures.,Hydroxychloroquine Sulfate
750,0,"men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent",Hydroxychloroquine Sulfate
751,0,"men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent",Hydroxychloroquine Sulfate
752,0,willing and able to provide informed consent,Hydroxychloroquine Sulfate
753,0,willing and able to provide informed consent,Hydroxychloroquine Sulfate
754,0,"laboratory confirmed sars-cov-2 infection, with test results within past 72 hours",Hydroxychloroquine Sulfate
755,0,"laboratory confirmed sars-cov-2 infection, with test results within past 72 hours",Hydroxychloroquine Sulfate
756,0,access to device and internet for telehealth visits,Hydroxychloroquine Sulfate
757,0,access to device and internet for telehealth visits,Hydroxychloroquine Sulfate
758,0,at increased risk of developing severe covid-19 disease (at least one of the following),Hydroxychloroquine Sulfate
759,0,at increased risk of developing severe covid-19 disease (at least one of the following),Hydroxychloroquine Sulfate
760,0,age ≥60 years,Hydroxychloroquine Sulfate
761,0,age ≥60 years,Hydroxychloroquine Sulfate
762,0,"presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema",Hydroxychloroquine Sulfate
763,0,"presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema",Hydroxychloroquine Sulfate
764,0,"diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment",Hydroxychloroquine Sulfate
765,0,"diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment",Hydroxychloroquine Sulfate
766,0,"hypertension, requiring at least 1 oral medication for treatment",Hydroxychloroquine Sulfate
767,0,"hypertension, requiring at least 1 oral medication for treatment",Hydroxychloroquine Sulfate
768,0,"immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cd4 t-cell count of <200/mm3)",Hydroxychloroquine Sulfate
769,0,"immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cd4 t-cell count of <200/mm3)",Hydroxychloroquine Sulfate
770,0,"immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies)",Hydroxychloroquine Sulfate
771,0,"immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies)",Hydroxychloroquine Sulfate
772,0,body mass index ≥30 (self-reported),Hydroxychloroquine Sulfate
773,0,body mass index ≥30 (self-reported),Hydroxychloroquine Sulfate
774,0,patients aged more than equal to 18 years.,Convalescent plasma
775,0,covid-19 confirmed by reverse transcriptase-polymerase chain reaction (rt-pcr),Convalescent plasma
776,0,having severe pneumonia.,Convalescent plasma
777,0,pao2 / fio2 <300.,Convalescent plasma
778,0,using mechanical ventilation.,Convalescent plasma
779,0,age ≥18 years,Hydroxychloroquine
780,0,age ≥18 years,Hydroxychloroquine
781,0,laboratory-confirmed severe acute respiratory syndrome- coronavirus-2 (sars-cov-2) infection by reverse transcription polymerase chain reaction (rt-pcr) or other molecular test within the past 6 days,Hydroxychloroquine
782,0,laboratory-confirmed severe acute respiratory syndrome- coronavirus-2 (sars-cov-2) infection by reverse transcription polymerase chain reaction (rt-pcr) or other molecular test within the past 6 days,Hydroxychloroquine
783,0,"current symptoms of acute respiratory infection for ≤6 days, defined as one or more of the following: cough, fever, shortness of breath, chest pain, abdominal pain, nausea/vomiting, diarrhea, body aches, weakness/fatigue, chills/sweating, headache, confusion, sore throat, runny nose/congestion, loss of taste or smell",Hydroxychloroquine
784,0,"current symptoms of acute respiratory infection for ≤6 days, defined as one or more of the following: cough, fever, shortness of breath, chest pain, abdominal pain, nausea/vomiting, diarrhea, body aches, weakness/fatigue, chills/sweating, headache, confusion, sore throat, runny nose/congestion, loss of taste or smell",Hydroxychloroquine
785,0,confirmed cases of covid-19 (all by rt-pcr from same laboratory),Hydroxychloroquine 200 Mg Oral Tablet
786,0,confirmed cases of covid-19 (all by rt-pcr from same laboratory),Hydroxychloroquine 200 Mg Oral Tablet
787,0,mild to severe clinical presentation (identified at the time of admission to ward by national early warning score news-2; mild 0-4; severe 5-6),Hydroxychloroquine 200 Mg Oral Tablet
788,0,mild to severe clinical presentation (identified at the time of admission to ward by national early warning score news-2; mild 0-4; severe 5-6),Hydroxychloroquine 200 Mg Oral Tablet
789,0,-,Convalescent Plasma Transfusion
790,0,recipient:,Convalescent Plasma Transfusion
791,0,severe covid -19 infections defined as who interim guidance and the guideline of diagnosis and treatment of covid-19 of national health commission of china (version 5.0) with confirmation by real-time rt-pcr assay with severe disease i.e. meeting any 2 of the following criteria-,Convalescent Plasma Transfusion
792,0,"respiratory distress, rr ≥30 beats/min",Convalescent Plasma Transfusion
793,0,oxygen saturation level less than 93% in resting state,Convalescent Plasma Transfusion
794,0,partial pressure of oxygen (pao2)/oxygen concentration (fio2) ≤ 300 mmhg.,Convalescent Plasma Transfusion
795,0,lung infiltrates > 50% within 24 to 48 hours,Convalescent Plasma Transfusion
796,0,"very sick (on ventilator) and patients with co-morbidities such as patients with known co-morbid diseases (copd, cad, cld, ckd, cardiopulmonary disease-structural or valvular heart disease)",Convalescent Plasma Transfusion
797,0,patient presenting with multi organ failure or requiring mechanical ventilation.,Convalescent Plasma Transfusion
798,0,donor:,Convalescent Plasma Transfusion
799,0,"known case of recovered covid-19 infection, and",Convalescent Plasma Transfusion
800,0,"complete resolution of symptoms at least 28 days prior to donation or complete resolution of symptoms at least 14 days prior to donation and negative results for covid-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from the blood, and negative rt-pcr for covid-19 on two sequential paired nasopharyngeal and throat specimens > 24 hrs apart (who-cdc guideline).",Convalescent Plasma Transfusion
801,0,"donor plasma after 2 negative tests and 2 weeks of remaining asymptomatic, without antibody titre & presence of igg/igm antibodies to covid-19 by serological as per manufacturers instructions. donors negative for these will be deferred).",Convalescent Plasma Transfusion
802,0,"fulfill all criteria of donor eligibility for donor plasmapheresis under the drugs & cosmetics act and rules 1945, amended 11.03.2020.",Convalescent Plasma Transfusion
803,0,"male or female, aged >= 18 years",Hydroxychloroquine
804,0,"male or female, aged >= 18 years",Hydroxychloroquine
805,0,"sars-cov-2-exposed subjects, as household members and/or contacts of covid-19 patients (group 1). in this group are included health care professionals in contact with covid-19 patients.",Hydroxychloroquine
806,0,"sars-cov-2-exposed subjects, as household members and/or contacts of covid-19 patients (group 1). in this group are included health care professionals in contact with covid-19 patients.",Hydroxychloroquine
807,0,or,Hydroxychloroquine
808,0,or,Hydroxychloroquine
809,0,"covid-19 patients, asymptomatic or paucisymptomatic in home situation who are not in treatment with any anti covid-19 medication (group 2)",Hydroxychloroquine
810,0,"covid-19 patients, asymptomatic or paucisymptomatic in home situation who are not in treatment with any anti covid-19 medication (group 2)",Hydroxychloroquine
811,0,"absence of any covid-19 symptom in last week before randomization (fever >37.5°c, cough, dyspnea) (only for group 1 subjects)",Hydroxychloroquine
812,0,"absence of any covid-19 symptom in last week before randomization (fever >37.5°c, cough, dyspnea) (only for group 1 subjects)",Hydroxychloroquine
813,0,paracetamol treatment is accepted only for group 2.,Hydroxychloroquine
814,0,paracetamol treatment is accepted only for group 2.,Hydroxychloroquine
815,0,participant is willing and able to give informed consent for participation in the study (either recorded during a telephonic interview or signed in person) and agrees with the study and its conduct.,Hydroxychloroquine
816,0,participant is willing and able to give informed consent for participation in the study (either recorded during a telephonic interview or signed in person) and agrees with the study and its conduct.,Hydroxychloroquine
817,0,- a healthcare worker at high risk for covid-19 exposure (defined below):,Hydroxychloroquine
818,0,- a healthcare worker at high risk for covid-19 exposure (defined below):,Hydroxychloroquine
819,0,"persons primarily working in emergency departments (physicians, nurses, ancillary staff, triage personnel)",Hydroxychloroquine
820,0,"persons primarily working in emergency departments (physicians, nurses, ancillary staff, triage personnel)",Hydroxychloroquine
821,0,"persons primarily working in intensive care units (physicians, nurses, ancillary staff, respiratory therapists)",Hydroxychloroquine
822,0,"persons primarily working in intensive care units (physicians, nurses, ancillary staff, respiratory therapists)",Hydroxychloroquine
823,0,"persons performing aerosol generating procedures (i.e. anesthesiologists, nurse anesthetists (crnas)",Hydroxychloroquine
824,0,"persons performing aerosol generating procedures (i.e. anesthesiologists, nurse anesthetists (crnas)",Hydroxychloroquine
825,0,"first responders (i.e. emts, paramedics)",Hydroxychloroquine
826,0,"first responders (i.e. emts, paramedics)",Hydroxychloroquine
827,0,symptomatic with covid illness (either rt-pcr test confirmed or highly suspect clinical symptoms),Hydroxychloroquine
828,0,symptomatic with covid illness (either rt-pcr test confirmed or highly suspect clinical symptoms),Hydroxychloroquine
829,0,call into office within the first 7 days of illness,Hydroxychloroquine
830,0,call into office within the first 7 days of illness,Hydroxychloroquine
831,0,have any of the following high risk conditions:,Hydroxychloroquine
832,0,have any of the following high risk conditions:,Hydroxychloroquine
833,0,age >60,Hydroxychloroquine
834,0,age >60,Hydroxychloroquine
835,0,"htn, cad, or chronic heart disease",Hydroxychloroquine
836,0,"htn, cad, or chronic heart disease",Hydroxychloroquine
837,0,diabetes,Hydroxychloroquine
838,0,diabetes,Hydroxychloroquine
839,0,chronic kidney disease,Hydroxychloroquine
840,0,chronic kidney disease,Hydroxychloroquine
841,0,chronic lung disease,Hydroxychloroquine
842,0,chronic lung disease,Hydroxychloroquine
843,0,active or recent chemotherapy for malignancy,Hydroxychloroquine
844,0,active or recent chemotherapy for malignancy,Hydroxychloroquine
845,0,organ transplant,Hydroxychloroquine
846,0,organ transplant,Hydroxychloroquine
847,0,taking immune-suppressing medications,Hydroxychloroquine
848,0,taking immune-suppressing medications,Hydroxychloroquine
849,0,hiv with cd4 <200 cells/mm3,Hydroxychloroquine
850,0,hiv with cd4 <200 cells/mm3,Hydroxychloroquine
851,0,experiencing at least one of the following high risk symptoms:,Hydroxychloroquine
852,0,experiencing at least one of the following high risk symptoms:,Hydroxychloroquine
853,0,severe cough,Hydroxychloroquine
854,0,severe cough,Hydroxychloroquine
855,0,fever 100.0f or greater,Hydroxychloroquine
856,0,fever 100.0f or greater,Hydroxychloroquine
857,0,diarrhea,Hydroxychloroquine
858,0,diarrhea,Hydroxychloroquine
859,0,shortness of breath,Hydroxychloroquine
860,0,shortness of breath,Hydroxychloroquine
861,0,hypoxia,Hydroxychloroquine
862,0,hypoxia,Hydroxychloroquine
863,0,age > 18 years,hydroxychloroquine
864,0,age > 18 years,hydroxychloroquine
865,0,nasopharyngeal swab positive for covid-19,hydroxychloroquine
866,0,nasopharyngeal swab positive for covid-19,hydroxychloroquine
867,0,covid-19 stages i - ii - iii (*1),hydroxychloroquine
868,0,covid-19 stages i - ii - iii (*1),hydroxychloroquine
869,0,hospitalization in the department of infectious diseases,hydroxychloroquine
870,0,hospitalization in the department of infectious diseases,hydroxychloroquine
871,0,"i1. age 18 or older at the time of enrolment. i2. histologically or cytologically confirmed diagnosis of advanced or metastatic hematological or solid tumor (hematological or solid tumor, any type and any localization).",Chloroquine analog (GNS651)
872,0,"i3. documented diagnosis of covid-19 (diagnostic test performed in a certified laboratory) or symptoms of covid-19 associated with radiological signs of pneumonia as described by shi et al.; i4. cohort 2: patients with pneumonia confirmed by chest imaging, and an oxygen saturation (sao2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (pao2) to the fraction of inspired oxygen (fio2) (pao2:fio2) at or below 300 mg hg.",Chloroquine analog (GNS651)
873,0,i5. patient not eligible for a transfer to resuscitation unit (either due to underlying medical condition - including cancer - or due to lack of available bed).,Chloroquine analog (GNS651)
874,0,i6. life-expectancy longer than 3 months.,Chloroquine analog (GNS651)
875,0,i7. adequate bone marrow and end-organ function defined by the following laboratory results:,Chloroquine analog (GNS651)
876,0,bone marrow:,Chloroquine analog (GNS651)
877,0,"hemoglobin ≥ 7.0 g/dl,",Chloroquine analog (GNS651)
878,0,"absolute neutrophils count (anc) ≥ 1.0 gi/l,",Chloroquine analog (GNS651)
879,0,platelets ≥ 100 gi/l;,Chloroquine analog (GNS651)
880,0,hepatic function:,Chloroquine analog (GNS651)
881,0,"total serum bilirubin ≤ 1.5 x uln (except patients with gilbert's syndrome who must have total serum bilirubin ≤ 3.0 x uln),",Chloroquine analog (GNS651)
882,0,ast and alt ≤ 5 uln,Chloroquine analog (GNS651)
883,0,renal function:,Chloroquine analog (GNS651)
884,0,"serum creatinine ≤ 2.0 x uln or cr. cl. ≥ 30ml/min/1.73m² (mdrd or ckd-epi formula); i8. willingness and ability to comply with the study requirements; i9. signed and dated informed consent indicating that the patient has been informed of all the aspects of the trial prior to enrolment (in case of emergency situation, please refer to protocol section 13.1 patient information and informed consent); i10. women of childbearing potential (appendix 2) are required to have a negative serum pregnancy test within 72 hours prior to study treatment start. a positive urine test must be confirmed by a serum pregnancy test; i11. women of childbearing potential and male patients must agree to use adequate highly effective contraception (appendix 2) for the duration of study participation and up to 6 months following completion of therapy; i12. patient must be covered by a medical insurance.",Chloroquine analog (GNS651)
885,0,"age ≥18 years,",Chloroquine
886,0,employment by new york presbyterian hospital,Chloroquine
887,0,clear assignment to areas of the hospital that involve patient contact and possible exposures for at least 2 days a week >/= 8 hours a day,Chloroquine
888,0,"suspected cases of covid-19, due to clinical and radiological data, during the epidemic;",Chloroquine Diphosphate
889,0,"adult aged 18 or over, at the time of inclusion",Chloroquine Diphosphate
890,0,"not having severe acute respiratory syndrome (sars), that is, not using mechanical ventilation or supplemental oxygen, peripheral oxygen saturation> 94% in room air, and having a respiratory rate below 24 incursions per minute.",Chloroquine Diphosphate
891,0,"patients with comorbidities only, due to the increased risk of developing sars",Chloroquine Diphosphate
892,0,plasma donation:,Convalescent Plasma 1 Unit
893,0,plasma donation:,Convalescent Plasma 2 Units
894,0,prior diagnosis of covid-19 documented by a laboratory test,Convalescent Plasma 1 Unit
895,0,prior diagnosis of covid-19 documented by a laboratory test,Convalescent Plasma 2 Units
896,0,abbott realtime sars-cov-2 real-time reverse transcription polymerase chain reaction (rrt-pcr) test on the abbott m2000 system (inpatient wvu testing),Convalescent Plasma 1 Unit
897,0,abbott realtime sars-cov-2 real-time reverse transcription polymerase chain reaction (rrt-pcr) test on the abbott m2000 system (inpatient wvu testing),Convalescent Plasma 2 Units
898,0,other testing methods and vendors using fda approved detection methods of sars-cov-2 under the emergency use authorization (eua),Convalescent Plasma 1 Unit
899,0,other testing methods and vendors using fda approved detection methods of sars-cov-2 under the emergency use authorization (eua),Convalescent Plasma 2 Units
900,0,complete resolution of symptoms at least 28 days prior to donation,Convalescent Plasma 1 Unit
901,0,complete resolution of symptoms at least 28 days prior to donation,Convalescent Plasma 2 Units
902,0,complete resolution of symptoms for at least 14 days with negative repeat covid-19 testing approved by the fda eua,Convalescent Plasma 1 Unit
903,0,complete resolution of symptoms for at least 14 days with negative repeat covid-19 testing approved by the fda eua,Convalescent Plasma 2 Units
904,0,female donors age 18+ that have never been pregnant or negative for hla antibodies,Convalescent Plasma 1 Unit
905,0,female donors age 18+ that have never been pregnant or negative for hla antibodies,Convalescent Plasma 2 Units
906,0,male donors age 18+,Convalescent Plasma 1 Unit
907,0,male donors age 18+,Convalescent Plasma 2 Units
908,0,negative results for covid-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood. a partial list of available tests can be accessed at https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.,Convalescent Plasma 1 Unit
909,0,negative results for covid-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood. a partial list of available tests can be accessed at https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.,Convalescent Plasma 2 Units
910,0,"defined sars-cov-2 neutralizing antibody titers, if testing can be conducted (e.g., of at least 1:1602, 1:360 up to 1:640 is preferred. in shortage case 1:80 is acceptable)",Convalescent Plasma 1 Unit
911,0,"defined sars-cov-2 neutralizing antibody titers, if testing can be conducted (e.g., of at least 1:1602, 1:360 up to 1:640 is preferred. in shortage case 1:80 is acceptable)",Convalescent Plasma 2 Units
912,0,at least or greater than 50kg of weight,Convalescent Plasma 1 Unit
913,0,at least or greater than 50kg of weight,Convalescent Plasma 2 Units
914,0,plasma recipients:,Convalescent Plasma 1 Unit
915,0,plasma recipients:,Convalescent Plasma 2 Units
916,0,"individuals of any age above 30 days of life, sex, or pregnancy status suffering from confirmed covid19 and in rapid progression, severe or critical condition meeting the fda ind guidelines.",Convalescent Plasma 1 Unit
917,0,"individuals of any age above 30 days of life, sex, or pregnancy status suffering from confirmed covid19 and in rapid progression, severe or critical condition meeting the fda ind guidelines.",Convalescent Plasma 2 Units
918,0,must have laboratory confirmed covid19,Convalescent Plasma 1 Unit
919,0,must have laboratory confirmed covid19,Convalescent Plasma 2 Units
920,0,must have severe or immediately life-threatening covid19,Convalescent Plasma 1 Unit
921,0,must have severe or immediately life-threatening covid19,Convalescent Plasma 2 Units
922,0,must provide informed consent/assent,Convalescent Plasma 1 Unit
923,0,must provide informed consent/assent,Convalescent Plasma 2 Units
924,0,hospitalization for management of sars cov-2 infection,Hydroxychloroquine Sulfate
925,0,hospitalization for management of sars cov-2 infection,Hydroxychloroquine Sulfate
926,0,hospitalization for management of sars cov-2 infection,Chloroquine Sulfate
927,0,positive sars cov-2 test,Hydroxychloroquine Sulfate
928,0,positive sars cov-2 test,Hydroxychloroquine Sulfate
929,0,positive sars cov-2 test,Chloroquine Sulfate
930,0,age >=18 years,Hydroxychloroquine Sulfate
931,0,age >=18 years,Hydroxychloroquine Sulfate
932,0,age >=18 years,Chloroquine Sulfate
933,0,provision of informed consent,Hydroxychloroquine Sulfate
934,0,provision of informed consent,Hydroxychloroquine Sulfate
935,0,provision of informed consent,Chloroquine Sulfate
936,0,electrocardiogram (ecg) ≤48 hours prior to enrollment,Hydroxychloroquine Sulfate
937,0,electrocardiogram (ecg) ≤48 hours prior to enrollment,Hydroxychloroquine Sulfate
938,0,electrocardiogram (ecg) ≤48 hours prior to enrollment,Chloroquine Sulfate
939,0,"complete blood count, glucose-6 phosphate-dehydrogenase (g6pd), comprehensive metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.",Hydroxychloroquine Sulfate
940,0,"complete blood count, glucose-6 phosphate-dehydrogenase (g6pd), comprehensive metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.",Hydroxychloroquine Sulfate
941,0,"complete blood count, glucose-6 phosphate-dehydrogenase (g6pd), comprehensive metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.",Chloroquine Sulfate
942,0,"if participating in sexual activity that could lead to pregnancy, individuals of reproductive potential who can become pregnant must agree to use contraception throughout the study. at least one of the following must be used throughout the study:",Hydroxychloroquine Sulfate
943,0,"if participating in sexual activity that could lead to pregnancy, individuals of reproductive potential who can become pregnant must agree to use contraception throughout the study. at least one of the following must be used throughout the study:",Hydroxychloroquine Sulfate
944,0,"if participating in sexual activity that could lead to pregnancy, individuals of reproductive potential who can become pregnant must agree to use contraception throughout the study. at least one of the following must be used throughout the study:",Chloroquine Sulfate
945,0,condom (male or female) with or without spermicide,Hydroxychloroquine Sulfate
946,0,condom (male or female) with or without spermicide,Hydroxychloroquine Sulfate
947,0,condom (male or female) with or without spermicide,Chloroquine Sulfate
948,0,diaphragm or cervical cap with spermicide,Hydroxychloroquine Sulfate
949,0,diaphragm or cervical cap with spermicide,Hydroxychloroquine Sulfate
950,0,diaphragm or cervical cap with spermicide,Chloroquine Sulfate
951,0,intrauterine device (iud),Hydroxychloroquine Sulfate
952,0,intrauterine device (iud),Hydroxychloroquine Sulfate
953,0,intrauterine device (iud),Chloroquine Sulfate
954,0,hormone-based contraceptive,Hydroxychloroquine Sulfate
955,0,hormone-based contraceptive,Hydroxychloroquine Sulfate
956,0,hormone-based contraceptive,Chloroquine Sulfate
957,1,female subjects who are pregnant or breastfeeding.,Hydroxychloroquine
958,1,female subjects who are pregnant or breastfeeding.,Hydroxychloroquine
959,1,patients with prior allergic reactions to transfusions.,Hydroxychloroquine
960,1,patients with prior allergic reactions to transfusions.,Hydroxychloroquine
961,1,critical ill patients in intensive care units.,Hydroxychloroquine
962,1,critical ill patients in intensive care units.,Hydroxychloroquine
963,1,patients with surgical procedures in the last 30 days.,Hydroxychloroquine
964,1,patients with surgical procedures in the last 30 days.,Hydroxychloroquine
965,1,patients with active treatment for cancer (radiotherapy or chemotherapy).,Hydroxychloroquine
966,1,patients with active treatment for cancer (radiotherapy or chemotherapy).,Hydroxychloroquine
967,1,"hiv diagnosed patients with viral failure (detectable viral load> 1000 copies / ml persistent, two consecutive viral load measurements within a 3 month interval, with medication adherence between measurements after at least 6 months of starting a new regimen antiretrovirals).",Hydroxychloroquine
968,1,"hiv diagnosed patients with viral failure (detectable viral load> 1000 copies / ml persistent, two consecutive viral load measurements within a 3 month interval, with medication adherence between measurements after at least 6 months of starting a new regimen antiretrovirals).",Hydroxychloroquine
969,1,patients who have suspicion or evidence of coinfections.,Hydroxychloroquine
970,1,patients who have suspicion or evidence of coinfections.,Hydroxychloroquine
971,1,end-stage chronic kidney disease (glomerular filtration rate <15 ml / min / 1.73 m2).,Hydroxychloroquine
972,1,end-stage chronic kidney disease (glomerular filtration rate <15 ml / min / 1.73 m2).,Hydroxychloroquine
973,1,child pugh c stage liver cirrhosis.,Hydroxychloroquine
974,1,child pugh c stage liver cirrhosis.,Hydroxychloroquine
975,1,high cardiac output diseases.,Hydroxychloroquine
976,1,high cardiac output diseases.,Hydroxychloroquine
977,1,autoimmune diseases or immunoglobulin a nephropathy.,Hydroxychloroquine
978,1,autoimmune diseases or immunoglobulin a nephropathy.,Hydroxychloroquine
979,1,patients have any condition that in the judgement of the investigators would make the subject inappropriate for entry into this study.,Hydroxychloroquine
980,1,patients have any condition that in the judgement of the investigators would make the subject inappropriate for entry into this study.,Hydroxychloroquine
981,1,does not meet inclusion criteria.,Hydroxychloroquine - Daily Dosing
982,1,does not meet inclusion criteria.,Hydroxychloroquine - Weekly Dosing
983,1,does not meet inclusion criteria.,Hydroxychloroquine - Daily Dosing
984,1,does not meet inclusion criteria.,Hydroxychloroquine - Weekly Dosing
985,1,participant unable or unwilling to provide informed consent.,Hydroxychloroquine - Daily Dosing
986,1,participant unable or unwilling to provide informed consent.,Hydroxychloroquine - Weekly Dosing
987,1,participant unable or unwilling to provide informed consent.,Hydroxychloroquine - Daily Dosing
988,1,participant unable or unwilling to provide informed consent.,Hydroxychloroquine - Weekly Dosing
989,1,participant has any of the symptoms above or screens positive for possible covid-19 disease.,Hydroxychloroquine - Daily Dosing
990,1,participant has any of the symptoms above or screens positive for possible covid-19 disease.,Hydroxychloroquine - Weekly Dosing
991,1,participant has any of the symptoms above or screens positive for possible covid-19 disease.,Hydroxychloroquine - Daily Dosing
992,1,participant has any of the symptoms above or screens positive for possible covid-19 disease.,Hydroxychloroquine - Weekly Dosing
993,1,participant is currently enrolled in a study to evaluate an investigational drug.,Hydroxychloroquine - Daily Dosing
994,1,participant is currently enrolled in a study to evaluate an investigational drug.,Hydroxychloroquine - Weekly Dosing
995,1,participant is currently enrolled in a study to evaluate an investigational drug.,Hydroxychloroquine - Daily Dosing
996,1,participant is currently enrolled in a study to evaluate an investigational drug.,Hydroxychloroquine - Weekly Dosing
997,1,vulnerable populations deemed inappropriate for study by the site principal investigator.,Hydroxychloroquine - Daily Dosing
998,1,vulnerable populations deemed inappropriate for study by the site principal investigator.,Hydroxychloroquine - Weekly Dosing
999,1,vulnerable populations deemed inappropriate for study by the site principal investigator.,Hydroxychloroquine - Daily Dosing
1000,1,vulnerable populations deemed inappropriate for study by the site principal investigator.,Hydroxychloroquine - Weekly Dosing
1001,1,"the participant has a known allergy/hypersensitivity or has a medication or co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or renal failure) that prevents the use of hcq (see pharmacy section).",Hydroxychloroquine - Daily Dosing
1002,1,"the participant has a known allergy/hypersensitivity or has a medication or co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or renal failure) that prevents the use of hcq (see pharmacy section).",Hydroxychloroquine - Weekly Dosing
1003,1,"the participant has a known allergy/hypersensitivity or has a medication or co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or renal failure) that prevents the use of hcq (see pharmacy section).",Hydroxychloroquine - Daily Dosing
1004,1,"the participant has a known allergy/hypersensitivity or has a medication or co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or renal failure) that prevents the use of hcq (see pharmacy section).",Hydroxychloroquine - Weekly Dosing
1005,1,the participant is a woman of childbearing age whose pregnancy status is unknown and is not willing to use 2 methods of contraception.,Hydroxychloroquine - Daily Dosing
1006,1,the participant is a woman of childbearing age whose pregnancy status is unknown and is not willing to use 2 methods of contraception.,Hydroxychloroquine - Weekly Dosing
1007,1,the participant is a woman of childbearing age whose pregnancy status is unknown and is not willing to use 2 methods of contraception.,Hydroxychloroquine - Daily Dosing
1008,1,the participant is a woman of childbearing age whose pregnancy status is unknown and is not willing to use 2 methods of contraception.,Hydroxychloroquine - Weekly Dosing
1009,1,the participant is pregnant or nursing.,Hydroxychloroquine - Daily Dosing
1010,1,the participant is pregnant or nursing.,Hydroxychloroquine - Weekly Dosing
1011,1,the participant is pregnant or nursing.,Hydroxychloroquine - Daily Dosing
1012,1,the participant is pregnant or nursing.,Hydroxychloroquine - Weekly Dosing
1013,1,the participant was diagnosed with retinopathy prior to study entry.,Hydroxychloroquine - Daily Dosing
1014,1,the participant was diagnosed with retinopathy prior to study entry.,Hydroxychloroquine - Weekly Dosing
1015,1,the participant was diagnosed with retinopathy prior to study entry.,Hydroxychloroquine - Daily Dosing
1016,1,the participant was diagnosed with retinopathy prior to study entry.,Hydroxychloroquine - Weekly Dosing
1017,1,the participant has a diagnosis of porphyria prior to study entry.,Hydroxychloroquine - Daily Dosing
1018,1,the participant has a diagnosis of porphyria prior to study entry.,Hydroxychloroquine - Weekly Dosing
1019,1,the participant has a diagnosis of porphyria prior to study entry.,Hydroxychloroquine - Daily Dosing
1020,1,the participant has a diagnosis of porphyria prior to study entry.,Hydroxychloroquine - Weekly Dosing
1021,1,"the participant has renal failure with a creatinine clearance of <10 ml/min, pre-dialysis or requiring dialysis.",Hydroxychloroquine - Daily Dosing
1022,1,"the participant has renal failure with a creatinine clearance of <10 ml/min, pre-dialysis or requiring dialysis.",Hydroxychloroquine - Weekly Dosing
1023,1,"the participant has renal failure with a creatinine clearance of <10 ml/min, pre-dialysis or requiring dialysis.",Hydroxychloroquine - Daily Dosing
1024,1,"the participant has renal failure with a creatinine clearance of <10 ml/min, pre-dialysis or requiring dialysis.",Hydroxychloroquine - Weekly Dosing
1025,1,the participant has a family history of sudden cardiac death.,Hydroxychloroquine - Daily Dosing
1026,1,the participant has a family history of sudden cardiac death.,Hydroxychloroquine - Weekly Dosing
1027,1,the participant has a family history of sudden cardiac death.,Hydroxychloroquine - Daily Dosing
1028,1,the participant has a family history of sudden cardiac death.,Hydroxychloroquine - Weekly Dosing
1029,1,the participant is currently on diuretic therapy.,Hydroxychloroquine - Daily Dosing
1030,1,the participant is currently on diuretic therapy.,Hydroxychloroquine - Weekly Dosing
1031,1,the participant is currently on diuretic therapy.,Hydroxychloroquine - Daily Dosing
1032,1,the participant is currently on diuretic therapy.,Hydroxychloroquine - Weekly Dosing
1033,1,the participant has a history of known prolonged qt syndrome.,Hydroxychloroquine - Daily Dosing
1034,1,the participant has a history of known prolonged qt syndrome.,Hydroxychloroquine - Weekly Dosing
1035,1,the participant has a history of known prolonged qt syndrome.,Hydroxychloroquine - Daily Dosing
1036,1,the participant has a history of known prolonged qt syndrome.,Hydroxychloroquine - Weekly Dosing
1037,1,"the participant is already taking any of the following medications: abiraterone acetate, agalsidase, amodiaquine, azithromycin, conivaptan, dabrafenib, dacomitinib, dapsone (systemic), digoxin, enzalutamide, fusidic acid (systemic), idelalisib, lanthanum, lumefantrine, mefloquine, mifepristone, mitotane, pimozide, qt-prolonging agents, stiripentol).",Hydroxychloroquine - Daily Dosing
1038,1,"the participant is already taking any of the following medications: abiraterone acetate, agalsidase, amodiaquine, azithromycin, conivaptan, dabrafenib, dacomitinib, dapsone (systemic), digoxin, enzalutamide, fusidic acid (systemic), idelalisib, lanthanum, lumefantrine, mefloquine, mifepristone, mitotane, pimozide, qt-prolonging agents, stiripentol).",Hydroxychloroquine - Weekly Dosing
1039,1,"the participant is already taking any of the following medications: abiraterone acetate, agalsidase, amodiaquine, azithromycin, conivaptan, dabrafenib, dacomitinib, dapsone (systemic), digoxin, enzalutamide, fusidic acid (systemic), idelalisib, lanthanum, lumefantrine, mefloquine, mifepristone, mitotane, pimozide, qt-prolonging agents, stiripentol).",Hydroxychloroquine - Daily Dosing
1040,1,"the participant is already taking any of the following medications: abiraterone acetate, agalsidase, amodiaquine, azithromycin, conivaptan, dabrafenib, dacomitinib, dapsone (systemic), digoxin, enzalutamide, fusidic acid (systemic), idelalisib, lanthanum, lumefantrine, mefloquine, mifepristone, mitotane, pimozide, qt-prolonging agents, stiripentol).",Hydroxychloroquine - Weekly Dosing
1041,1,"contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products).",Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1042,1,"in the opinion of the site investigator or primary clinical care team, anticipated to die within 48 hours.",Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1043,1,"acute or chronic disease/illness that, in the opinion of the site investigator, has an expected life expectancy of less than 28 days unrelated to covid-19 induced pneumonia (e.g.; stage iv malignancy, neurodegenerative disease, anoxic brain injury, etc.)",Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1044,1,use of home oxygen at baseline,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1045,1,use of home mechanical ventilation at baseline (cpap or bipap without need for oxygen is not an exclusion),Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1046,1,respiratory failure caused by illness other than sars-cov-2,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1047,1,other documented uncontrolled infection.,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1048,1,more than 72 hours have elapsed since first meeting inclusion criteria,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1049,1,"severe dic, ttp, or antithrombin iii deficiency needing factor replacement, ffp, cryoprecipitate.",Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1050,1,patient is on warfarin and it is deemed necessary to maintain therapeutic inr (because the cp will reverse the warfarin effect).,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1051,1,on dialysis at the time enrollment is considered.,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1052,1,active intracranial bleeding.,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1053,1,clinically significant myocardial ischemia.,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1054,1,prisoner or incarceration,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1055,1,pregnancy or active breast feeding,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1056,1,has already received convalescent plasma for covid-19 infection during current admission,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1057,1,current participation in another interventional research study,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1058,1,inability or unwillingness of subject or legal surrogate/representative to give written informed consent,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
1059,1,"contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator.",COVID-19 Convalescent Plasma
1060,1,clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than covid-19,COVID-19 Convalescent Plasma
1061,1,"receipt of other investigational therapy as a part of another clinical trial. note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.",COVID-19 Convalescent Plasma
1062,1,known to be allergic to research drugs or drug excipients,Hydroxychloroquine
1063,1,known to be allergic to research drugs or drug excipients,Hydroxychloroquine
1064,1,incapable of providing informed consent,Hydroxychloroquine
1065,1,incapable of providing informed consent,Hydroxychloroquine
1066,1,participation in any other clinical trial of an experimental treatment for sars-cov2 infection,Hydroxychloroquine
1067,1,participation in any other clinical trial of an experimental treatment for sars-cov2 infection,Hydroxychloroquine
1068,1,"pregnancy, possible pregnancy or breast feeding",Hydroxychloroquine
1069,1,"pregnancy, possible pregnancy or breast feeding",Hydroxychloroquine
1070,1,prolonged qt interval (>450),Hydroxychloroquine
1071,1,prolonged qt interval (>450),Hydroxychloroquine
1072,1,moderate to severe symptoms of sars-cov2,Hydroxychloroquine
1073,1,moderate to severe symptoms of sars-cov2,Hydroxychloroquine
1074,1,renal failure,Hydroxychloroquine
1075,1,renal failure,Hydroxychloroquine
1076,1,hepatic failure,Hydroxychloroquine
1077,1,hepatic failure,Hydroxychloroquine
1078,1,nsaid use,Hydroxychloroquine
1079,1,nsaid use,Hydroxychloroquine
1080,1,known allergy to plasma,Convalescent Plasma from COVID-19 donors
1081,1,severe multiple organic failure,Convalescent Plasma from COVID-19 donors
1082,1,active intra brain hemorrhage,Convalescent Plasma from COVID-19 donors
1083,1,disseminated intravascular coagulation with blood products requirements,Convalescent Plasma from COVID-19 donors
1084,1,patient with an adult respiratory distress longer than 10 days,Convalescent Plasma from COVID-19 donors
1085,1,patients with active cancer and life expectancy shorter than 12 months according with medical criteria,Convalescent Plasma from COVID-19 donors
1086,1,age < 65,COVID-19 Convalescent Plasma
1087,1,pao2/fio2 < 300 mmhg,COVID-19 Convalescent Plasma
1088,1,pending cardiopulmonary arrest,COVID-19 Convalescent Plasma
1089,1,refusal to blood product transfusions,COVID-19 Convalescent Plasma
1090,1,severe iga deficiency,COVID-19 Convalescent Plasma
1091,1,"any life-threatening comorbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion",COVID-19 Convalescent Plasma
1092,1,"contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator.",COVID-19 Convalescent Plasma
1093,1,clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than covid-19,COVID-19 Convalescent Plasma
1094,1,receipt of other investigational therapy for the treatment of the covid-19 as a part of another clinical trial or prior enrollment into pennccp-02.,COVID-19 Convalescent Plasma
1095,1,fcbp with positive pregnancy test (mandatory),anti-SARS-CoV-2 convalescent plasma
1096,1,breastfeeding females,anti-SARS-CoV-2 convalescent plasma
1097,1,receipt of pooled immunoglobulin (e.g. ivig or other hyperimmune globulin products) in past 14 days. this does not apply to monoclonal antibodies .,anti-SARS-CoV-2 convalescent plasma
1098,1,mechanical ventilation for > 14 days,anti-SARS-CoV-2 convalescent plasma
1099,1,days from symptom onset >21 days,anti-SARS-CoV-2 convalescent plasma
1100,1,expected survival < 72 hours,anti-SARS-CoV-2 convalescent plasma
1101,1,contraindication to transfusion or history of prior reactions to transfusion blood products including any proven history of trali,anti-SARS-CoV-2 convalescent plasma
1102,1,patients who were previously admitted to icu cannot be enrolled in the non-icu cohort. these patients could need icu level care subsequently and at that time point could be considered for icu cohort .,anti-SARS-CoV-2 convalescent plasma
1103,1,"i. history of liver failure ii. history of stage 4 severe chronic kidney disease or requiring dialysis iii. self-reported pregnant or breast feeding. iv. allergy to hydroxychloroquine or choloroquine v. known contraindication to hydroxychloroquine, including retinopathy, g6pd deficiency, qt prolongation",Hydroxychloroquine
1104,1,"i. history of liver failure ii. history of stage 4 severe chronic kidney disease or requiring dialysis iii. self-reported pregnant or breast feeding. iv. allergy to hydroxychloroquine or choloroquine v. known contraindication to hydroxychloroquine, including retinopathy, g6pd deficiency, qt prolongation",Hydroxychloroquine
1105,1,no matching plasma donor (exact matching in both the abo system is required),SARS-CoV-2 convalescent plasma
1106,1,unavailability of plasma,SARS-CoV-2 convalescent plasma
1107,1,significant growth of alternative lower airway pathogen such as streptococcus pneumoniae or haemophilus influenzae in sputum,SARS-CoV-2 convalescent plasma
1108,1,estimated glomerular filtration rate <60 (kidney failure stage iii or more),SARS-CoV-2 convalescent plasma
1109,1,pregnancy (urinary-hcg),SARS-CoV-2 convalescent plasma
1110,1,breast feeding,SARS-CoV-2 convalescent plasma
1111,1,history of severe allergic reactions to foods or other substances that the donor may have been exposed to (for example severe peanut allergy),SARS-CoV-2 convalescent plasma
1112,1,inability to give informed consent,SARS-CoV-2 convalescent plasma
1113,1,age < 18 years,Hydroxychloroquine
1114,1,age < 18 years,Hydroxychloroquine
1115,1,"history of ventricular arrhythmia or use of class ia, ic and iii anti-arrhythmics",Hydroxychloroquine
1116,1,"history of ventricular arrhythmia or use of class ia, ic and iii anti-arrhythmics",Hydroxychloroquine
1117,1,known prolonged qtc interval,Hydroxychloroquine
1118,1,known prolonged qtc interval,Hydroxychloroquine
1119,1,history of retinal disease,Hydroxychloroquine
1120,1,history of retinal disease,Hydroxychloroquine
1121,1,kidney failure with gfr <10%,Hydroxychloroquine
1122,1,kidney failure with gfr <10%,Hydroxychloroquine
1123,1,chronic hepatic disease w/ child-pugh class b or c,Hydroxychloroquine
1124,1,chronic hepatic disease w/ child-pugh class b or c,Hydroxychloroquine
1125,1,hypersensitivity to chloroquine or hydroxychloroquine,Hydroxychloroquine
1126,1,hypersensitivity to chloroquine or hydroxychloroquine,Hydroxychloroquine
1127,1,currently taking chloroquine or hydroxychloroquine,Hydroxychloroquine
1128,1,currently taking chloroquine or hydroxychloroquine,Hydroxychloroquine
1129,1,unwilling to participate,Hydroxychloroquine
1130,1,unwilling to participate,Hydroxychloroquine
1131,1,unable to understand and/or sign the informed consent form.,Hydroxychloroquine
1132,1,unable to understand and/or sign the informed consent form.,Hydroxychloroquine
1133,1,receipt of pooled immunoglobulin in past 30 days,Convalescent Plasma
1134,1,contraindication to transfusion or history of prior reactions to transfusion blood products,Convalescent Plasma
1135,1,prisoner,pathogen reduced SARS-CoV-2 convalescent plasma
1136,1,unable to randomize within 14 days after onset of acute respiratory infection symptoms,pathogen reduced SARS-CoV-2 convalescent plasma
1137,1,unable to randomize within 48 hours after hospital arrival,pathogen reduced SARS-CoV-2 convalescent plasma
1138,1,inability to be contacted on day 29-36 for clinical outcome assessment,pathogen reduced SARS-CoV-2 convalescent plasma
1139,1,receipt of pooled immunoglobulin in the past 30 days,pathogen reduced SARS-CoV-2 convalescent plasma
1140,1,contraindications to transfusion or history of prior reactions to transfusion blood products,pathogen reduced SARS-CoV-2 convalescent plasma
1141,1,previous enrollment in this trial,pathogen reduced SARS-CoV-2 convalescent plasma
1142,1,group b: sars-cov-2 pcr positive but asymptomatic or mild symptoms at screening,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1143,1,receipt of any blood product in past 120 days.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1144,1,"psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance.",Convalescent Plasma (anti-SARS-CoV-2 plasma)
1145,1,confirmed or self-reported presumed covid-19 at least one week before index case first became ill with covid-19.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1146,1,symptoms consistent with covid--‐19 infection that are more than mild (as defined above) at time of screening. subjects who report fever (tmax > 100.4 f) are not eligible for enrollment.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1147,1,symptoms that have worsened in the period between screening and enrollment such that the subject is deemed to be medical unstable on the day of planned enrollment.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1148,1,history of allergic reaction to transfusion blood products,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1149,1,inability to complete infusion of the product within 48 hours after randomization.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1150,1,pregnancy (or planning for pregnancy in next three months) or breastfeeding.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1151,1,resident of a long term or skilled nursing facility,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1152,1,known prior diagnosis of immunoglobulin a (iga) deficiency,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1153,1,oxygen saturation that is < 95% at the screening visit,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1154,1,participation in another clinical trial of anti-viral agent(s) for covid-19,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1155,1,group c: sars-cov-2 pcr negative (uninfected) at time of screening,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1156,1,receipt any blood product in past 120 days.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1157,1,"psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principle investigator, would affect subject safety and/or compliance.",Convalescent Plasma (anti-SARS-CoV-2 plasma)
1158,1,confirmed or self-reported presumed covid-19 at least one week before index case first became ill with covid-19.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1159,1,symptoms consistent with severe covid-19 infection that are more than mild (as defined above) at time of screening. subjects who report fever (tmax > 100.4 f) are not eligible for enrollment.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1160,1,symptoms that have worsened in the period between screening and enrollment such that the subject is deemed to be medically unstable on the day of planned enrollment.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1161,1,laboratory evidence of sars-cov-2 infection (i.e. rt-pcr) at time of screening,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1162,1,history of allergic reaction to blood products,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1163,1,inability to complete infusion of the product within 48 hours after randomization.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1164,1,pregnancy (or planning for pregnancy in next three months) or breastfeeding.,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1165,1,resident of a long term or skilled nursing facility,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1166,1,known history of immunoglobulin a (iga) deficiency,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1167,1,oxygen saturation that is < 95% at the screening visit,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1168,1,participation in another clinical trial of anti-viral agent(s) for covid-19,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1169,1,currently or imminently planned admission to hospital,Hydroxychloroquine
1170,1,currently or imminently planned admission to hospital,Hydroxychloroquine
1171,1,any contraindication to hydroxychloroquine :,Hydroxychloroquine
1172,1,any contraindication to hydroxychloroquine :,Hydroxychloroquine
1173,1,"known hypersensitivity to hydroxychloroquine, chloroquine, or other 4-aminoquinoline derivatives, or any component of the formulation",Hydroxychloroquine
1174,1,"known hypersensitivity to hydroxychloroquine, chloroquine, or other 4-aminoquinoline derivatives, or any component of the formulation",Hydroxychloroquine
1175,1,known diagnosis of g6pd deficiency or porphyria,Hydroxychloroquine
1176,1,known diagnosis of g6pd deficiency or porphyria,Hydroxychloroquine
1177,1,"known retinal eye disease with vision impairment, in which hydroxychloroquine is a known contraindication",Hydroxychloroquine
1178,1,"known retinal eye disease with vision impairment, in which hydroxychloroquine is a known contraindication",Hydroxychloroquine
1179,1,"known history of qtc prolongation or qtc of > 470 msec (males) or > 480 msec (females) on any ecg within the previous year, if available",Hydroxychloroquine
1180,1,"known history of qtc prolongation or qtc of > 470 msec (males) or > 480 msec (females) on any ecg within the previous year, if available",Hydroxychloroquine
1181,1,unexplained syncope or family history of long qt syndrome or family history of premature sudden cardiac death at < 50 years of age,Hydroxychloroquine
1182,1,unexplained syncope or family history of long qt syndrome or family history of premature sudden cardiac death at < 50 years of age,Hydroxychloroquine
1183,1,severe diarrhea and/or vomiting or any eating disorders or any persistent vomiting condition,Hydroxychloroquine
1184,1,severe diarrhea and/or vomiting or any eating disorders or any persistent vomiting condition,Hydroxychloroquine
1185,1,"known significant liver disease including cirrhosis associated with any history of ascites, encephalopathy, or variceal bleeding as per history or medical chart (or child pugh b&c) or alcoholic hepatitis",Hydroxychloroquine
1186,1,"known significant liver disease including cirrhosis associated with any history of ascites, encephalopathy, or variceal bleeding as per history or medical chart (or child pugh b&c) or alcoholic hepatitis",Hydroxychloroquine
1187,1,uncontrolled epilepsy (more than 2 seizures within the previous year or any hospitalizations for status epilepticus within the previous 2 years),Hydroxychloroquine
1188,1,uncontrolled epilepsy (more than 2 seizures within the previous year or any hospitalizations for status epilepticus within the previous 2 years),Hydroxychloroquine
1189,1,"current use of hydroxychloroquine (plaquenil), chloroquine, lumefantrine, mefloquine, quinine, artemether, cyclosporine, dapsone, digoxin, and drugs that are known to prolong the qtc as per section 7.5.2.",Hydroxychloroquine
1190,1,"current use of hydroxychloroquine (plaquenil), chloroquine, lumefantrine, mefloquine, quinine, artemether, cyclosporine, dapsone, digoxin, and drugs that are known to prolong the qtc as per section 7.5.2.",Hydroxychloroquine
1191,1,"score of 7 or more on the tisdale scale modified such that instead of (1) admission potassium, any known serum potassium within the previous 30 days will be used; if no serum potassium is available the sub-score will be 0, and (2) admission ecg, any known ecg within the previous year will be used; if no ecg is available, the sub-score will be 0; (3) use of hcq will be included as one risk factor and anyone concurrently using a medication from the list of drugs known to prolong the qtc will already be excluded. (the other major risk factors for prolonged qtc are sepsis, heart failure, acute myocardial infarction, none of which are likely to be encountered in the outpatient setting).",Hydroxychloroquine
1192,1,"score of 7 or more on the tisdale scale modified such that instead of (1) admission potassium, any known serum potassium within the previous 30 days will be used; if no serum potassium is available the sub-score will be 0, and (2) admission ecg, any known ecg within the previous year will be used; if no ecg is available, the sub-score will be 0; (3) use of hcq will be included as one risk factor and anyone concurrently using a medication from the list of drugs known to prolong the qtc will already be excluded. (the other major risk factors for prolonged qtc are sepsis, heart failure, acute myocardial infarction, none of which are likely to be encountered in the outpatient setting).",Hydroxychloroquine
1193,1,participation in an ongoing interventional clinical trial within the previous 30 days,Hydroxychloroquine
1194,1,participation in an ongoing interventional clinical trial within the previous 30 days,Hydroxychloroquine
1195,1,"use of hydroxychloroquine (plaquenil) or chloroquine, lumefantrine, mefloquine, or quinine within the previous 30 days.",Hydroxychloroquine
1196,1,"use of hydroxychloroquine (plaquenil) or chloroquine, lumefantrine, mefloquine, or quinine within the previous 30 days.",Hydroxychloroquine
1197,1,inability to swallow pills or any other reason that compliance with the medical regimen is not likely,Hydroxychloroquine
1198,1,inability to swallow pills or any other reason that compliance with the medical regimen is not likely,Hydroxychloroquine
1199,1,pregnant or breastfeeding,Hydroxychloroquine
1200,1,pregnant or breastfeeding,Hydroxychloroquine
1201,1,severe underlying disease where treatment is not likely to be beneficial to the patient.,Hydroxychloroquine
1202,1,severe underlying disease where treatment is not likely to be beneficial to the patient.,Hydroxychloroquine
1203,1,"allergy history for plasma, sodium citrate and methylene blue",convalescent plasma
1204,1,"for patients with history of autoimmune system diseases or selective iga deficiency, the application of convalescent plasma should be evaluated cautiously by clinicians.",convalescent plasma
1205,1,patients having evidence of uncontrolled cytokine release syndrome leading to end-stage multi organ failure.,convalescent plasma
1206,1,"allergic to hydroxychloroquine or chloroquine, or azithromycin",Hydroxychloroquine and azithromycin treatment
1207,1,"allergic to hydroxychloroquine or chloroquine, or azithromycin",Hydroxychloroquine and azithromycin treatment
1208,1,"contraindication to hydroxychloroquine: retinopathy, g6pd deficiency, long qt syndrome, any other heart rhythm abnormality on pre-recruitment electrocardiogram, hypokalemia, porphyria, psoriasis.",Hydroxychloroquine and azithromycin treatment
1209,1,"contraindication to hydroxychloroquine: retinopathy, g6pd deficiency, long qt syndrome, any other heart rhythm abnormality on pre-recruitment electrocardiogram, hypokalemia, porphyria, psoriasis.",Hydroxychloroquine and azithromycin treatment
1210,1,"contraindication to azithromycin: long qt syndrome, liver failure, myasthenia",Hydroxychloroquine and azithromycin treatment
1211,1,"contraindication to azithromycin: long qt syndrome, liver failure, myasthenia",Hydroxychloroquine and azithromycin treatment
1212,1,"receiving simultaneous treatments contraindicated in case of hydroxychloroquine uptake: citalopram (seropram), escitalopram (seroplex), hydroxyzin (atarax), domperidone (motilium), piperaquine (eurartesim), disopyramide (isorythm, rythmodan), hydroquinidine chlorydrate (serecor), amiodarone (cordarone), dronedaron (multaq), tricyclic antidepressant, anti-infectious drugs (macrolids, fluoroquinolones, trimethoprime-sulfamethoxazole (bactrim).",Hydroxychloroquine and azithromycin treatment
1213,1,"receiving simultaneous treatments contraindicated in case of hydroxychloroquine uptake: citalopram (seropram), escitalopram (seroplex), hydroxyzin (atarax), domperidone (motilium), piperaquine (eurartesim), disopyramide (isorythm, rythmodan), hydroquinidine chlorydrate (serecor), amiodarone (cordarone), dronedaron (multaq), tricyclic antidepressant, anti-infectious drugs (macrolids, fluoroquinolones, trimethoprime-sulfamethoxazole (bactrim).",Hydroxychloroquine and azithromycin treatment
1214,1,"receiving simultaneous treatments contraindicated in case of azithromycin uptake: cisapride, colchicine, dihydroergotamine, bromocriptine, cabergoline, lisurid, pergolide, atorvastatin, ciclosporin, digoxin, simvastatin, anti-vitamine k, macrolids, ketolide",Hydroxychloroquine and azithromycin treatment
1215,1,"receiving simultaneous treatments contraindicated in case of azithromycin uptake: cisapride, colchicine, dihydroergotamine, bromocriptine, cabergoline, lisurid, pergolide, atorvastatin, ciclosporin, digoxin, simvastatin, anti-vitamine k, macrolids, ketolide",Hydroxychloroquine and azithromycin treatment
1216,1,hypoxemic respiratory failure due to severe pneumonia (needing supplemental oxygen),Hydroxychloroquine and azithromycin treatment
1217,1,hypoxemic respiratory failure due to severe pneumonia (needing supplemental oxygen),Hydroxychloroquine and azithromycin treatment
1218,1,"maternal disorders: type i or ii diabetes, congenital cardiopathy, liver or kidney disease, liver failure, renal failure",Hydroxychloroquine and azithromycin treatment
1219,1,"maternal disorders: type i or ii diabetes, congenital cardiopathy, liver or kidney disease, liver failure, renal failure",Hydroxychloroquine and azithromycin treatment
1220,1,"obstetrical disorders: insulin-dependent gestational diabetes, preterm delivery threat, preterm rupture of membranes, bleeding, pre-eclampsia, gestational hypertension, gestational cholestasis",Hydroxychloroquine and azithromycin treatment
1221,1,"obstetrical disorders: insulin-dependent gestational diabetes, preterm delivery threat, preterm rupture of membranes, bleeding, pre-eclampsia, gestational hypertension, gestational cholestasis",Hydroxychloroquine and azithromycin treatment
1222,1,previous positive test for sars-cov-2,Hydroxychloroquine
1223,1,previous positive test for sars-cov-2,Hydroxychloroquine
1224,1,previous positive serology test for sars-cov-2,Hydroxychloroquine
1225,1,previous positive serology test for sars-cov-2,Hydroxychloroquine
1226,1,recent chest ct meeting ct exclusion criteria,Hydroxychloroquine
1227,1,recent chest ct meeting ct exclusion criteria,Hydroxychloroquine
1228,1,"live in a skilled nursing facility with covid-19 symptoms (temp >38 c in addition to sore throat, cough, wheezing, chest tightness, shortness of breath, body aches or chills, diarrhea, anosmia)",Hydroxychloroquine
1229,1,"live in a skilled nursing facility with covid-19 symptoms (temp >38 c in addition to sore throat, cough, wheezing, chest tightness, shortness of breath, body aches or chills, diarrhea, anosmia)",Hydroxychloroquine
1230,1,known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives,Hydroxychloroquine
1231,1,known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives,Hydroxychloroquine
1232,1,pre-existing retinopathy,Hydroxychloroquine
1233,1,pre-existing retinopathy,Hydroxychloroquine
1234,1,"known chronic kidney disease, stage 4 or 5, or receiving dialysis",Hydroxychloroquine
1235,1,"known chronic kidney disease, stage 4 or 5, or receiving dialysis",Hydroxychloroquine
1236,1,breast feeding,Hydroxychloroquine
1237,1,breast feeding,Hydroxychloroquine
1238,1,tamoxifen,Hydroxychloroquine
1239,1,tamoxifen,Hydroxychloroquine
1240,1,"absolute neutrophil count <1,000/ml at registration",Hydroxychloroquine
1241,1,"absolute neutrophil count <1,000/ml at registration",Hydroxychloroquine
1242,1,concurrent use of any other quinine derivative,Hydroxychloroquine
1243,1,concurrent use of any other quinine derivative,Hydroxychloroquine
1244,1,"antiarrhythmic medications: amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide",Hydroxychloroquine
1245,1,"antiarrhythmic medications: amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide",Hydroxychloroquine
1246,1,glucose-6-phosphate dehydrogenase deficiency,Hydroxychloroquine
1247,1,glucose-6-phosphate dehydrogenase deficiency,Hydroxychloroquine
1248,1,pre-treatment corrected qt interval (qtc) ≥470 milliseconds**,Hydroxychloroquine
1249,1,pre-treatment corrected qt interval (qtc) ≥470 milliseconds**,Hydroxychloroquine
1250,1,prisoners,Hydroxychloroquine
1251,1,prisoners,Hydroxychloroquine
1252,1,inability to participate,Hydroxychloroquine
1253,1,inability to participate,Hydroxychloroquine
1254,1,psoriasis,Hydroxychloroquine
1255,1,psoriasis,Hydroxychloroquine
1256,1,history of suicidal ideation,Hydroxychloroquine
1257,1,history of suicidal ideation,Hydroxychloroquine
1258,1,"ct criteria for enrollment exclusion (optional - only for patients who received a diagnostic ct as part of standard of care or a thoracic ct as part of radiation simulation): all patients with covid-19 typical radiographic findings on ct chest as defined by the rsna will be excluded. patients with any new covid-19 indeterminate radiographic findings on ct chest that are concerning for covid-19 will be excluded. covid-19 indeterminate features are permitted if they can be demonstrated as stable on prior (>14 calendar days) ct chest or pet/ct. if no prior comparison is available and any intermediate or typical feature is present, the patient is not eligible.",Hydroxychloroquine
1259,1,"ct criteria for enrollment exclusion (optional - only for patients who received a diagnostic ct as part of standard of care or a thoracic ct as part of radiation simulation): all patients with covid-19 typical radiographic findings on ct chest as defined by the rsna will be excluded. patients with any new covid-19 indeterminate radiographic findings on ct chest that are concerning for covid-19 will be excluded. covid-19 indeterminate features are permitted if they can be demonstrated as stable on prior (>14 calendar days) ct chest or pet/ct. if no prior comparison is available and any intermediate or typical feature is present, the patient is not eligible.",Hydroxychloroquine
1260,1,covid-19 atypical features,Hydroxychloroquine
1261,1,covid-19 atypical features,Hydroxychloroquine
1262,1,isolated lobar or segmental consolidation without ggo,Hydroxychloroquine
1263,1,isolated lobar or segmental consolidation without ggo,Hydroxychloroquine
1264,1,"discrete small nodules (centrilobular, ""tree-in-bud"")",Hydroxychloroquine
1265,1,"discrete small nodules (centrilobular, ""tree-in-bud"")",Hydroxychloroquine
1266,1,lung cavitation,Hydroxychloroquine
1267,1,lung cavitation,Hydroxychloroquine
1268,1,smooth interlobular septal thickening with pleural effusion,Hydroxychloroquine
1269,1,smooth interlobular septal thickening with pleural effusion,Hydroxychloroquine
1270,1,covid-19 indeterminate features,Hydroxychloroquine
1271,1,covid-19 indeterminate features,Hydroxychloroquine
1272,1,"multifocal, diffuse, perihilar, or unilateral ggo with or without consolidation lacking a specific distribution and are non-rounded or non-peripheral",Hydroxychloroquine
1273,1,"multifocal, diffuse, perihilar, or unilateral ggo with or without consolidation lacking a specific distribution and are non-rounded or non-peripheral",Hydroxychloroquine
1274,1,few very small ggo with a non-rounded and non-peripheral distribution,Hydroxychloroquine
1275,1,few very small ggo with a non-rounded and non-peripheral distribution,Hydroxychloroquine
1276,1,covid-19 typical features,Hydroxychloroquine
1277,1,covid-19 typical features,Hydroxychloroquine
1278,1,"peripheral, bilateral ggo with or without consolidation or visible intralobular lines (""crazy paving"")",Hydroxychloroquine
1279,1,"peripheral, bilateral ggo with or without consolidation or visible intralobular lines (""crazy paving"")",Hydroxychloroquine
1280,1,"multifocal ggo of rounded morphology with or without consolidation or visible intralobular lines (""crazy paving"")",Hydroxychloroquine
1281,1,"multifocal ggo of rounded morphology with or without consolidation or visible intralobular lines (""crazy paving"")",Hydroxychloroquine
1282,1,"reverse halo sign or other findings of organizing pneumonia ** if pre-treatment qtc can be decreased to <470, the patient can be re-considered for trial.",Hydroxychloroquine
1283,1,"reverse halo sign or other findings of organizing pneumonia ** if pre-treatment qtc can be decreased to <470, the patient can be re-considered for trial.",Hydroxychloroquine
1284,1,age <18 years old,Hydroxychloroquine
1285,1,age <18 years old,Hydroxychloroquine
1286,1,"suspected or confirmed current covid-19, defined as: (1) temperature > 38 celsius; (2) cough; (3) shortness of breath; (4) sore throat; or, if available (not required), (5) positive confirmatory testing for covid-19",Hydroxychloroquine
1287,1,"suspected or confirmed current covid-19, defined as: (1) temperature > 38 celsius; (2) cough; (3) shortness of breath; (4) sore throat; or, if available (not required), (5) positive confirmatory testing for covid-19",Hydroxychloroquine
1288,1,"suspected or confirmed convalescent covid-19, defined as any of the above symptoms within the prior 4 weeks.",Hydroxychloroquine
1289,1,"suspected or confirmed convalescent covid-19, defined as any of the above symptoms within the prior 4 weeks.",Hydroxychloroquine
1290,1,inability to take medications orally,Hydroxychloroquine
1291,1,inability to take medications orally,Hydroxychloroquine
1292,1,inability to provide written consent,Hydroxychloroquine
1293,1,inability to provide written consent,Hydroxychloroquine
1294,1,known sensitivity/allergy to hydroxychloroquine,Hydroxychloroquine
1295,1,known sensitivity/allergy to hydroxychloroquine,Hydroxychloroquine
1296,1,current use of hydroxychloroquine for another indication,Hydroxychloroquine
1297,1,current use of hydroxychloroquine for another indication,Hydroxychloroquine
1298,1,pregnancy,Hydroxychloroquine
1299,1,pregnancy,Hydroxychloroquine
1300,1,prior diagnosis of retinopathy,Hydroxychloroquine
1301,1,prior diagnosis of retinopathy,Hydroxychloroquine
1302,1,prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency,Hydroxychloroquine
1303,1,prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency,Hydroxychloroquine
1304,1,"major comorbidities increasing risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval",Hydroxychloroquine
1305,1,"major comorbidities increasing risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval",Hydroxychloroquine
1306,1,known hypersensitivity/allergy to hydroxychloroquine or to 4-aminoquinoline compounds.,Hydroxychloroquine Pre-Exposure Prophylaxis
1307,1,known hypersensitivity/allergy to hydroxychloroquine or to 4-aminoquinoline compounds.,Hydroxychloroquine Pre-Exposure Prophylaxis
1308,1,current use of hydroxychloroquine for the treatment of a medical condition.,Hydroxychloroquine Pre-Exposure Prophylaxis
1309,1,current use of hydroxychloroquine for the treatment of a medical condition.,Hydroxychloroquine Pre-Exposure Prophylaxis
1310,1,"known prolonged qt syndrome, or concomitant medications which simultaneously may prolong the qtc that cannot be temporarily suspended/replaced. these are including but not limited to class ia, ic and iii antiarrhythmics; certain antidepressants, antipsychotics, and anti-infectives; domperidone; 5-hydroxytryptamine (5-ht)3 receptor antagonists; kinase inhibitors; histone deacetylase inhibitors beta-2 adrenoceptor agonists.",Hydroxychloroquine Pre-Exposure Prophylaxis
1311,1,"known prolonged qt syndrome, or concomitant medications which simultaneously may prolong the qtc that cannot be temporarily suspended/replaced. these are including but not limited to class ia, ic and iii antiarrhythmics; certain antidepressants, antipsychotics, and anti-infectives; domperidone; 5-hydroxytryptamine (5-ht)3 receptor antagonists; kinase inhibitors; histone deacetylase inhibitors beta-2 adrenoceptor agonists.",Hydroxychloroquine Pre-Exposure Prophylaxis
1312,1,known pre-existing retinopathy of the eye.,Hydroxychloroquine Pre-Exposure Prophylaxis
1313,1,known pre-existing retinopathy of the eye.,Hydroxychloroquine Pre-Exposure Prophylaxis
1314,1,disclosure of self-administered use of hydroxychloroquine or chloroquine currently under investigation <4 weeks prior to study. this window is intended to account for the drug half-life of hcq (21 days).,Hydroxychloroquine Pre-Exposure Prophylaxis
1315,1,disclosure of self-administered use of hydroxychloroquine or chloroquine currently under investigation <4 weeks prior to study. this window is intended to account for the drug half-life of hcq (21 days).,Hydroxychloroquine Pre-Exposure Prophylaxis
1316,1,"baseline symptom of covid-19 disease at enrollment and baseline viral detection specimen positive for sars-cov-2. all participants with covid-19 symptoms at enrollment will be directed to have confirmatory testing (within the department or occupational health as per the site guidelines). participants who are negative for sars-cov-2 will be redirected to enrollment procedures, those testing positive will be excluded.",Hydroxychloroquine Pre-Exposure Prophylaxis
1317,1,"baseline symptom of covid-19 disease at enrollment and baseline viral detection specimen positive for sars-cov-2. all participants with covid-19 symptoms at enrollment will be directed to have confirmatory testing (within the department or occupational health as per the site guidelines). participants who are negative for sars-cov-2 will be redirected to enrollment procedures, those testing positive will be excluded.",Hydroxychloroquine Pre-Exposure Prophylaxis
1318,1,participation in another clinical trial of anti-viral agent(s) for covid-19,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1319,1,participation in another clinical trial of anti-viral agent(s) for covid-19,Non-convalescent Plasma (control plasma)
1320,1,receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1321,1,receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration,Non-convalescent Plasma (control plasma)
1322,1,mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1323,1,mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days,Non-convalescent Plasma (control plasma)
1324,1,severe multi-organ failure,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1325,1,severe multi-organ failure,Non-convalescent Plasma (control plasma)
1326,1,"history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria",Convalescent Plasma (anti-SARS-CoV-2 plasma)
1327,1,"history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria",Non-convalescent Plasma (control plasma)
1328,1,known immunoglobulin a (iga) deficiency,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1329,1,known immunoglobulin a (iga) deficiency,Non-convalescent Plasma (control plasma)
1330,1,females who are pregnant,Convalescent Plasma (anti-SARS-CoV-2 plasma)
1331,1,females who are pregnant,Non-convalescent Plasma (control plasma)
1332,1,allergy to hydroxychloroquine or azithromycin,Hydroxychloroquine
1333,1,allergy to hydroxychloroquine or azithromycin,Hydroxychloroquine
1334,1,history of bone marrow transplant,Hydroxychloroquine
1335,1,history of bone marrow transplant,Hydroxychloroquine
1336,1,known g6pd deficiency,Hydroxychloroquine
1337,1,known g6pd deficiency,Hydroxychloroquine
1338,1,chronic hemodialysis or glomerular filtration rate < 20ml/min,Hydroxychloroquine
1339,1,chronic hemodialysis or glomerular filtration rate < 20ml/min,Hydroxychloroquine
1340,1,psoriasis,Hydroxychloroquine
1341,1,psoriasis,Hydroxychloroquine
1342,1,porphyria,Hydroxychloroquine
1343,1,porphyria,Hydroxychloroquine
1344,1,"concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone",Hydroxychloroquine
1345,1,"concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone",Hydroxychloroquine
1346,1,known history of long qt syndrome,Hydroxychloroquine
1347,1,known history of long qt syndrome,Hydroxychloroquine
1348,1,current known qtc>500 msec,Hydroxychloroquine
1349,1,current known qtc>500 msec,Hydroxychloroquine
1350,1,pregnant or nursing,Hydroxychloroquine
1351,1,pregnant or nursing,Hydroxychloroquine
1352,1,prisoner,Hydroxychloroquine
1353,1,prisoner,Hydroxychloroquine
1354,1,weight < 35kg,Hydroxychloroquine
1355,1,weight < 35kg,Hydroxychloroquine
1356,1,severe liver disease,Hydroxychloroquine
1357,1,severe liver disease,Hydroxychloroquine
1358,1,seizure disorder,Hydroxychloroquine
1359,1,seizure disorder,Hydroxychloroquine
1360,1,known hypersensitivity to hcq or other 4-aminoquinoline compounds,Hydroxychloroquine Sulfate
1361,1,known hypersensitivity to hcq or other 4-aminoquinoline compounds,Hydroxychloroquine Sulfate
1362,1,currently hospitalized,Hydroxychloroquine Sulfate
1363,1,currently hospitalized,Hydroxychloroquine Sulfate
1364,1,"symptomatic with subjective fever, cough, or sore throat",Hydroxychloroquine Sulfate
1365,1,"symptomatic with subjective fever, cough, or sore throat",Hydroxychloroquine Sulfate
1366,1,current medications exclude concomitant use of hcq,Hydroxychloroquine Sulfate
1367,1,current medications exclude concomitant use of hcq,Hydroxychloroquine Sulfate
1368,1,concomitant use of other anti-malarial treatment or chemoprophylaxis,Hydroxychloroquine Sulfate
1369,1,concomitant use of other anti-malarial treatment or chemoprophylaxis,Hydroxychloroquine Sulfate
1370,1,history of retinopathy of any etiology,Hydroxychloroquine Sulfate
1371,1,history of retinopathy of any etiology,Hydroxychloroquine Sulfate
1372,1,psoriasis,Hydroxychloroquine Sulfate
1373,1,psoriasis,Hydroxychloroquine Sulfate
1374,1,porphyria,Hydroxychloroquine Sulfate
1375,1,porphyria,Hydroxychloroquine Sulfate
1376,1,known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes < 1500) or thrombocytopenia (< 100 k),Hydroxychloroquine Sulfate
1377,1,known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes < 1500) or thrombocytopenia (< 100 k),Hydroxychloroquine Sulfate
1378,1,"concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen",Hydroxychloroquine Sulfate
1379,1,"concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen",Hydroxychloroquine Sulfate
1380,1,known liver disease,Hydroxychloroquine Sulfate
1381,1,known liver disease,Hydroxychloroquine Sulfate
1382,1,known long qt syndrome,Hydroxychloroquine Sulfate
1383,1,known long qt syndrome,Hydroxychloroquine Sulfate
1384,1,"use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of the study drugs, or planned use during the study period",Hydroxychloroquine Sulfate
1385,1,"use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of the study drugs, or planned use during the study period",Hydroxychloroquine Sulfate
1386,1,onset of symptoms >12 days prior to randomization,Convalescent plasma
1387,1,intubated or plan in place for intubation,Convalescent plasma
1388,1,plasma is contraindicated (e.g. history of anaphylaxis from transfusion),Convalescent plasma
1389,1,decision in place for no active treatment,Convalescent plasma
1390,1,refusal to provide informed consent,Hydroxychloroquine
1391,1,refusal to provide informed consent,Hydroxychloroquine
1392,1,any previous positive test for covid-19 by rt-pcr,Hydroxychloroquine
1393,1,any previous positive test for covid-19 by rt-pcr,Hydroxychloroquine
1394,1,symptomatic for covid-19,Hydroxychloroquine
1395,1,symptomatic for covid-19,Hydroxychloroquine
1396,1,diarrhea prior to the start of treatment,Hydroxychloroquine
1397,1,diarrhea prior to the start of treatment,Hydroxychloroquine
1398,1,type i or ii diabetes,Hydroxychloroquine
1399,1,type i or ii diabetes,Hydroxychloroquine
1400,1,atherosclerotic coronary artery disease,Hydroxychloroquine
1401,1,atherosclerotic coronary artery disease,Hydroxychloroquine
1402,1,any contraindication for treatment with hydroxychloroquine including:,Hydroxychloroquine
1403,1,any contraindication for treatment with hydroxychloroquine including:,Hydroxychloroquine
1404,1,hypoglycemia,Hydroxychloroquine
1405,1,hypoglycemia,Hydroxychloroquine
1406,1,g6pd deficiency,Hydroxychloroquine
1407,1,g6pd deficiency,Hydroxychloroquine
1408,1,porphyria,Hydroxychloroquine
1409,1,porphyria,Hydroxychloroquine
1410,1,anemia,Hydroxychloroquine
1411,1,anemia,Hydroxychloroquine
1412,1,neutropenia,Hydroxychloroquine
1413,1,neutropenia,Hydroxychloroquine
1414,1,alcoholism,Hydroxychloroquine
1415,1,alcoholism,Hydroxychloroquine
1416,1,myasthenia gravis,Hydroxychloroquine
1417,1,myasthenia gravis,Hydroxychloroquine
1418,1,skeletal muscle disorder,Hydroxychloroquine
1419,1,skeletal muscle disorder,Hydroxychloroquine
1420,1,maculopathy,Hydroxychloroquine
1421,1,maculopathy,Hydroxychloroquine
1422,1,changes in the visual field,Hydroxychloroquine
1423,1,changes in the visual field,Hydroxychloroquine
1424,1,"liver disease, with alt/ast > 2.5 upper limit normal and total bilirubin >2.5 upper limit normal",Hydroxychloroquine
1425,1,"liver disease, with alt/ast > 2.5 upper limit normal and total bilirubin >2.5 upper limit normal",Hydroxychloroquine
1426,1,psoriasis,Hydroxychloroquine
1427,1,psoriasis,Hydroxychloroquine
1428,1,any contraindicated medications found in appendix 2,Hydroxychloroquine
1429,1,any contraindicated medications found in appendix 2,Hydroxychloroquine
1430,1,"any comorbidities which, in the opinion of the investigator, constitute health risk for the subject.",Hydroxychloroquine
1431,1,"any comorbidities which, in the opinion of the investigator, constitute health risk for the subject.",Hydroxychloroquine
1432,1,patients requiring mechanical ventilation or >6 liters per minute nasal cannula oxygen,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
1433,1,"patients on other anti-covid-19 trials being treated with tocilizumab (anti-il-6 receptor), siltuximab (anti-il-2), remdesivir, or other pharmacological trials that may be initiated hereafter.",High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
1434,1,"a pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk of thrombosis (e.g., cryoglobulinemia, severe refractory hypertriglyceridemia, or clinically significant monoclonal gammopathy).",High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
1435,1,contraindication to transfusion or history of prior reactions to transfusion blood products.,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
1436,1,"medical conditions for which receipt of 500-600 ml of intravenous fluid may be dangerous to the subject (e.g., decompensated congestive heart failure).",High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
1437,1,participation in any other clinical trial of an experimental agent treatment for covid-19,Hydroxychloroquine
1438,1,participation in any other clinical trial of an experimental agent treatment for covid-19,Hydroxychloroquine
1439,1,current hospitalization,Hydroxychloroquine
1440,1,current hospitalization,Hydroxychloroquine
1441,1,known hypersensitivity to hydroxyxhloroquine or chloroquine,Hydroxychloroquine
1442,1,known hypersensitivity to hydroxyxhloroquine or chloroquine,Hydroxychloroquine
1443,1,"known chronic kidney disease, stage 4-5, or receiving dialysis",Hydroxychloroquine
1444,1,"known chronic kidney disease, stage 4-5, or receiving dialysis",Hydroxychloroquine
1445,1,history of retinal disease,Hydroxychloroquine
1446,1,history of retinal disease,Hydroxychloroquine
1447,1,"history of uncontrolled hypertension, defined as systolic blood pressure > 180 mmhg and or diastolic blood pressure > 100 mmhg at the most recent physical medical encounter or by patient report.",Hydroxychloroquine
1448,1,"history of uncontrolled hypertension, defined as systolic blood pressure > 180 mmhg and or diastolic blood pressure > 100 mmhg at the most recent physical medical encounter or by patient report.",Hydroxychloroquine
1449,1,history of qt prolongation (qt > 500 ms) or history of torsades de pointes,Hydroxychloroquine
1450,1,history of qt prolongation (qt > 500 ms) or history of torsades de pointes,Hydroxychloroquine
1451,1,history of arrhythmias,Hydroxychloroquine
1452,1,history of arrhythmias,Hydroxychloroquine
1453,1,current use of loop diuretics and potassium supplementation or documented history of hypokalemia.,Hydroxychloroquine
1454,1,current use of loop diuretics and potassium supplementation or documented history of hypokalemia.,Hydroxychloroquine
1455,1,pregnancy and lactation,Hydroxychloroquine
1456,1,pregnancy and lactation,Hydroxychloroquine
1457,1,known glucose-6-phosphate dehydrogenase (g6pd) deficiency,Hydroxychloroquine
1458,1,known glucose-6-phosphate dehydrogenase (g6pd) deficiency,Hydroxychloroquine
1459,1,"current use of any of the following medications: flecainide (tambocor), amiodarone (cordarone, pacerone), digoxin (digox, digitek), procainamide (procan, procanbid), propafenone (rythmal), antiepileptic agents (phenytoin, phenobarbital, valproic acid, lamotrigine, topiramate), tamoxifen, tricyclic antidepressants (nortriptyline, amitriptyline, imipramine, clomipramine)",Hydroxychloroquine
1460,1,"current use of any of the following medications: flecainide (tambocor), amiodarone (cordarone, pacerone), digoxin (digox, digitek), procainamide (procan, procanbid), propafenone (rythmal), antiepileptic agents (phenytoin, phenobarbital, valproic acid, lamotrigine, topiramate), tamoxifen, tricyclic antidepressants (nortriptyline, amitriptyline, imipramine, clomipramine)",Hydroxychloroquine
1461,1,"inability to monitor body temperature (oral, axillary, tympanic or frontal) at least twice a day from study enrollment day (day 1) to the end of the study (day 14).",Hydroxychloroquine
1462,1,"inability to monitor body temperature (oral, axillary, tympanic or frontal) at least twice a day from study enrollment day (day 1) to the end of the study (day 14).",Hydroxychloroquine
1463,1,inability to provide informed consent to the study.,Hydroxychloroquine
1464,1,inability to provide informed consent to the study.,Hydroxychloroquine
1465,1,participation in any other clinical trial of an experimental treatment for covid-19,Hydroxychloroquine sulfate
1466,1,participation in any other clinical trial of an experimental treatment for covid-19,Hydroxychloroquine sulfate
1467,1,concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to study medication initiation,Hydroxychloroquine sulfate
1468,1,concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to study medication initiation,Hydroxychloroquine sulfate
1469,1,sofa >10,Hydroxychloroquine sulfate
1470,1,sofa >10,Hydroxychloroquine sulfate
1471,1,alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln),Hydroxychloroquine sulfate
1472,1,alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln),Hydroxychloroquine sulfate
1473,1,stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr < 30),Hydroxychloroquine sulfate
1474,1,stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr < 30),Hydroxychloroquine sulfate
1475,1,pregnant women or women who are breastfeeding,Hydroxychloroquine sulfate
1476,1,pregnant women or women who are breastfeeding,Hydroxychloroquine sulfate
1477,1,immunocompromised patients taking medication upon screening,Hydroxychloroquine sulfate
1478,1,immunocompromised patients taking medication upon screening,Hydroxychloroquine sulfate
1479,1,"consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment",Hydroxychloroquine sulfate
1480,1,"consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment",Hydroxychloroquine sulfate
1481,1,current hospitalization,Hydroxychloroquine
1482,1,current hospitalization,Hydroxychloroquine
1483,1,allergy to hydroxychloroquine,Hydroxychloroquine
1484,1,allergy to hydroxychloroquine,Hydroxychloroquine
1485,1,retinal eye disease,Hydroxychloroquine
1486,1,retinal eye disease,Hydroxychloroquine
1487,1,known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency,Hydroxychloroquine
1488,1,known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency,Hydroxychloroquine
1489,1,"known chronic kidney disease, stage 4 or 5 or receiving dialysis",Hydroxychloroquine
1490,1,"known chronic kidney disease, stage 4 or 5 or receiving dialysis",Hydroxychloroquine
1491,1,structural or ischemic heart disease,Hydroxychloroquine
1492,1,structural or ischemic heart disease,Hydroxychloroquine
1493,1,personal or family history of prolonged qt syndrome,Hydroxychloroquine
1494,1,personal or family history of prolonged qt syndrome,Hydroxychloroquine
1495,1,weight < 40 kg,Hydroxychloroquine
1496,1,weight < 40 kg,Hydroxychloroquine
1497,1,known porphyria,Hydroxychloroquine
1498,1,known porphyria,Hydroxychloroquine
1499,1,"current use of: hydroxychloroquine or cardiac medicines of: flecainide, tambocor; amiodarone, cordarone, pacerone; digoxin or digox, digitek, lanoxin; procainamide or procan, procanbid, propafenone, rythmal, sotalol;",Hydroxychloroquine
1500,1,"current use of: hydroxychloroquine or cardiac medicines of: flecainide, tambocor; amiodarone, cordarone, pacerone; digoxin or digox, digitek, lanoxin; procainamide or procan, procanbid, propafenone, rythmal, sotalol;",Hydroxychloroquine
1501,1,current use of medicines which prolong the qt interval including:,Hydroxychloroquine
1502,1,current use of medicines which prolong the qt interval including:,Hydroxychloroquine
1503,1,"antimicrobials: levofloxacin, ciprofloxacin, moxifloxacin, azithromycin, clarithromycin, erythromycin, ketoconazole, itraconazole, or mefloquine",Hydroxychloroquine
1504,1,"antimicrobials: levofloxacin, ciprofloxacin, moxifloxacin, azithromycin, clarithromycin, erythromycin, ketoconazole, itraconazole, or mefloquine",Hydroxychloroquine
1505,1,"antidepressants: amitriptyline, citalopram, desipramine, escitalopram, imipramine, doxepin, fluoxetine, wellbutrin, or venlafaxine",Hydroxychloroquine
1506,1,"antidepressants: amitriptyline, citalopram, desipramine, escitalopram, imipramine, doxepin, fluoxetine, wellbutrin, or venlafaxine",Hydroxychloroquine
1507,1,"antipsychotic or mood stabilizers: haloperidol, droperidol, lithium, quetiapine, thioridazine, ziprasidone",Hydroxychloroquine
1508,1,"antipsychotic or mood stabilizers: haloperidol, droperidol, lithium, quetiapine, thioridazine, ziprasidone",Hydroxychloroquine
1509,1,methadone,Hydroxychloroquine
1510,1,methadone,Hydroxychloroquine
1511,1,"sumatriptan, zolmitriptan",Hydroxychloroquine
1512,1,"sumatriptan, zolmitriptan",Hydroxychloroquine
1513,1,"the patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.",Hydroxychloroquine
1514,1,"the patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.",Hydroxychloroquine
1515,1,"judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.",Hydroxychloroquine
1516,1,"judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.",Hydroxychloroquine
1517,1,"psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent.",Hydroxychloroquine
1518,1,"psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent.",Hydroxychloroquine
1519,1,"resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, qtcf prolongation >500 ms, electrolyte disturbances, etc.), or participants with congenital long qt syndrome",Hydroxychloroquine
1520,1,"resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, qtcf prolongation >500 ms, electrolyte disturbances, etc.), or participants with congenital long qt syndrome",Hydroxychloroquine
1521,1,patients with myesthenia gravis or other neuromuscular disorders,Hydroxychloroquine
1522,1,patients with myesthenia gravis or other neuromuscular disorders,Hydroxychloroquine
1523,1,patients with history of psoriasis.,Hydroxychloroquine
1524,1,patients with history of psoriasis.,Hydroxychloroquine
1525,1,a. may be waived at the discretion of the pi,Hydroxychloroquine
1526,1,a. may be waived at the discretion of the pi,Hydroxychloroquine
1527,1,patients with history of porphyria,Hydroxychloroquine
1528,1,patients with history of porphyria,Hydroxychloroquine
1529,1,a. may be waived at the discretion of the pi,Hydroxychloroquine
1530,1,a. may be waived at the discretion of the pi,Hydroxychloroquine
1531,1,"concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the principal investigator",Hydroxychloroquine
1532,1,"concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the principal investigator",Hydroxychloroquine
1533,1,"hypersensitivity to the study agent, or any of its excipients.",Hydroxychloroquine
1534,1,"hypersensitivity to the study agent, or any of its excipients.",Hydroxychloroquine
1535,1,females who are pregnant or lactating.,Hydroxychloroquine
1536,1,females who are pregnant or lactating.,Hydroxychloroquine
1537,1,alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal.,Remdesivir
1538,1,estimated glomerular filtration rate (egfr) < 30 ml/min (including patients receiving hemodialysis or hemofiltration).,Remdesivir
1539,1,pregnancy or breast feeding.,Remdesivir
1540,1,anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.,Remdesivir
1541,1,allergy to any study medication.,Remdesivir
1542,1,"participants already prescribed chloroquine, hydroxychloroquine, or azithromycin",Hydroxychloroquine
1543,1,"participants already prescribed chloroquine, hydroxychloroquine, or azithromycin",Hydroxychloroquine
1544,1,allergy to hydroxychloroquine or azithromycin,Hydroxychloroquine
1545,1,allergy to hydroxychloroquine or azithromycin,Hydroxychloroquine
1546,1,history of bone marrow transplant,Hydroxychloroquine
1547,1,history of bone marrow transplant,Hydroxychloroquine
1548,1,known g6pd (glucose-6-phosphate dehydrogenase deficiency) deficiency,Hydroxychloroquine
1549,1,known g6pd (glucose-6-phosphate dehydrogenase deficiency) deficiency,Hydroxychloroquine
1550,1,"chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate < 20ml/min/1.73m2",Hydroxychloroquine
1551,1,"chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate < 20ml/min/1.73m2",Hydroxychloroquine
1552,1,liver disease (e.g. child pugh score ≥ b or ast (aspartate transaminase)>2 times upper limit),Hydroxychloroquine
1553,1,liver disease (e.g. child pugh score ≥ b or ast (aspartate transaminase)>2 times upper limit),Hydroxychloroquine
1554,1,psoriasis,Hydroxychloroquine
1555,1,psoriasis,Hydroxychloroquine
1556,1,porphyria,Hydroxychloroquine
1557,1,porphyria,Hydroxychloroquine
1558,1,known cardiac conduction delay (qtc > 500msec) or taking any prescription medications known to prolong qt interval,Hydroxychloroquine
1559,1,known cardiac conduction delay (qtc > 500msec) or taking any prescription medications known to prolong qt interval,Hydroxychloroquine
1560,1,"concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone",Hydroxychloroquine
1561,1,"concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone",Hydroxychloroquine
1562,1,prisoner,Hydroxychloroquine
1563,1,prisoner,Hydroxychloroquine
1564,1,weight < 35kg,Hydroxychloroquine
1565,1,weight < 35kg,Hydroxychloroquine
1566,1,inability to follow-up - no cell phone or no address or not spanish or english speaking,Hydroxychloroquine
1567,1,inability to follow-up - no cell phone or no address or not spanish or english speaking,Hydroxychloroquine
1568,1,"receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation",Hydroxychloroquine
1569,1,"receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation",Hydroxychloroquine
1570,1,no symptoms attributable to covid-19,Hydroxychloroquine
1571,1,no symptoms attributable to covid-19,Hydroxychloroquine
1572,1,pregnant or nursing,Hydroxychloroquine
1573,1,pregnant or nursing,Hydroxychloroquine
1574,1,"mechanical ventilation, high-flow nasal oxygen, biphasic positive airway pressure (bipap)",Hydroxychloroquine
1575,1,"mechanical ventilation, high-flow nasal oxygen, biphasic positive airway pressure (bipap)",Hydroxychloroquine
1576,1,venous thromboembolism within 12 weeks or previously diagnosed thrombophilic conditions or conditions that increase the risk of thrombosis. individuals with > 1 episode of venous thromboembolism or pulmonary embolism in the past will also be excluded,Hydroxychloroquine
1577,1,venous thromboembolism within 12 weeks or previously diagnosed thrombophilic conditions or conditions that increase the risk of thrombosis. individuals with > 1 episode of venous thromboembolism or pulmonary embolism in the past will also be excluded,Hydroxychloroquine
1578,1,"prior receipt of other immunomodulatory drugs (e.g., any jak inhibitors, immunomodulatory biologics, or other immunomodulatory investigational products) within 14 days prior to enrollment",Hydroxychloroquine
1579,1,"prior receipt of other immunomodulatory drugs (e.g., any jak inhibitors, immunomodulatory biologics, or other immunomodulatory investigational products) within 14 days prior to enrollment",Hydroxychloroquine
1580,1,current treatment with probenecid,Hydroxychloroquine
1581,1,current treatment with probenecid,Hydroxychloroquine
1582,1,"known infection with human immunodeficiency syndrome (hiv), or active infection with hepatitis b or hepatitis c",Hydroxychloroquine
1583,1,"known infection with human immunodeficiency syndrome (hiv), or active infection with hepatitis b or hepatitis c",Hydroxychloroquine
1584,1,participant with known active or latent tuberculosis infection,Hydroxychloroquine
1585,1,participant with known active or latent tuberculosis infection,Hydroxychloroquine
1586,1,pregnancy and lactation,Hydroxychloroquine
1587,1,pregnancy and lactation,Hydroxychloroquine
1588,1,any serious acute infections or known active or latent tuberculosis,Hydroxychloroquine
1589,1,any serious acute infections or known active or latent tuberculosis,Hydroxychloroquine
1590,1,"all enrolled participants will be screened for latent tuberculosis infection by testing quantiferon-tb gold plus, but a documented negative test will not be required prior to entry. if a participant is found to have positive quantiferon that results after enrollment, baricitinib will be discontinued",Hydroxychloroquine
1591,1,"all enrolled participants will be screened for latent tuberculosis infection by testing quantiferon-tb gold plus, but a documented negative test will not be required prior to entry. if a participant is found to have positive quantiferon that results after enrollment, baricitinib will be discontinued",Hydroxychloroquine
1592,1,solid organ transplant recipient,Hydroxychloroquine
1593,1,solid organ transplant recipient,Hydroxychloroquine
1594,1,alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal,Hydroxychloroquine
1595,1,alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal,Hydroxychloroquine
1596,1,absolute neutrophil count < 1000/mm^3,Hydroxychloroquine
1597,1,absolute neutrophil count < 1000/mm^3,Hydroxychloroquine
1598,1,absolute lymphocyte count < 200/mm^3,Hydroxychloroquine
1599,1,absolute lymphocyte count < 200/mm^3,Hydroxychloroquine
1600,1,hemoglobin < 8 g/dl,Hydroxychloroquine
1601,1,hemoglobin < 8 g/dl,Hydroxychloroquine
1602,1,estimated glomerular filtration rate (gfr) < 30 ml/min/1.73 m^2,Hydroxychloroquine
1603,1,estimated glomerular filtration rate (gfr) < 30 ml/min/1.73 m^2,Hydroxychloroquine
1604,1,any medical condition in the opinion of the investigator that would place the participant at undue high risk for participation in the trial,Hydroxychloroquine
1605,1,any medical condition in the opinion of the investigator that would place the participant at undue high risk for participation in the trial,Hydroxychloroquine
1606,1,hypersensitivity to the active substance or to any of the excipients,Hydroxychloroquine
1607,1,hypersensitivity to the active substance or to any of the excipients,Hydroxychloroquine
1608,1,requires supplemental o2 >10 litres per minute or mechanical ventilation on admission,Hydroxychloroquine
1609,1,requires supplemental o2 >10 litres per minute or mechanical ventilation on admission,Hydroxychloroquine
1610,1,pregnancy,Hydroxychloroquine
1611,1,pregnancy,Hydroxychloroquine
1612,1,ast/alt > 5 times the upper limit normal,Hydroxychloroquine
1613,1,ast/alt > 5 times the upper limit normal,Hydroxychloroquine
1614,1,baseline prolonged qt,Hydroxychloroquine
1615,1,baseline prolonged qt,Hydroxychloroquine
1616,1,child-pugh score b or greater,Hydroxychloroquine
1617,1,child-pugh score b or greater,Hydroxychloroquine
1618,1,esrd(end-stage renal disease) requiring dialysis,Hydroxychloroquine
1619,1,esrd(end-stage renal disease) requiring dialysis,Hydroxychloroquine
1620,1,"known allergy to medication component,",Hydroxychloroquine
1621,1,"known allergy to medication component,",Hydroxychloroquine
1622,1,history of severe g6pd (glucose-6-phosphate dehydrogenase),Hydroxychloroquine
1623,1,history of severe g6pd (glucose-6-phosphate dehydrogenase),Hydroxychloroquine
1624,1,myasthenia gravis,Hydroxychloroquine
1625,1,myasthenia gravis,Hydroxychloroquine
1626,1,porphyria,Hydroxychloroquine
1627,1,porphyria,Hydroxychloroquine
1628,1,ongoing treatment for epilepsy,Hydroxychloroquine
1629,1,ongoing treatment for epilepsy,Hydroxychloroquine
1630,1,"life expectancy < 6 months,",Hydroxychloroquine
1631,1,"life expectancy < 6 months,",Hydroxychloroquine
1632,1,patient lacks capacity to provide consent and does not have a surrogate decision maker.,Hydroxychloroquine
1633,1,patient lacks capacity to provide consent and does not have a surrogate decision maker.,Hydroxychloroquine
1634,1,retinal disease,Hydroxychloroquine
1635,1,retinal disease,Hydroxychloroquine
1636,1,1. pregnant women 2. breastfeeding women 3. known hypersensitivity to blood products 4. receipt of pooled immunoglobulin in last 30 days 5. participating in any other clinical trial 6. clinical status precluding infusion of blood products,Convalescent Plasma
1637,1,pregnancy or breastfeeding;,Hydroxychloroquine
1638,1,pregnancy or breastfeeding;,Hydroxychloroquine
1639,1,"major allergy to hidroxychloroquine, chloroquine or 4-aminoquinolines;",Hydroxychloroquine
1640,1,"major allergy to hidroxychloroquine, chloroquine or 4-aminoquinolines;",Hydroxychloroquine
1641,1,serum potassium lower than 3.4 meq/l;,Hydroxychloroquine
1642,1,serum potassium lower than 3.4 meq/l;,Hydroxychloroquine
1643,1,serum calcium lower than 4.65 mg/dl;,Hydroxychloroquine
1644,1,serum calcium lower than 4.65 mg/dl;,Hydroxychloroquine
1645,1,serum magnesium lower than 1.7 mg/dl;,Hydroxychloroquine
1646,1,serum magnesium lower than 1.7 mg/dl;,Hydroxychloroquine
1647,1,known history of long qt syndrome;,Hydroxychloroquine
1648,1,known history of long qt syndrome;,Hydroxychloroquine
1649,1,qtc interval > 450 ms;,Hydroxychloroquine
1650,1,qtc interval > 450 ms;,Hydroxychloroquine
1651,1,weight < 40 kg;,Hydroxychloroquine
1652,1,weight < 40 kg;,Hydroxychloroquine
1653,1,severe liver disease;,Hydroxychloroquine
1654,1,severe liver disease;,Hydroxychloroquine
1655,1,severe kidney disease;,Hydroxychloroquine
1656,1,severe kidney disease;,Hydroxychloroquine
1657,1,"concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone;",Hydroxychloroquine
1658,1,"concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone;",Hydroxychloroquine
1659,1,known retinal disease.,Hydroxychloroquine
1660,1,known retinal disease.,Hydroxychloroquine
1661,1,"anticipated transfer to another hospital, within 72 hours, which is not a study site",Hydroxychloroquine
1662,1,"anticipated transfer to another hospital, within 72 hours, which is not a study site",Hydroxychloroquine
1663,1,"anticipated transfer to another hospital, within 72 hours, which is not a study site",remdesivir
1664,1,expected to not survive beyond 24 hours,Hydroxychloroquine
1665,1,expected to not survive beyond 24 hours,Hydroxychloroquine
1666,1,expected to not survive beyond 24 hours,remdesivir
1667,1,known allergy to study medication or its components (non-medicinal ingredients),Hydroxychloroquine
1668,1,known allergy to study medication or its components (non-medicinal ingredients),Hydroxychloroquine
1669,1,known allergy to study medication or its components (non-medicinal ingredients),remdesivir
1670,1,receiving one of the study drugs at time of enrolment,Hydroxychloroquine
1671,1,receiving one of the study drugs at time of enrolment,Hydroxychloroquine
1672,1,receiving one of the study drugs at time of enrolment,remdesivir
1673,1,known pregnancy,Hydroxychloroquine
1674,1,known pregnancy,Hydroxychloroquine
1675,1,known pregnancy,remdesivir
1676,1,participation in any other clinical trial of an experimental treatment for covid-19,Remdesivir
1677,1,concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to study drug dosing,Remdesivir
1678,1,evidence of multiorgan failure,Remdesivir
1679,1,"mechanically ventilated (including v-v ecmo) ≥ 5 days, or any duration of v-a ecmo.",Remdesivir
1680,1,alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln),Remdesivir
1681,1,creatinine clearance < 50 ml/min using the cockcroft-gault formula for participants ≥ 18 years of age {cockcroft 1976} and schwartz formula for participants < 18 years of age,Remdesivir
1682,1,note: other protocol defined inclusion/exclusion criteria may apply.,Remdesivir
1683,1,pregnant or breastfeeding female,Hydroxychloroquine
1684,1,pregnant or breastfeeding female,Hydroxychloroquine
1685,1,severe covid-19 requiring admission for inpatient treatment,Hydroxychloroquine
1686,1,severe covid-19 requiring admission for inpatient treatment,Hydroxychloroquine
1687,1,need for any oxygen supplementation,Hydroxychloroquine
1688,1,need for any oxygen supplementation,Hydroxychloroquine
1689,1,need for mechanical ventilatory support,Hydroxychloroquine
1690,1,need for mechanical ventilatory support,Hydroxychloroquine
1691,1,history of oxygen supplementation dependency,Hydroxychloroquine
1692,1,history of oxygen supplementation dependency,Hydroxychloroquine
1693,1,history of cancer with ongoing chemotherapy or radiation therapy,Hydroxychloroquine
1694,1,history of cancer with ongoing chemotherapy or radiation therapy,Hydroxychloroquine
1695,1,concurrent antimicrobial therapy,Hydroxychloroquine
1696,1,concurrent antimicrobial therapy,Hydroxychloroquine
1697,1,known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds,Hydroxychloroquine
1698,1,known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds,Hydroxychloroquine
1699,1,already taking hydroxychloroquine or chloroquine within 1 month,Hydroxychloroquine
1700,1,already taking hydroxychloroquine or chloroquine within 1 month,Hydroxychloroquine
1701,1,known g6-pd deficiency,Hydroxychloroquine
1702,1,known g6-pd deficiency,Hydroxychloroquine
1703,1,history of retinopathy,Hydroxychloroquine
1704,1,history of retinopathy,Hydroxychloroquine
1705,1,"history of current cardiac diseases (heart failure, ventricular arrhythmias, left bundle branch block and/or right bundle branch block, qtc prolongation >480ms), or family history of sudden cardiac death",Hydroxychloroquine
1706,1,"history of current cardiac diseases (heart failure, ventricular arrhythmias, left bundle branch block and/or right bundle branch block, qtc prolongation >480ms), or family history of sudden cardiac death",Hydroxychloroquine
1707,1,"ongoing use of drugs that prolong the qtc interval (antipsychotics, antidepressants, class i and iii antiarrhythmics, triptans)",Hydroxychloroquine
1708,1,"ongoing use of drugs that prolong the qtc interval (antipsychotics, antidepressants, class i and iii antiarrhythmics, triptans)",Hydroxychloroquine
1709,1,severe renal disease: glomerular filtration rate (gfr) <30ml/min,Hydroxychloroquine
1710,1,severe renal disease: glomerular filtration rate (gfr) <30ml/min,Hydroxychloroquine
1711,1,"severe hepatic impairment (elevated total bilirubin >2 mg/dl, decreased albumin <2.8 g/dl, signs of jaundice and ascites.)",Hydroxychloroquine
1712,1,"severe hepatic impairment (elevated total bilirubin >2 mg/dl, decreased albumin <2.8 g/dl, signs of jaundice and ascites.)",Hydroxychloroquine
1713,1,active alcohol abuse (>5 drinks per day or >20 drinks per week.),Hydroxychloroquine
1714,1,active alcohol abuse (>5 drinks per day or >20 drinks per week.),Hydroxychloroquine
1715,1,"seizure disorder, currently on medications",Hydroxychloroquine
1716,1,"seizure disorder, currently on medications",Hydroxychloroquine
1717,1,known hypersensitivity to any tetracyclines.,Hydroxychloroquine
1718,1,known hypersensitivity to any tetracyclines.,Hydroxychloroquine
1719,1,participation in any other clinical trial of an experimental treatment for covid-19,Remdesivir
1720,1,concurrent treatment or planned concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2,Remdesivir
1721,1,requiring mechanical ventilation at screening,Remdesivir
1722,1,alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln),Remdesivir
1723,1,creatinine clearance < 50 ml/min using the cockcroft-gault formula for participants ≥ 18 years of age {cockcroft 1976} and schwartz formula for participants < 18 years of age,Remdesivir
1724,1,note: other protocol defined inclusion/exclusion criteria may apply.,Remdesivir
1725,1,acute myocardial infarction in past 30 days acute stroke in past 30 days vv ecmo va ecmo,Convalescent plasma
1726,1,onset of symptoms began >12 days before screening,Convalescent plasma (CP)
1727,1,history of adverse reactions to blood products or other contraindication to transfusion,Convalescent plasma (CP)
1728,1,refusal of plasma for religious or other reasons,Convalescent plasma (CP)
1729,1,acute heart failure with fluid overload,Convalescent plasma (CP)
1730,1,"any condition or diagnosis, that could in the opinion of the site principal investigator interfere with the participant's ability to comply with study instructions, or put the participant at risk",Convalescent plasma (CP)
1731,1,anticipated discharge within 24 hours,Convalescent plasma (CP)
1732,1,pregnancy or women who are breast feeding,Hydroxychloroquine Sulfate + Azithromycin
1733,1,pregnancy or women who are breast feeding,Hydroxychloroquine Sulfate
1734,1,pregnancy or women who are breast feeding,Hydroxychloroquine Sulfate + Azithromycin
1735,1,pregnancy or women who are breast feeding,Hydroxychloroquine Sulfate
1736,1,two consecutive negative assays for sars-cov-2 infection,Hydroxychloroquine Sulfate + Azithromycin
1737,1,two consecutive negative assays for sars-cov-2 infection,Hydroxychloroquine Sulfate
1738,1,two consecutive negative assays for sars-cov-2 infection,Hydroxychloroquine Sulfate + Azithromycin
1739,1,two consecutive negative assays for sars-cov-2 infection,Hydroxychloroquine Sulfate
1740,1,patients that lack decision-making capacity will not be approached to participate in this study,Hydroxychloroquine Sulfate + Azithromycin
1741,1,patients that lack decision-making capacity will not be approached to participate in this study,Hydroxychloroquine Sulfate
1742,1,patients that lack decision-making capacity will not be approached to participate in this study,Hydroxychloroquine Sulfate + Azithromycin
1743,1,patients that lack decision-making capacity will not be approached to participate in this study,Hydroxychloroquine Sulfate
1744,1,inability to tolerate oral medications,Hydroxychloroquine Sulfate + Azithromycin
1745,1,inability to tolerate oral medications,Hydroxychloroquine Sulfate
1746,1,inability to tolerate oral medications,Hydroxychloroquine Sulfate + Azithromycin
1747,1,inability to tolerate oral medications,Hydroxychloroquine Sulfate
1748,1,allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate,Hydroxychloroquine Sulfate + Azithromycin
1749,1,allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate,Hydroxychloroquine Sulfate
1750,1,allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate,Hydroxychloroquine Sulfate + Azithromycin
1751,1,allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate,Hydroxychloroquine Sulfate
1752,1,qtc interval > 470 msec,Hydroxychloroquine Sulfate + Azithromycin
1753,1,qtc interval > 470 msec,Hydroxychloroquine Sulfate
1754,1,qtc interval > 470 msec,Hydroxychloroquine Sulfate + Azithromycin
1755,1,qtc interval > 470 msec,Hydroxychloroquine Sulfate
1756,1,history of ongoing ventricular cardiac dysrhythmias of grade 2 as described by nci ctcae 5.0 criteria,Hydroxychloroquine Sulfate + Azithromycin
1757,1,history of ongoing ventricular cardiac dysrhythmias of grade 2 as described by nci ctcae 5.0 criteria,Hydroxychloroquine Sulfate
1758,1,history of ongoing ventricular cardiac dysrhythmias of grade 2 as described by nci ctcae 5.0 criteria,Hydroxychloroquine Sulfate + Azithromycin
1759,1,history of ongoing ventricular cardiac dysrhythmias of grade 2 as described by nci ctcae 5.0 criteria,Hydroxychloroquine Sulfate
1760,1,history of serious ventricular arrhythmia (vt or vf > 3 beats in a row),Hydroxychloroquine Sulfate + Azithromycin
1761,1,history of serious ventricular arrhythmia (vt or vf > 3 beats in a row),Hydroxychloroquine Sulfate
1762,1,history of serious ventricular arrhythmia (vt or vf > 3 beats in a row),Hydroxychloroquine Sulfate + Azithromycin
1763,1,history of serious ventricular arrhythmia (vt or vf > 3 beats in a row),Hydroxychloroquine Sulfate
1764,1,participation in another intervention trial on the treatment of covid-19 that falls under the dutch law human research (wmo) and in which individual patients are randomized to different treatment options,Convalescent plasma
1765,1,known iga deficiency,Convalescent plasma
1766,1,invasive ventilation for already >96 hours,Convalescent plasma
1767,1,donors: eligibility for plasma donation,Convalescent plasma
1768,1,inclusions criteria:,Convalescent plasma
1769,1,a history of covid infection that was documented by pcr,Convalescent plasma
1770,1,known abo-resus(d) blood group,Convalescent plasma
1771,1,a screening for irregular antibodies with a titer ≤ 1:32,Convalescent plasma
1772,1,asymptomatic for at least 14 days,Convalescent plasma
1773,1,written informed consent regarding the plasmapheresis procedure,Convalescent plasma
1774,1,"tested negative for hiv, hbv, hcv, hev, htlv and syfilis",Convalescent plasma
1775,1,qtc greater than 450 milliseconds on screening ekg,Hydroxychloroquine
1776,1,qtc greater than 450 milliseconds on screening ekg,Hydroxychloroquine
1777,1,pregnant or lactating women,Hydroxychloroquine
1778,1,pregnant or lactating women,Hydroxychloroquine
1779,1,inability to take oral pills or inability to use a feeding tube,Hydroxychloroquine
1780,1,inability to take oral pills or inability to use a feeding tube,Hydroxychloroquine
1781,1,inability to obtain informed consent either from the patient or from the next of kin if patient is incapacitated. for the purpose of this study obtaining a verbal consent from a family member on the phone with a witness will be considered acceptable since there is a 'no visitor' policy in force at hospitals.,Hydroxychloroquine
1782,1,inability to obtain informed consent either from the patient or from the next of kin if patient is incapacitated. for the purpose of this study obtaining a verbal consent from a family member on the phone with a witness will be considered acceptable since there is a 'no visitor' policy in force at hospitals.,Hydroxychloroquine
1783,1,patients requiring icu level care,Hydroxychloroquine
1784,1,patients requiring icu level care,Hydroxychloroquine
1785,1,use of azithromycin or hydroxychloroquine within 30 days prior to admission,Hydroxychloroquine
1786,1,use of azithromycin or hydroxychloroquine within 30 days prior to admission,Hydroxychloroquine
1787,1,prisoner,Hydroxychloroquine
1788,1,prisoner,Hydroxychloroquine
1789,1,pregnancy,Hydroxychloroquine
1790,1,pregnancy,Hydroxychloroquine
1791,1,breast feeding,Hydroxychloroquine
1792,1,breast feeding,Hydroxychloroquine
1793,1,symptoms of acute respiratory infection for >10 days before randomization,Hydroxychloroquine
1794,1,symptoms of acute respiratory infection for >10 days before randomization,Hydroxychloroquine
1795,1,>48 hours between meeting inclusion criteria and randomization,Hydroxychloroquine
1796,1,>48 hours between meeting inclusion criteria and randomization,Hydroxychloroquine
1797,1,seizure disorder,Hydroxychloroquine
1798,1,seizure disorder,Hydroxychloroquine
1799,1,porphyria cutanea tarda,Hydroxychloroquine
1800,1,porphyria cutanea tarda,Hydroxychloroquine
1801,1,diagnosis of long qt syndrome,Hydroxychloroquine
1802,1,diagnosis of long qt syndrome,Hydroxychloroquine
1803,1,qtc >500 ms on electrocardiogram within 72 hours prior to enrollment,Hydroxychloroquine
1804,1,qtc >500 ms on electrocardiogram within 72 hours prior to enrollment,Hydroxychloroquine
1805,1,"known allergy to hydroxychloroquine, chloroquine, or amodiaquine",Hydroxychloroquine
1806,1,"known allergy to hydroxychloroquine, chloroquine, or amodiaquine",Hydroxychloroquine
1807,1,"receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol",Hydroxychloroquine
1808,1,"receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol",Hydroxychloroquine
1809,1,receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment,Hydroxychloroquine
1810,1,receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment,Hydroxychloroquine
1811,1,inability to receive enteral medications,Hydroxychloroquine
1812,1,inability to receive enteral medications,Hydroxychloroquine
1813,1,refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15,Hydroxychloroquine
1814,1,refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15,Hydroxychloroquine
1815,1,previous enrollment in this trial,Hydroxychloroquine
1816,1,previous enrollment in this trial,Hydroxychloroquine
1817,1,the treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient,Hydroxychloroquine
1818,1,the treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient,Hydroxychloroquine
1819,1,"moribund or estimated life expectancy <1 month (e.g. terminal cancer, etc.)",Chloroquine or Hydroxychloroquine
1820,1,"moribund or estimated life expectancy <1 month (e.g. terminal cancer, etc.)",Chloroquine or Hydroxychloroquine
1821,1,pregnancy or breastfeeding,Chloroquine or Hydroxychloroquine
1822,1,pregnancy or breastfeeding,Chloroquine or Hydroxychloroquine
1823,1,severe liver dysfunction (e.g. alt/ast > 5 times upper limit of normal),Chloroquine or Hydroxychloroquine
1824,1,severe liver dysfunction (e.g. alt/ast > 5 times upper limit of normal),Chloroquine or Hydroxychloroquine
1825,1,stage 4 chronic kidney disease or requiring dialysis (except for ritonavir/lopinavir),Chloroquine or Hydroxychloroquine
1826,1,stage 4 chronic kidney disease or requiring dialysis (except for ritonavir/lopinavir),Chloroquine or Hydroxychloroquine
1827,1,allergy or intolerances to any of the experimental substances -> exclusion for the respective treatment arm,Chloroquine or Hydroxychloroquine
1828,1,allergy or intolerances to any of the experimental substances -> exclusion for the respective treatment arm,Chloroquine or Hydroxychloroquine
1829,1,anticipated discharge of hospital within 48 hours (for anti-viral treatment arms),Chloroquine or Hydroxychloroquine
1830,1,anticipated discharge of hospital within 48 hours (for anti-viral treatment arms),Chloroquine or Hydroxychloroquine
1831,1,"contraindications treatment arm 1: chloroquine/ hydroxychloroquine: concomitant amiodarone treatment, retinopathy, psoriasis, glucose-6-phosphate deficiency, severe cardiomyopathy and known, clinically relevant arrhythmias, porphyria cutanea tarda",Chloroquine or Hydroxychloroquine
1832,1,"contraindications treatment arm 1: chloroquine/ hydroxychloroquine: concomitant amiodarone treatment, retinopathy, psoriasis, glucose-6-phosphate deficiency, severe cardiomyopathy and known, clinically relevant arrhythmias, porphyria cutanea tarda",Chloroquine or Hydroxychloroquine
1833,1,clinically relevant qtc prolongation during screening,Chloroquine or Hydroxychloroquine
1834,1,clinically relevant qtc prolongation during screening,Chloroquine or Hydroxychloroquine
1835,1,"contraindications treatment arm 2: severe hepatic impairment, cyp3a4/5 metabolized drugs as deemed relevant by treating physicians, hiv positive",Chloroquine or Hydroxychloroquine
1836,1,"contraindications treatment arm 2: severe hepatic impairment, cyp3a4/5 metabolized drugs as deemed relevant by treating physicians, hiv positive",Chloroquine or Hydroxychloroquine
1837,1,contraindications treatment arm 3: iga deficiency,Chloroquine or Hydroxychloroquine
1838,1,contraindications treatment arm 3: iga deficiency,Chloroquine or Hydroxychloroquine
1839,1,"sub-study a contraindications: active bleeding or bleeding diathesis, lesion or condition considered as major risk factor for bleeding, recent brain or spinal injury, recent brain or spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms, major intraspinal or intracerebral vascular abnormalities.",Chloroquine or Hydroxychloroquine
1840,1,"sub-study a contraindications: active bleeding or bleeding diathesis, lesion or condition considered as major risk factor for bleeding, recent brain or spinal injury, recent brain or spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms, major intraspinal or intracerebral vascular abnormalities.",Chloroquine or Hydroxychloroquine
1841,1,"sub-study a: ongoing therapeutic anticoagulation, which will continue, according to clinical practice",Chloroquine or Hydroxychloroquine
1842,1,"sub-study a: ongoing therapeutic anticoagulation, which will continue, according to clinical practice",Chloroquine or Hydroxychloroquine
1843,1,"sub-study b contraindications chronic heart failure, allergies, hypersensitivities and intolerances, severe hepatic impairment and/or cholestasis, concomitant therapy with aliskiren-containing medications (for patients with diabetes mellitus or a gfr<60ml/min/1.73m2), known significant bilateral renal artery stenosis or renal artery stenosis of a solitary kidney",Chloroquine or Hydroxychloroquine
1844,1,"sub-study b contraindications chronic heart failure, allergies, hypersensitivities and intolerances, severe hepatic impairment and/or cholestasis, concomitant therapy with aliskiren-containing medications (for patients with diabetes mellitus or a gfr<60ml/min/1.73m2), known significant bilateral renal artery stenosis or renal artery stenosis of a solitary kidney",Chloroquine or Hydroxychloroquine
1845,1,"sub-study b: control group 1: with or without ras blockers, control group 2: healthy volunteers: concomitant medication with ras-blockers",Chloroquine or Hydroxychloroquine
1846,1,"sub-study b: control group 1: with or without ras blockers, control group 2: healthy volunteers: concomitant medication with ras-blockers",Chloroquine or Hydroxychloroquine
1847,1,"sub-study c: contraindications clazakizumab arm: history of gastrointestinal perforation, diverticulitis, or inflammatory bowel disease, treatment with an il-6 or il-6r blocking drug (e.g. tocilizumab, sarilumab, siltuximab) <30 days before study inclusion.",Chloroquine or Hydroxychloroquine
1848,1,"sub-study c: contraindications clazakizumab arm: history of gastrointestinal perforation, diverticulitis, or inflammatory bowel disease, treatment with an il-6 or il-6r blocking drug (e.g. tocilizumab, sarilumab, siltuximab) <30 days before study inclusion.",Chloroquine or Hydroxychloroquine
1849,1,covid-19 diagnosed > 5 days prior to randomization;,Chloroquine or hydroxychloroquine
1850,1,covid-19 diagnosed > 5 days prior to randomization;,Chloroquine or hydroxychloroquine
1851,1,active tuberculosis;,Chloroquine or hydroxychloroquine
1852,1,active tuberculosis;,Chloroquine or hydroxychloroquine
1853,1,need for concomitant drugs that are contraindicated with the use of chloroquine/hydroxychloroquine;,Chloroquine or hydroxychloroquine
1854,1,need for concomitant drugs that are contraindicated with the use of chloroquine/hydroxychloroquine;,Chloroquine or hydroxychloroquine
1855,1,qtcf interval > 480 ms;,Chloroquine or hydroxychloroquine
1856,1,qtcf interval > 480 ms;,Chloroquine or hydroxychloroquine
1857,1,known glomerular filtration rate < 10 ml/min;,Chloroquine or hydroxychloroquine
1858,1,known glomerular filtration rate < 10 ml/min;,Chloroquine or hydroxychloroquine
1859,1,known with glucose-6-phosphate dehydrogenase deficiency (g6pd);,Chloroquine or hydroxychloroquine
1860,1,known with glucose-6-phosphate dehydrogenase deficiency (g6pd);,Chloroquine or hydroxychloroquine
1861,1,previous adverse drug reaction to investigational product;,Chloroquine or hydroxychloroquine
1862,1,previous adverse drug reaction to investigational product;,Chloroquine or hydroxychloroquine
1863,1,"concurrent involvement in other research or use of chloroquine, hydroxychloroquine or any other 4-aminoquinolone or another experimental investigational medicinal product that is likely to interfere with the study medication.",Chloroquine or hydroxychloroquine
1864,1,"concurrent involvement in other research or use of chloroquine, hydroxychloroquine or any other 4-aminoquinolone or another experimental investigational medicinal product that is likely to interfere with the study medication.",Chloroquine or hydroxychloroquine
1865,1,note: pregnancy and breastfeeding are not exclusions for entry,Chloroquine or hydroxychloroquine
1866,1,note: pregnancy and breastfeeding are not exclusions for entry,Chloroquine or hydroxychloroquine
1867,1,alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal.,Remdesivir
1868,1,estimated glomerular filtration rate (egfr) < 30 ml/min or patient receiving hemodialysis or hemofiltration.,Remdesivir
1869,1,neutropenia (absolute neutrophil count < 1000 cells/microliter) (< 1.0 x 103/microliter or < 1.0 gi/l).,Remdesivir
1870,1,lymphopenia (absolute lymphocyte count < 200 cells/microliter) (< 0.20 x 103/microliter or < 0.20 gi/l),Remdesivir
1871,1,pregnancy or breast feeding.,Remdesivir
1872,1,anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.,Remdesivir
1873,1,allergy to any study medication.,Remdesivir
1874,1,"received cytotoxic or biologic treatments (such as anti-interleukin-1 [il-1], anti-il-6 [tocilizumab or sarilumab], or t-cell or b-cell targeted therapies (e.g., rituximab), tyrosine kinase inhibitors including baricitinib, or interferon within 4 weeks prior to screening.",Remdesivir
1875,1,received tnf inhibitors within 2 weeks prior to screening.,Remdesivir
1876,1,received convalescent plasma or intravenous immunoglobulin [ivig]) for covid-19.,Remdesivir
1877,1,"has received or is receiving corticosteroids at high doses (i.e., prednisone > 10 mg per day or equivalent) within 2 weeks of screening.",Remdesivir
1878,1,use of probenecid that cannot be discontinued at study enrollment.,Remdesivir
1879,1,"have diagnosis of current active tuberculosis (tb) or, if known, latent tb treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening required).",Remdesivir
1880,1,"suspected serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking investigational product.",Remdesivir
1881,1,"have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. note: use of non-live (inactivated) vaccinations is allowed for all subjects.",Remdesivir
1882,1,have a history of venous thromboembolism (vte) (deep vein thrombosis [dvt] or pulmonary embolism [pe]) within 12 weeks prior to screening or have a history of recurrent (> 1) vte (dvt/pe).,Remdesivir
1883,1,"patients with known hypersensitivity to hydroxychloroquine or chloroquine, azithromycin, erythromycin, or any other macrolide, ketolide or any of the excipients of the hydroxychloroquine and/or azithromycin-based specialty used.",Hydroxychloroquine
1884,1,"patients with known hypersensitivity to hydroxychloroquine or chloroquine, azithromycin, erythromycin, or any other macrolide, ketolide or any of the excipients of the hydroxychloroquine and/or azithromycin-based specialty used.",Hydroxychloroquine
1885,1,severe hepatic impairment and patients with severe cholestasis.,Hydroxychloroquine
1886,1,severe hepatic impairment and patients with severe cholestasis.,Hydroxychloroquine
1887,1,patients with renal insufficiency with creatinine clearance < 40 ml/min.,Hydroxychloroquine
1888,1,patients with renal insufficiency with creatinine clearance < 40 ml/min.,Hydroxychloroquine
1889,1,combinations of drugs contraindicated in accordance with the approvals of the specialties used.,Hydroxychloroquine
1890,1,combinations of drugs contraindicated in accordance with the approvals of the specialties used.,Hydroxychloroquine
1891,1,patients currently treated with tamoxifen,Hydroxychloroquine
1892,1,patients currently treated with tamoxifen,Hydroxychloroquine
1893,1,patients already treated by hydroxychloroquine or azithromycin for covid19 disease or currently treated with other antiviral drugs against coronavirus.,Hydroxychloroquine
1894,1,patients already treated by hydroxychloroquine or azithromycin for covid19 disease or currently treated with other antiviral drugs against coronavirus.,Hydroxychloroquine
1895,1,"patients with known contra-indication to treatment with the study drug, including retinopathy, g6pd deficiency, qt prolongation and severe hepato-cellular insufficiency.",Hydroxychloroquine
1896,1,"patients with known contra-indication to treatment with the study drug, including retinopathy, g6pd deficiency, qt prolongation and severe hepato-cellular insufficiency.",Hydroxychloroquine
1897,1,patients post allogeneic hematopoietic stem cell transplantation are eligible to the part b treatments but the potential toxic effects of hydroxychloroquin and azithromycin on hematopoietic stem cells should be taken into consideration by prescribers.,Hydroxychloroquine
1898,1,patients post allogeneic hematopoietic stem cell transplantation are eligible to the part b treatments but the potential toxic effects of hydroxychloroquin and azithromycin on hematopoietic stem cells should be taken into consideration by prescribers.,Hydroxychloroquine
1899,1,"pregnant or breastfeeding women. women of childbearing potential (wocbp, as defined in appendix 2) should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",Hydroxychloroquine
1900,1,"pregnant or breastfeeding women. women of childbearing potential (wocbp, as defined in appendix 2) should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",Hydroxychloroquine
1901,1,participating in any other clinical trial of an experimental agent for covid-19,Hydroxychloroquine
1902,1,participating in any other clinical trial of an experimental agent for covid-19,Hydroxychloroquine
1903,1,"on hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for covid-19 regardless of indication",Hydroxychloroquine
1904,1,"on hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for covid-19 regardless of indication",Hydroxychloroquine
1905,1,"history of g6pd deficiency, cirrhosis, long qt syndrome or porphyria of any classification",Hydroxychloroquine
1906,1,"history of g6pd deficiency, cirrhosis, long qt syndrome or porphyria of any classification",Hydroxychloroquine
1907,1,most recent ecg prior to time of screening with qtc of ≥500 msec,Hydroxychloroquine
1908,1,most recent ecg prior to time of screening with qtc of ≥500 msec,Hydroxychloroquine
1909,1,known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives,Hydroxychloroquine
1910,1,known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives,Hydroxychloroquine
1911,1,death anticipated within 48 hours of enrollment,Hydroxychloroquine
1912,1,death anticipated within 48 hours of enrollment,Hydroxychloroquine
1913,1,inability to obtain informed consent from the patient or designated medical decision maker,Hydroxychloroquine
1914,1,inability to obtain informed consent from the patient or designated medical decision maker,Hydroxychloroquine
1915,1,retinal eye disease,Hydroxychloroquine sulfate &Azithromycin
1916,1,retinal eye disease,Hydroxychloroquine sulfate &Azithromycin
1917,1,known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency,Hydroxychloroquine sulfate &Azithromycin
1918,1,known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency,Hydroxychloroquine sulfate &Azithromycin
1919,1,"known chronic kidney disease, stage 4 or 5 or receiving dialysis",Hydroxychloroquine sulfate &Azithromycin
1920,1,"known chronic kidney disease, stage 4 or 5 or receiving dialysis",Hydroxychloroquine sulfate &Azithromycin
1921,1,current use of:,Hydroxychloroquine sulfate &Azithromycin
1922,1,current use of:,Hydroxychloroquine sulfate &Azithromycin
1923,1,"class 3 aad - amiodarone, dronaderone, dofetilide, sotalol)",Hydroxychloroquine sulfate &Azithromycin
1924,1,"class 3 aad - amiodarone, dronaderone, dofetilide, sotalol)",Hydroxychloroquine sulfate &Azithromycin
1925,1,"class 1a aad (procainamide, quinidine, disopyramide)",Hydroxychloroquine sulfate &Azithromycin
1926,1,"class 1a aad (procainamide, quinidine, disopyramide)",Hydroxychloroquine sulfate &Azithromycin
1927,1,flecainide,Hydroxychloroquine sulfate &Azithromycin
1928,1,flecainide,Hydroxychloroquine sulfate &Azithromycin
1929,1,chlorpromazine,Hydroxychloroquine sulfate &Azithromycin
1930,1,chlorpromazine,Hydroxychloroquine sulfate &Azithromycin
1931,1,cilostazol (pletal),Hydroxychloroquine sulfate &Azithromycin
1932,1,cilostazol (pletal),Hydroxychloroquine sulfate &Azithromycin
1933,1,donepezil (aricept),Hydroxychloroquine sulfate &Azithromycin
1934,1,donepezil (aricept),Hydroxychloroquine sulfate &Azithromycin
1935,1,droperidol,Hydroxychloroquine sulfate &Azithromycin
1936,1,droperidol,Hydroxychloroquine sulfate &Azithromycin
1937,1,fluconazole,Hydroxychloroquine sulfate &Azithromycin
1938,1,fluconazole,Hydroxychloroquine sulfate &Azithromycin
1939,1,methadone,Hydroxychloroquine sulfate &Azithromycin
1940,1,methadone,Hydroxychloroquine sulfate &Azithromycin
1941,1,ondansetron(zofran),Hydroxychloroquine sulfate &Azithromycin
1942,1,ondansetron(zofran),Hydroxychloroquine sulfate &Azithromycin
1943,1,thioridazine,Hydroxychloroquine sulfate &Azithromycin
1944,1,thioridazine,Hydroxychloroquine sulfate &Azithromycin
1945,1,"macrolides (clarithromycin, erythromycin)",Hydroxychloroquine sulfate &Azithromycin
1946,1,"macrolides (clarithromycin, erythromycin)",Hydroxychloroquine sulfate &Azithromycin
1947,1,"fluroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)",Hydroxychloroquine sulfate &Azithromycin
1948,1,"fluroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)",Hydroxychloroquine sulfate &Azithromycin
1949,1,pregnancy or women who are breast feeding,Hydroxychloroquine sulfate &Azithromycin
1950,1,pregnancy or women who are breast feeding,Hydroxychloroquine sulfate &Azithromycin
1951,1,inability to tolerate oral medications,Hydroxychloroquine sulfate &Azithromycin
1952,1,inability to tolerate oral medications,Hydroxychloroquine sulfate &Azithromycin
1953,1,allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate,Hydroxychloroquine sulfate &Azithromycin
1954,1,allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate,Hydroxychloroquine sulfate &Azithromycin
1955,1,allergy to adhesives,Hydroxychloroquine sulfate &Azithromycin
1956,1,allergy to adhesives,Hydroxychloroquine sulfate &Azithromycin
1957,1,qtc interval > 450 msec for men and women,Hydroxychloroquine sulfate &Azithromycin
1958,1,qtc interval > 450 msec for men and women,Hydroxychloroquine sulfate &Azithromycin
1959,1,history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval,Hydroxychloroquine sulfate &Azithromycin
1960,1,history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval,Hydroxychloroquine sulfate &Azithromycin
1961,1,non-english-speaking,Hydroxychloroquine sulfate &Azithromycin
1962,1,non-english-speaking,Hydroxychloroquine sulfate &Azithromycin
1963,1,previous treatment with convalescent plasma for covid-19.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
1964,1,current use of investigational antiviral therapy targeting sars-cov-2.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
1965,1,history of anaphylactic transfusion reaction.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
1966,1,clinical diagnosis of acute decompensated heart failure.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
1967,1,objection to blood transfusion.,High-Titer COVID-19 Convalescent Plasma (HT-CCP)
1968,1,patients with asymptomatic/mild disease for covid-19,convalescent plasma
1969,1,children less than 16 years old,convalescent plasma
1970,1,patients with atypical pneumonia without covid-19 diagnostic for pcr-rt,convalescent plasma
1971,1,participate in another clinical trial for covid- 19,Inactivated convalescent plasma
1972,1,"history of acute allergic transfusion reactions due to transfusion of blood or other components, especially plasma components (fresh frozen plasma, cryoprecipitate and platelets),",Inactivated convalescent plasma
1973,1,history of allergic reaction due to iga deficiency,Inactivated convalescent plasma
1974,1,allergic reaction to sodium citrate or riboflavin (vitamin b2),Inactivated convalescent plasma
1975,1,history of immunosuppression,Inactivated convalescent plasma
1976,1,age <18 years,Hydroxychloroquine Sulfate
1977,1,age <18 years,Hydroxychloroquine Sulfate
1978,1,failure to meet the inclusion criteria,Hydroxychloroquine Sulfate
1979,1,failure to meet the inclusion criteria,Hydroxychloroquine Sulfate
1980,1,leukopenia <1000,Hydroxychloroquine Sulfate
1981,1,leukopenia <1000,Hydroxychloroquine Sulfate
1982,1,pregnancy,Hydroxychloroquine Sulfate
1983,1,pregnancy,Hydroxychloroquine Sulfate
1984,1,not understanding or refusing the purpose of the study,Hydroxychloroquine Sulfate
1985,1,not understanding or refusing the purpose of the study,Hydroxychloroquine Sulfate
1986,1,"prior receipt of hydroxychloroquine for treatment or prophylaxis of sars-cov-2 or patient is taking hydroxychloroquine for other approved indications (e.g., lupus, rheumatoid arthritis)",Hydroxychloroquine
1987,1,"prior receipt of hydroxychloroquine for treatment or prophylaxis of sars-cov-2 or patient is taking hydroxychloroquine for other approved indications (e.g., lupus, rheumatoid arthritis)",Hydroxychloroquine
1988,1,no documented sars-cov-2 infection,Hydroxychloroquine
1989,1,no documented sars-cov-2 infection,Hydroxychloroquine
1990,1,mechanical ventilation,Hydroxychloroquine
1991,1,mechanical ventilation,Hydroxychloroquine
1992,1,known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives preexisting retinopathy documented in medical history,Hydroxychloroquine
1993,1,known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives preexisting retinopathy documented in medical history,Hydroxychloroquine
1994,1,pregnancy or breastfeeding,Hydroxychloroquine
1995,1,pregnancy or breastfeeding,Hydroxychloroquine
1996,1,"concurrent use of any other quinine derivative (chloroquine, mefloquine) or rifamycins (rifampin, rifabutin)",Hydroxychloroquine
1997,1,"concurrent use of any other quinine derivative (chloroquine, mefloquine) or rifamycins (rifampin, rifabutin)",Hydroxychloroquine
1998,1,"antiarrhythmic medications (amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide)",Hydroxychloroquine
1999,1,"antiarrhythmic medications (amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide)",Hydroxychloroquine
2000,1,history of glucose-6-phosphate dehydrogenase deficiency,Hydroxychloroquine
2001,1,history of glucose-6-phosphate dehydrogenase deficiency,Hydroxychloroquine
2002,1,pre-treatment corrected qt interval (qtc) >500 milliseconds,Hydroxychloroquine
2003,1,pre-treatment corrected qt interval (qtc) >500 milliseconds,Hydroxychloroquine
2004,1,pressor requirement to maintain blood pressure,Hydroxychloroquine
2005,1,pressor requirement to maintain blood pressure,Hydroxychloroquine
2006,1,alanine aminotransferase (alt) and/or asparate aminotransferase (ast) level > 5x upper limit of normal,Hydroxychloroquine
2007,1,alanine aminotransferase (alt) and/or asparate aminotransferase (ast) level > 5x upper limit of normal,Hydroxychloroquine
2008,1,creatinine clearance <30 ml/min or requirement of dialysis or continuous venovenous hemofiltration,Hydroxychloroquine
2009,1,creatinine clearance <30 ml/min or requirement of dialysis or continuous venovenous hemofiltration,Hydroxychloroquine
2010,1,concomitant participation in a therapeutic trial for sars-cov-2 or receiving any experimental treatment for sars-cov-2 within 7 days of randomization,Hydroxychloroquine
2011,1,concomitant participation in a therapeutic trial for sars-cov-2 or receiving any experimental treatment for sars-cov-2 within 7 days of randomization,Hydroxychloroquine
2012,1,any condition that in the opinion of the principal investigator would prevent participation in the trial or would interfere with the trial endpoints,Hydroxychloroquine
2013,1,any condition that in the opinion of the principal investigator would prevent participation in the trial or would interfere with the trial endpoints,Hydroxychloroquine
2014,1,known covid-19 positivity defined as: a laboratory confirmed case as defined by the local public health institutes,Apo-Hydroxychloroquine
2015,1,known covid-19 positivity defined as: a laboratory confirmed case as defined by the local public health institutes,Apo-Hydroxychloroquine
2016,1,"suspected covid-19 positivity defined as possessing symptoms consistent with covid-19 infections such as: headache, fever, nausea, vomiting, diarrhea, dyspnea, dry cough",Apo-Hydroxychloroquine
2017,1,"suspected covid-19 positivity defined as possessing symptoms consistent with covid-19 infections such as: headache, fever, nausea, vomiting, diarrhea, dyspnea, dry cough",Apo-Hydroxychloroquine
2018,1,healthcare workers with pre-existing retinopathy or serious visual problems,Apo-Hydroxychloroquine
2019,1,healthcare workers with pre-existing retinopathy or serious visual problems,Apo-Hydroxychloroquine
2020,1,healthcare workers with known malignancies receiving active chemotherapy or immune modifying medications,Apo-Hydroxychloroquine
2021,1,healthcare workers with known malignancies receiving active chemotherapy or immune modifying medications,Apo-Hydroxychloroquine
2022,1,healthcare workers with known autoimmune disorders,Apo-Hydroxychloroquine
2023,1,healthcare workers with known autoimmune disorders,Apo-Hydroxychloroquine
2024,1,healthcare workers with known qt prolongation,Apo-Hydroxychloroquine
2025,1,healthcare workers with known qt prolongation,Apo-Hydroxychloroquine
2026,1,history of ventricular arrhythmias,Apo-Hydroxychloroquine
2027,1,history of ventricular arrhythmias,Apo-Hydroxychloroquine
2028,1,"participants at risk of malignant arrythmias ○ at risk defined as: a sudden loss of consciousness with injury; anyone in their immediate family, under the age of 45year, with sudden cardiac death; anyone family history of long qt syndrome",Apo-Hydroxychloroquine
2029,1,"participants at risk of malignant arrythmias ○ at risk defined as: a sudden loss of consciousness with injury; anyone in their immediate family, under the age of 45year, with sudden cardiac death; anyone family history of long qt syndrome",Apo-Hydroxychloroquine
2030,1,known sensitivity/allergy to hydroxychloroquine,Apo-Hydroxychloroquine
2031,1,known sensitivity/allergy to hydroxychloroquine,Apo-Hydroxychloroquine
2032,1,healthcare workers that are currently pregnant,Apo-Hydroxychloroquine
2033,1,healthcare workers that are currently pregnant,Apo-Hydroxychloroquine
2034,1,healthcare workers that are already taking chloroquine or hydroxychloroquine,Apo-Hydroxychloroquine
2035,1,healthcare workers that are already taking chloroquine or hydroxychloroquine,Apo-Hydroxychloroquine
2036,1,healthcare workers on colchicine or any other anti-viral medication,Apo-Hydroxychloroquine
2037,1,healthcare workers on colchicine or any other anti-viral medication,Apo-Hydroxychloroquine
2038,1,healthcare workers taking a medication that may interact with hydroxychloroquine (see table below,Apo-Hydroxychloroquine
2039,1,healthcare workers taking a medication that may interact with hydroxychloroquine (see table below,Apo-Hydroxychloroquine
2040,1,inability to take oral medications,Apo-Hydroxychloroquine
2041,1,inability to take oral medications,Apo-Hydroxychloroquine
2042,1,inability to provide written consent,Apo-Hydroxychloroquine
2043,1,inability to provide written consent,Apo-Hydroxychloroquine
2044,1,known g6pd deficiency,Apo-Hydroxychloroquine
2045,1,known g6pd deficiency,Apo-Hydroxychloroquine
2046,1,patient already prescribed chloroquine or hydroxychloroquine,Hydroxychloroquine
2047,1,patient already prescribed chloroquine or hydroxychloroquine,Hydroxychloroquine
2048,1,allergy to hydroxychloroquine,Hydroxychloroquine
2049,1,allergy to hydroxychloroquine,Hydroxychloroquine
2050,1,history of bone marrow or solid organ transplant,Hydroxychloroquine
2051,1,history of bone marrow or solid organ transplant,Hydroxychloroquine
2052,1,known g6pd deficiency,Hydroxychloroquine
2053,1,known g6pd deficiency,Hydroxychloroquine
2054,1,"chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate < 20ml/min/1.73m2",Hydroxychloroquine
2055,1,"chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate < 20ml/min/1.73m2",Hydroxychloroquine
2056,1,known liver disease (e.g. child pugh score ≥ b or ast>2 times upper limit),Hydroxychloroquine
2057,1,known liver disease (e.g. child pugh score ≥ b or ast>2 times upper limit),Hydroxychloroquine
2058,1,psoriasis,Hydroxychloroquine
2059,1,psoriasis,Hydroxychloroquine
2060,1,porphyria,Hydroxychloroquine
2061,1,porphyria,Hydroxychloroquine
2062,1,known cardiac conduction delay (qtc > 500msec) or taking any prescription medications known to prolong qt interval,Hydroxychloroquine
2063,1,known cardiac conduction delay (qtc > 500msec) or taking any prescription medications known to prolong qt interval,Hydroxychloroquine
2064,1,"concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone",Hydroxychloroquine
2065,1,"concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone",Hydroxychloroquine
2066,1,seizure disorder,Hydroxychloroquine
2067,1,seizure disorder,Hydroxychloroquine
2068,1,prisoner,Hydroxychloroquine
2069,1,prisoner,Hydroxychloroquine
2070,1,weight < 35kg,Hydroxychloroquine
2071,1,weight < 35kg,Hydroxychloroquine
2072,1,inability to follow-up - no cell phone or no address or not spanish or english speaking,Hydroxychloroquine
2073,1,inability to follow-up - no cell phone or no address or not spanish or english speaking,Hydroxychloroquine
2074,1,"receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation",Hydroxychloroquine
2075,1,"receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation",Hydroxychloroquine
2076,1,patient or another member of patient's household has been already enrolled in this study.,Hydroxychloroquine
2077,1,patient or another member of patient's household has been already enrolled in this study.,Hydroxychloroquine
2078,1,receipt of pooled immunoglobulin in past 30 days,Convalescent Plasma
2079,1,contraindication to transfusion or history of prior reactions to transfusion blood products,Convalescent Plasma
2080,1,invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo),Convalescent Plasma
2081,1,volume overload secondary to congestive heart failure or renal failure,Convalescent Plasma
2082,1,intracranial bleed,Convalescent Plasma
2083,1,patients with hypersensitivity or severe adverse effects to ivermectin,Hydroxychloroquine Sulfate
2084,1,patients with hypersensitivity or severe adverse effects to ivermectin,Hydroxychloroquine Sulfate
2085,1,renal impairment,Hydroxychloroquine Sulfate
2086,1,renal impairment,Hydroxychloroquine Sulfate
2087,1,hepatic impairment.,Hydroxychloroquine Sulfate
2088,1,hepatic impairment.,Hydroxychloroquine Sulfate
2089,1,pregnancy or a desire to become pregnant (drug considered pregnancy category c),Hydroxychloroquine Sulfate
2090,1,pregnancy or a desire to become pregnant (drug considered pregnancy category c),Hydroxychloroquine Sulfate
2091,1,breast feeding.,Hydroxychloroquine Sulfate
2092,1,breast feeding.,Hydroxychloroquine Sulfate
2093,1,patient with covid 19 positive and mild no pneumonia,Hydroxychloroquine Sulfate
2094,1,patient with covid 19 positive and mild no pneumonia,Hydroxychloroquine Sulfate
2095,1,children under the age of five or those who weigh less than 15 kilograms,Hydroxychloroquine Sulfate
2096,1,children under the age of five or those who weigh less than 15 kilograms,Hydroxychloroquine Sulfate
2097,1,known hypersensitivity to hcq or other 4-aminoquinoline compounds,Hydroxychloroquine Sulfate
2098,1,known hypersensitivity to hcq or other 4-aminoquinoline compounds,Hydroxychloroquine Sulfate
2099,1,known hypersensitivity to azithromycin or other azalide or macrolide antibiotics,Hydroxychloroquine Sulfate
2100,1,known hypersensitivity to azithromycin or other azalide or macrolide antibiotics,Hydroxychloroquine Sulfate
2101,1,currently hospitalized,Hydroxychloroquine Sulfate
2102,1,currently hospitalized,Hydroxychloroquine Sulfate
2103,1,"signs of respiratory distress prior to randomization, including respiratory rate >24",Hydroxychloroquine Sulfate
2104,1,"signs of respiratory distress prior to randomization, including respiratory rate >24",Hydroxychloroquine Sulfate
2105,1,current medications include hcq,Hydroxychloroquine Sulfate
2106,1,current medications include hcq,Hydroxychloroquine Sulfate
2107,1,concomitant use of other anti-malarial treatment or chemoprophylaxis,Hydroxychloroquine Sulfate
2108,1,concomitant use of other anti-malarial treatment or chemoprophylaxis,Hydroxychloroquine Sulfate
2109,1,history of retinopathy of any etiology,Hydroxychloroquine Sulfate
2110,1,history of retinopathy of any etiology,Hydroxychloroquine Sulfate
2111,1,psoriasis,Hydroxychloroquine Sulfate
2112,1,psoriasis,Hydroxychloroquine Sulfate
2113,1,porphyria,Hydroxychloroquine Sulfate
2114,1,porphyria,Hydroxychloroquine Sulfate
2115,1,chronic kidney disease (stage iv or receiving dialysis),Hydroxychloroquine Sulfate
2116,1,chronic kidney disease (stage iv or receiving dialysis),Hydroxychloroquine Sulfate
2117,1,known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes <1500) or thrombocytopenia (<100 k),Hydroxychloroquine Sulfate
2118,1,known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes <1500) or thrombocytopenia (<100 k),Hydroxychloroquine Sulfate
2119,1,"concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen",Hydroxychloroquine Sulfate
2120,1,"concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen",Hydroxychloroquine Sulfate
2121,1,known cirrhosis,Hydroxychloroquine Sulfate
2122,1,known cirrhosis,Hydroxychloroquine Sulfate
2123,1,known personal or family history of long qt syndrome,Hydroxychloroquine Sulfate
2124,1,known personal or family history of long qt syndrome,Hydroxychloroquine Sulfate
2125,1,history of coronary artery disease with a history of graft or stent,Hydroxychloroquine Sulfate
2126,1,history of coronary artery disease with a history of graft or stent,Hydroxychloroquine Sulfate
2127,1,"history of heart failure, class 2 or greater using the new york heart association functional class",Hydroxychloroquine Sulfate
2128,1,"history of heart failure, class 2 or greater using the new york heart association functional class",Hydroxychloroquine Sulfate
2129,1,"taking medications associated with prolonged qt such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial",Hydroxychloroquine Sulfate
2130,1,"taking medications associated with prolonged qt such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial",Hydroxychloroquine Sulfate
2131,1,taking warfarin (coumadin or jantoven),Hydroxychloroquine Sulfate
2132,1,taking warfarin (coumadin or jantoven),Hydroxychloroquine Sulfate
2133,1,known history of glucose-6-phosphate-dehydrogenase deficiency,Hydroxychloroquine Sulfate
2134,1,known history of glucose-6-phosphate-dehydrogenase deficiency,Hydroxychloroquine Sulfate
2135,1,history of myasthenia gravis,Hydroxychloroquine Sulfate
2136,1,history of myasthenia gravis,Hydroxychloroquine Sulfate
2137,1,"contraindication to blood transfusions (fluid overload, history of anaphylaxis of blood products)",Convalescent plasma
2138,1,"multiple and severe organ failure, hemodynamically unstable",Convalescent plasma
2139,1,other uncontrolled infections,Convalescent plasma
2140,1,disseminated intravascular coagulation (dic) which requires a replacement factor/ffp,Convalescent plasma
2141,1,hemodialysis patients or crrt (continuous renal replacement therapy),Convalescent plasma
2142,1,active intracranial bleeding,Convalescent plasma
2143,1,significant myocardial ischemia,Convalescent plasma
2144,1,receiving tocilizumab treatment,Convalescent plasma
2145,1,prisoner,Hydroxychloroquine
2146,1,prisoner,Hydroxychloroquine
2147,1,pregnancy,Hydroxychloroquine
2148,1,pregnancy,Hydroxychloroquine
2149,1,breast feeding,Hydroxychloroquine
2150,1,breast feeding,Hydroxychloroquine
2151,1,unable to randomize within 6 days after onset of acute respiratory infection symptoms,Hydroxychloroquine
2152,1,unable to randomize within 6 days after onset of acute respiratory infection symptoms,Hydroxychloroquine
2153,1,hospitalization within the 6 days prior to randomization,Hydroxychloroquine
2154,1,hospitalization within the 6 days prior to randomization,Hydroxychloroquine
2155,1,inability to receive enteral medications,Hydroxychloroquine
2156,1,inability to receive enteral medications,Hydroxychloroquine
2157,1,refusal or inability to be contacted and participate in daily symptom/safety monitoring in english or spanish during the two-week follow-up period,Hydroxychloroquine
2158,1,refusal or inability to be contacted and participate in daily symptom/safety monitoring in english or spanish during the two-week follow-up period,Hydroxychloroquine
2159,1,previous enrollment in this trial,Hydroxychloroquine
2160,1,previous enrollment in this trial,Hydroxychloroquine
2161,1,known severe chronic kidney disease requiring dialysis,Hydroxychloroquine
2162,1,known severe chronic kidney disease requiring dialysis,Hydroxychloroquine
2163,1,known severe liver disease [cirrhosis or >5 times upper limit of normal for aspartate aminotransferase (ast) or alanine aminotransferease (alt)],Hydroxychloroquine
2164,1,known severe liver disease [cirrhosis or >5 times upper limit of normal for aspartate aminotransferase (ast) or alanine aminotransferease (alt)],Hydroxychloroquine
2165,1,known seizure disorder,Hydroxychloroquine
2166,1,known seizure disorder,Hydroxychloroquine
2167,1,known hiv infection,Hydroxychloroquine
2168,1,known hiv infection,Hydroxychloroquine
2169,1,known history of pancreatitis,Hydroxychloroquine
2170,1,known history of pancreatitis,Hydroxychloroquine
2171,1,known porphyria cutanea tarda,Hydroxychloroquine
2172,1,known porphyria cutanea tarda,Hydroxychloroquine
2173,1,"known history of prolonged qt interval [long qt syndrome, patient report, or (corrected qt interval) qtc >500 milliseconds on most recently available electrocardiogram within the past 2 years]",Hydroxychloroquine
2174,1,"known history of prolonged qt interval [long qt syndrome, patient report, or (corrected qt interval) qtc >500 milliseconds on most recently available electrocardiogram within the past 2 years]",Hydroxychloroquine
2175,1,known history of ventricular arrhythmia,Hydroxychloroquine
2176,1,known history of ventricular arrhythmia,Hydroxychloroquine
2177,1,known history of unexplained syncope or family history of premature sudden cardiac death,Hydroxychloroquine
2178,1,known history of unexplained syncope or family history of premature sudden cardiac death,Hydroxychloroquine
2179,1,"receipt of >1 dose of hydroxychloroquine, chloroquine, or lopinavir/ritonavir in the 10 days prior to enrollment",Hydroxychloroquine
2180,1,"receipt of >1 dose of hydroxychloroquine, chloroquine, or lopinavir/ritonavir in the 10 days prior to enrollment",Hydroxychloroquine
2181,1,"known allergy to hydroxychloroquine, chloroquine, amodiaquine, or lopinavir/ritonavir",Hydroxychloroquine
2182,1,"known allergy to hydroxychloroquine, chloroquine, amodiaquine, or lopinavir/ritonavir",Hydroxychloroquine
2183,1,currently prescribed (with planned continuation) or planned administration during 14-day study period of medication at high risk for qt prolongation as follows:,Hydroxychloroquine
2184,1,currently prescribed (with planned continuation) or planned administration during 14-day study period of medication at high risk for qt prolongation as follows:,Hydroxychloroquine
2185,1,"antiarrhythmics: amiodarone, disopyramide, dofetilide, dronedarone, flecainide, ibutilide, procainamide, propafenone, quinidine, sotalol anti-cancer: arsenic trioxide, oxaliplatin, vandetanib antidepressants: amitriptyline, citalopram, escitalopram, imipramine antimicrobials: azithromycin, ciprofloxacin, clarithromycin, erythromycin, fluconazole, levofloxacin, moxifloxacin, pentamidine antipsychotics: aloperidol, chlorpromazine, droperidol, olanzapine, pimozide, quetiapine, thioridazine, risperidone, ziprasidone others: cilostazol, cimetidine, cisapride, donepezil, methadone, ondansetron, sumatriptan",Hydroxychloroquine
2186,1,"antiarrhythmics: amiodarone, disopyramide, dofetilide, dronedarone, flecainide, ibutilide, procainamide, propafenone, quinidine, sotalol anti-cancer: arsenic trioxide, oxaliplatin, vandetanib antidepressants: amitriptyline, citalopram, escitalopram, imipramine antimicrobials: azithromycin, ciprofloxacin, clarithromycin, erythromycin, fluconazole, levofloxacin, moxifloxacin, pentamidine antipsychotics: aloperidol, chlorpromazine, droperidol, olanzapine, pimozide, quetiapine, thioridazine, risperidone, ziprasidone others: cilostazol, cimetidine, cisapride, donepezil, methadone, ondansetron, sumatriptan",Hydroxychloroquine
2187,1,"currently prescribed (with planned continuation) or planned administration during 14-day study period of any of the following medications: alfuzosin, apalutamide, astemizole, ergot-containing medicines (including dihydroergotamine mesylate, ergotamine tartrate, methylergonovine), lomitapide, lovastatin, lurasidone, midazolam, phenobarbital, phenytoin, ranolazine, rifampin, sildenafil, simvastatin, st. john's wort, terfenadine, triazolam",Hydroxychloroquine
2188,1,"currently prescribed (with planned continuation) or planned administration during 14-day study period of any of the following medications: alfuzosin, apalutamide, astemizole, ergot-containing medicines (including dihydroergotamine mesylate, ergotamine tartrate, methylergonovine), lomitapide, lovastatin, lurasidone, midazolam, phenobarbital, phenytoin, ranolazine, rifampin, sildenafil, simvastatin, st. john's wort, terfenadine, triazolam",Hydroxychloroquine
2189,1,"covid-19 critically ill patients (news-2 score <7),",Hydroxychloroquine 200 Mg Oral Tablet
2190,1,"covid-19 critically ill patients (news-2 score <7),",Hydroxychloroquine 200 Mg Oral Tablet
2191,1,"unable to take oral medication,",Hydroxychloroquine 200 Mg Oral Tablet
2192,1,"unable to take oral medication,",Hydroxychloroquine 200 Mg Oral Tablet
2193,1,"immunocompromised,",Hydroxychloroquine 200 Mg Oral Tablet
2194,1,"immunocompromised,",Hydroxychloroquine 200 Mg Oral Tablet
2195,1,"creatinine clearance (ccl) < 30 ml/min,",Hydroxychloroquine 200 Mg Oral Tablet
2196,1,"creatinine clearance (ccl) < 30 ml/min,",Hydroxychloroquine 200 Mg Oral Tablet
2197,1,"aspartate transaminase (ast) or alanine transaminase (alt) > 5 times upper limit of normal (uln),",Hydroxychloroquine 200 Mg Oral Tablet
2198,1,"aspartate transaminase (ast) or alanine transaminase (alt) > 5 times upper limit of normal (uln),",Hydroxychloroquine 200 Mg Oral Tablet
2199,1,"d-dimer > 2microgram per liter, or",Hydroxychloroquine 200 Mg Oral Tablet
2200,1,"d-dimer > 2microgram per liter, or",Hydroxychloroquine 200 Mg Oral Tablet
2201,1,"known comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, copd, cerebrovascular disorder, malignancy of any type, pregnancy,",Hydroxychloroquine 200 Mg Oral Tablet
2202,1,"known comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, copd, cerebrovascular disorder, malignancy of any type, pregnancy,",Hydroxychloroquine 200 Mg Oral Tablet
2203,1,bmi less than 18,Hydroxychloroquine 200 Mg Oral Tablet
2204,1,bmi less than 18,Hydroxychloroquine 200 Mg Oral Tablet
2205,1,smoking history (one pack per day) for past six months,Hydroxychloroquine 200 Mg Oral Tablet
2206,1,smoking history (one pack per day) for past six months,Hydroxychloroquine 200 Mg Oral Tablet
2207,1,- recipient,Convalescent Plasma Transfusion
2208,1,patients with age less than 18 years.,Convalescent Plasma Transfusion
2209,1,pregnancy,Convalescent Plasma Transfusion
2210,1,individual with hiv and hepatitis,Convalescent Plasma Transfusion
2211,1,morbid obesity bmi>35 kg/m2,Convalescent Plasma Transfusion
2212,1,extremely moribund patients with an expected life expectancy of less than 24 hours.,Convalescent Plasma Transfusion
2213,1,failure to give informed consent from the patient or family members.,Convalescent Plasma Transfusion
2214,1,hemodynamic instability requiring vasopressors.,Convalescent Plasma Transfusion
2215,1,previous allergic history to plasma.,Convalescent Plasma Transfusion
2216,1,donor:,Convalescent Plasma Transfusion
2217,1,donors age < 18 & ≥60 years old,Convalescent Plasma Transfusion
2218,1,"do not fulfil all criteria of donor eligibility for donor plasmapheresis under the drugs & cosmetics act and rules 1945, amended 11.03.2020.",Convalescent Plasma Transfusion
2219,1,females who have been pregnant and previously transfused donors (to prevent trali).,Convalescent Plasma Transfusion
2220,1,donors who have taken steroids during treatment for covid-19.,Convalescent Plasma Transfusion
2221,1,reported anamnesis for:,Hydroxychloroquine
2222,1,reported anamnesis for:,Hydroxychloroquine
2223,1,intolerance or previous toxicity for hydroxychloroquine/chloroquine,Hydroxychloroquine
2224,1,intolerance or previous toxicity for hydroxychloroquine/chloroquine,Hydroxychloroquine
2225,1,bradycardia or reduction rhythm of heart with arrythmias,Hydroxychloroquine
2226,1,bradycardia or reduction rhythm of heart with arrythmias,Hydroxychloroquine
2227,1,ischemic heart disease,Hydroxychloroquine
2228,1,ischemic heart disease,Hydroxychloroquine
2229,1,retinopathy,Hydroxychloroquine
2230,1,retinopathy,Hydroxychloroquine
2231,1,congestive heart failure under/with use of diuretics,Hydroxychloroquine
2232,1,congestive heart failure under/with use of diuretics,Hydroxychloroquine
2233,1,favism or glucose-6-phosphate dehydrogenase (g6pd) deficiency,Hydroxychloroquine
2234,1,favism or glucose-6-phosphate dehydrogenase (g6pd) deficiency,Hydroxychloroquine
2235,1,diabetes type 1,Hydroxychloroquine
2236,1,diabetes type 1,Hydroxychloroquine
2237,1,"major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy.",Hydroxychloroquine
2238,1,"major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy.",Hydroxychloroquine
2239,1,severe neurological and mental illness,Hydroxychloroquine
2240,1,severe neurological and mental illness,Hydroxychloroquine
2241,1,any other contraindication to take hydroxychloroquine,Hydroxychloroquine
2242,1,any other contraindication to take hydroxychloroquine,Hydroxychloroquine
2243,1,"already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks",Hydroxychloroquine
2244,1,"already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks",Hydroxychloroquine
2245,1,use of other antiviral agents in the last 3 weeks,Hydroxychloroquine
2246,1,use of other antiviral agents in the last 3 weeks,Hydroxychloroquine
2247,1,subject with a positive test for sars-cov-2 (for group 1),Hydroxychloroquine
2248,1,subject with a positive test for sars-cov-2 (for group 1),Hydroxychloroquine
2249,1,pregnant or lactating,Hydroxychloroquine
2250,1,pregnant or lactating,Hydroxychloroquine
2251,1,"current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, cyclosporine, phenylbutazone, drugs that inhibit cyp2d6",Hydroxychloroquine
2252,1,"current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, cyclosporine, phenylbutazone, drugs that inhibit cyp2d6",Hydroxychloroquine
2253,1,known prolonged qt syndrome or current use of drugs with known qt prolongation,Hydroxychloroquine
2254,1,known prolonged qt syndrome or current use of drugs with known qt prolongation,Hydroxychloroquine
2255,1,participation in another clinical trial with any investigational agents within 30 days prior to study screening.,Hydroxychloroquine
2256,1,participation in another clinical trial with any investigational agents within 30 days prior to study screening.,Hydroxychloroquine
2257,1,active covid-19 disease,Hydroxychloroquine
2258,1,active covid-19 disease,Hydroxychloroquine
2259,1,prior covid-19 disease,Hydroxychloroquine
2260,1,prior covid-19 disease,Hydroxychloroquine
2261,1,"current fever, cough, shortness of breath",Hydroxychloroquine
2262,1,"current fever, cough, shortness of breath",Hydroxychloroquine
2263,1,allergy to chloroquine or hydroxychloroquine,Hydroxychloroquine
2264,1,allergy to chloroquine or hydroxychloroquine,Hydroxychloroquine
2265,1,prior retinal eye disease,Hydroxychloroquine
2266,1,prior retinal eye disease,Hydroxychloroquine
2267,1,"known chronic kidney disease, stage 4 or 5 or dialysis",Hydroxychloroquine
2268,1,"known chronic kidney disease, stage 4 or 5 or dialysis",Hydroxychloroquine
2269,1,known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency,Hydroxychloroquine
2270,1,known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency,Hydroxychloroquine
2271,1,weight <40 kg,Hydroxychloroquine
2272,1,weight <40 kg,Hydroxychloroquine
2273,1,prolonged qt syndrome,Hydroxychloroquine
2274,1,prolonged qt syndrome,Hydroxychloroquine
2275,1,"current use of hydroxychloroquine, chloroquine, or cardiac medicines of flecainide, amiodarone, digoxin, procainamide, or propafenone",Hydroxychloroquine
2276,1,"current use of hydroxychloroquine, chloroquine, or cardiac medicines of flecainide, amiodarone, digoxin, procainamide, or propafenone",Hydroxychloroquine
2277,1,"current use of medications with known significant drug-drug interactions: artemether, lumefantrine, mefloquine, tamoxifen, or methotrexate.",Hydroxychloroquine
2278,1,"current use of medications with known significant drug-drug interactions: artemether, lumefantrine, mefloquine, tamoxifen, or methotrexate.",Hydroxychloroquine
2279,1,• hcw not meeting high-risk criteria or those with a contraindication to hcq will not be offered hcq,Hydroxychloroquine
2280,1,• hcw not meeting high-risk criteria or those with a contraindication to hcq will not be offered hcq,Hydroxychloroquine
2281,1,covid-19 stages iv - v - vi (*1),hydroxychloroquine
2282,1,covid-19 stages iv - v - vi (*1),hydroxychloroquine
2283,1,hospitalization in intensive care units,hydroxychloroquine
2284,1,hospitalization in intensive care units,hydroxychloroquine
2285,1,pregnancy,hydroxychloroquine
2286,1,pregnancy,hydroxychloroquine
2287,1,glucose-6-phosphate dehydrogenase (g6pd) deficiency,hydroxychloroquine
2288,1,glucose-6-phosphate dehydrogenase (g6pd) deficiency,hydroxychloroquine
2289,1,patients who deny consent to the proposed treatment,hydroxychloroquine
2290,1,patients who deny consent to the proposed treatment,hydroxychloroquine
2291,1,inability to provide informed consent,hydroxychloroquine
2292,1,inability to provide informed consent,hydroxychloroquine
2293,1,contraindications to performing oxygen-ozone therapy,hydroxychloroquine
2294,1,contraindications to performing oxygen-ozone therapy,hydroxychloroquine
2295,1,hyperhomocysteinemia,hydroxychloroquine
2296,1,hyperhomocysteinemia,hydroxychloroquine
2297,1,favism or thyroiditis,hydroxychloroquine
2298,1,favism or thyroiditis,hydroxychloroquine
2299,1,coagulopathies,hydroxychloroquine
2300,1,coagulopathies,hydroxychloroquine
2301,1,neurodegenerative diseases,hydroxychloroquine
2302,1,neurodegenerative diseases,hydroxychloroquine
2303,1,angina (in particular prinzmetal's angina) or with previous myocardial infarction,hydroxychloroquine
2304,1,angina (in particular prinzmetal's angina) or with previous myocardial infarction,hydroxychloroquine
2305,1,(*1) compliant with indications published by:,hydroxychloroquine
2306,1,(*1) compliant with indications published by:,hydroxychloroquine
2307,1,italian society of anesthesia analgesia resuscitation and intensive care (siaarti).,hydroxychloroquine
2308,1,italian society of anesthesia analgesia resuscitation and intensive care (siaarti).,hydroxychloroquine
2309,1,care pathway for the patient with covid-19.,hydroxychloroquine
2310,1,care pathway for the patient with covid-19.,hydroxychloroquine
2311,1,section 2 - recommendations for local management of the critically ill patient - version 2,hydroxychloroquine
2312,1,section 2 - recommendations for local management of the critically ill patient - version 2,hydroxychloroquine
2313,1,available on http://www.siaarti.it/siteassets/news/covid19%20-%20documenti%20siaarti/percorso%20covid-19%20-%20sezione%202%20-%20raccomandazioni%20per%20la%20gestione%20locale%20-%20rev%202.0.pdf,hydroxychloroquine
2314,1,available on http://www.siaarti.it/siteassets/news/covid19%20-%20documenti%20siaarti/percorso%20covid-19%20-%20sezione%202%20-%20raccomandazioni%20per%20la%20gestione%20locale%20-%20rev%202.0.pdf,hydroxychloroquine
2315,1,last accessed 20/04/2020,hydroxychloroquine
2316,1,last accessed 20/04/2020,hydroxychloroquine
2317,1,posted on 26.03.2020,hydroxychloroquine
2318,1,posted on 26.03.2020,hydroxychloroquine
2319,1,on page 2 of the previous document :,hydroxychloroquine
2320,1,on page 2 of the previous document :,hydroxychloroquine
2321,1,"""6 identified stages:",hydroxychloroquine
2322,1,"""6 identified stages:",hydroxychloroquine
2323,1,sick disease - mild covid-19 (i stage),hydroxychloroquine
2324,1,sick disease - mild covid-19 (i stage),hydroxychloroquine
2325,1,light pneumonia - mild covid-19 (ii stage),hydroxychloroquine
2326,1,light pneumonia - mild covid-19 (ii stage),hydroxychloroquine
2327,1,serious pneumonia - severe covid-19 (iii stage),hydroxychloroquine
2328,1,serious pneumonia - severe covid-19 (iii stage),hydroxychloroquine
2329,1,acute respiratory distress syndrome (ards) - critical covid-19 (iv stage),hydroxychloroquine
2330,1,acute respiratory distress syndrome (ards) - critical covid-19 (iv stage),hydroxychloroquine
2331,1,sepsis - critical covid-19 (v stage),hydroxychloroquine
2332,1,sepsis - critical covid-19 (v stage),hydroxychloroquine
2333,1,"septic shock - critical covid-19 (vi stage)""",hydroxychloroquine
2334,1,"septic shock - critical covid-19 (vi stage)""",hydroxychloroquine
2335,1,"e1. for cohort 1 only : patient currently receiving therapy with an anti- pd-1, anti- pd-l1, or anti-ctla4.",Chloroquine analog (GNS651)
2336,1,e2. for cohort 2 only: patient currently receiving therapy with an anti- il-6 or anti-il-6r.,Chloroquine analog (GNS651)
2337,1,"e3. contraindication to treatment with nivolumab (cohort 1 only) or to tocilizumab (cohort 2 only) as per respective spc, including known hypersensitivity to one of these study drugs or severe hypersensitivity reaction to any monoclonal antibody.",Chloroquine analog (GNS651)
2338,1,"e4. patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivates (e.g., quinine, chloroquine, mefloquine).",Chloroquine analog (GNS651)
2339,1,"e5. patient has active autoimmune disease that has required systemic treatment in the past 3 months before the date of randomisation or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids at doses higher than 10 mg/d prednisone equivalents or immunosuppressive agents.",Chloroquine analog (GNS651)
2340,1,note 1: patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. patients with hypothyroidism stable on hormone replacement or sjögren's syndrome will not be excluded from the study.,Chloroquine analog (GNS651)
2341,1,note 2: patients may receive corticosteroids as required for the management of sars-cov-2-related symptoms.,Chloroquine analog (GNS651)
2342,1,e6. patient requires the use of one of the following forbidden treatment during the study treatment period:,Chloroquine analog (GNS651)
2343,1,major surgery.,Chloroquine analog (GNS651)
2344,1,"live vaccines. examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever and bcg. seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. flu-mist®) are live attenuated vaccines, and are not allowed.",Chloroquine analog (GNS651)
2345,1,"e7. significant cardiovascular disease, such as new york heart association cardiac disease (class ii or greater), myocardial infarction within 3 months prior to the date of randomisation unstable arrhythmias or unstable angina, known left ventricular ejection fraction (lvef) < 50%.",Chloroquine analog (GNS651)
2346,1,"note: patients with known coronary artery disease, congestive heart failure not meeting the above criteria must be on a stable medical regimen that is optimized in the opinion of the treating physician and in consultation with a cardiologist if appropriate.",Chloroquine analog (GNS651)
2347,1,"e8. patient has active hepatitis b (chronic or acute; defined as having a positive hepatitis b surface antigen [hbsag] test at screening), active hepatitis c (patients positive for hepatitis c virus (hcv) antibody are eligible only if pcr is negative for hcv rna at screening) or human immunodeficiency virus (hiv) infection (hiv 1/2 antibodies).",Chloroquine analog (GNS651)
2348,1,e9. prior allogeneic bone marrow transplantation or solid organ transplant in the past.,Chloroquine analog (GNS651)
2349,1,"e10. has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.",Chloroquine analog (GNS651)
2350,1,e11. has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.,Chloroquine analog (GNS651)
2351,1,"e12. pregnant or breastfeeding patient, or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of study drugs.",Chloroquine analog (GNS651)
2352,1,individuals who are taking cq for other indications,Chloroquine
2353,1,new use of nsaids,Chloroquine
2354,1,"high risk background medications not limited to immunosuppressive regimens, steroids, anti-b cell therapies, anti-cytokine therapies, chemotherapies, janus kinase (jak)-inhibitors",Chloroquine
2355,1,individuals with a history of retinopathy that would contraindicate the use of cq,Chloroquine
2356,1,known allergy to cq or chloroquine,Chloroquine
2357,1,known qt prolongation and torsades de point,Chloroquine
2358,1,individuals who are pregnant or nursing,Chloroquine
2359,1,1. patients with chronic use of drugs known to prolong qtc interval.,Chloroquine Diphosphate
2360,1,plasma donation:,Convalescent Plasma 1 Unit
2361,1,plasma donation:,Convalescent Plasma 2 Units
2362,1,individuals that do not meet the requirement from the american red cross for plasma donation or equivalent,Convalescent Plasma 1 Unit
2363,1,individuals that do not meet the requirement from the american red cross for plasma donation or equivalent,Convalescent Plasma 2 Units
2364,1,individuals plasma that has not passed safety screening after procurement by the american red cross for plasma donation or equivalent,Convalescent Plasma 1 Unit
2365,1,individuals plasma that has not passed safety screening after procurement by the american red cross for plasma donation or equivalent,Convalescent Plasma 2 Units
2366,1,plasma recipients,Convalescent Plasma 1 Unit
2367,1,plasma recipients,Convalescent Plasma 2 Units
2368,1,"individuals with covid19 who are not in clinical concern for rapid progression, severe or critical condition",Convalescent Plasma 1 Unit
2369,1,"individuals with covid19 who are not in clinical concern for rapid progression, severe or critical condition",Convalescent Plasma 2 Units
2370,1,individuals who are in critical condition that are not confirmed to have covid19,Convalescent Plasma 1 Unit
2371,1,individuals who are in critical condition that are not confirmed to have covid19,Convalescent Plasma 2 Units
2372,1,"individuals with known selective iga deficiency, that has not been found to be absent of anti-iga antibodies",Convalescent Plasma 1 Unit
2373,1,"individuals with known selective iga deficiency, that has not been found to be absent of anti-iga antibodies",Convalescent Plasma 2 Units
2374,1,"contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin",Hydroxychloroquine Sulfate
2375,1,"contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin",Hydroxychloroquine Sulfate
2376,1,"contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin",Chloroquine Sulfate
2377,1,"current use hydroxychloroquine, chloroquine or azithromycin",Hydroxychloroquine Sulfate
2378,1,"current use hydroxychloroquine, chloroquine or azithromycin",Hydroxychloroquine Sulfate
2379,1,"current use hydroxychloroquine, chloroquine or azithromycin",Chloroquine Sulfate
2380,1,concurrent use of another investigational agent,Hydroxychloroquine Sulfate
2381,1,concurrent use of another investigational agent,Hydroxychloroquine Sulfate
2382,1,concurrent use of another investigational agent,Chloroquine Sulfate
2383,1,invasive mechanical ventilation,Hydroxychloroquine Sulfate
2384,1,invasive mechanical ventilation,Hydroxychloroquine Sulfate
2385,1,invasive mechanical ventilation,Chloroquine Sulfate
2386,1,participants who have any severe and/or uncontrolled medical conditions such as:,Hydroxychloroquine Sulfate
2387,1,participants who have any severe and/or uncontrolled medical conditions such as:,Hydroxychloroquine Sulfate
2388,1,participants who have any severe and/or uncontrolled medical conditions such as:,Chloroquine Sulfate
2389,1,"unstable angina pectoris,",Hydroxychloroquine Sulfate
2390,1,"unstable angina pectoris,",Hydroxychloroquine Sulfate
2391,1,"unstable angina pectoris,",Chloroquine Sulfate
2392,1,"symptomatic congestive heart failure,",Hydroxychloroquine Sulfate
2393,1,"symptomatic congestive heart failure,",Hydroxychloroquine Sulfate
2394,1,"symptomatic congestive heart failure,",Chloroquine Sulfate
2395,1,"myocardial infarction,",Hydroxychloroquine Sulfate
2396,1,"myocardial infarction,",Hydroxychloroquine Sulfate
2397,1,"myocardial infarction,",Chloroquine Sulfate
2398,1,"cardiac arrhythmias or know prolonged qtc >470 males, >480 female on ecg",Hydroxychloroquine Sulfate
2399,1,"cardiac arrhythmias or know prolonged qtc >470 males, >480 female on ecg",Hydroxychloroquine Sulfate
2400,1,"cardiac arrhythmias or know prolonged qtc >470 males, >480 female on ecg",Chloroquine Sulfate
2401,1,"pulmonary insufficiency,",Hydroxychloroquine Sulfate
2402,1,"pulmonary insufficiency,",Hydroxychloroquine Sulfate
2403,1,"pulmonary insufficiency,",Chloroquine Sulfate
2404,1,"epilepsy (interaction with chloroquine),",Hydroxychloroquine Sulfate
2405,1,"epilepsy (interaction with chloroquine),",Hydroxychloroquine Sulfate
2406,1,"epilepsy (interaction with chloroquine),",Chloroquine Sulfate
2407,1,prior retinal eye disease,Hydroxychloroquine Sulfate
2408,1,prior retinal eye disease,Hydroxychloroquine Sulfate
2409,1,prior retinal eye disease,Chloroquine Sulfate
2410,1,concurrent malignancy requiring chemotherapy,Hydroxychloroquine Sulfate
2411,1,concurrent malignancy requiring chemotherapy,Hydroxychloroquine Sulfate
2412,1,concurrent malignancy requiring chemotherapy,Chloroquine Sulfate
2413,1,"known chronic kidney disease, egfr<10 or dialysis",Hydroxychloroquine Sulfate
2414,1,"known chronic kidney disease, egfr<10 or dialysis",Hydroxychloroquine Sulfate
2415,1,"known chronic kidney disease, egfr<10 or dialysis",Chloroquine Sulfate
2416,1,"g-6-pd deficiency, if unknown requires g6pd testing prior to enrollment",Hydroxychloroquine Sulfate
2417,1,"g-6-pd deficiency, if unknown requires g6pd testing prior to enrollment",Hydroxychloroquine Sulfate
2418,1,"g-6-pd deficiency, if unknown requires g6pd testing prior to enrollment",Chloroquine Sulfate
2419,1,known porphyria,Hydroxychloroquine Sulfate
2420,1,known porphyria,Hydroxychloroquine Sulfate
2421,1,known porphyria,Chloroquine Sulfate
2422,1,known myasthenia gravis,Hydroxychloroquine Sulfate
2423,1,known myasthenia gravis,Hydroxychloroquine Sulfate
2424,1,known myasthenia gravis,Chloroquine Sulfate
2425,1,currently pregnant or planning on getting pregnant while on study,Hydroxychloroquine Sulfate
2426,1,currently pregnant or planning on getting pregnant while on study,Hydroxychloroquine Sulfate
2427,1,currently pregnant or planning on getting pregnant while on study,Chloroquine Sulfate
2428,1,breast feeding,Hydroxychloroquine Sulfate
2429,1,breast feeding,Hydroxychloroquine Sulfate
2430,1,breast feeding,Chloroquine Sulfate
2431,1,ast/alt >five times the upper limit of normal uln*,Hydroxychloroquine Sulfate
2432,1,ast/alt >five times the upper limit of normal uln*,Hydroxychloroquine Sulfate
2433,1,ast/alt >five times the upper limit of normal uln*,Chloroquine Sulfate
2434,1,bilirubin >five times the uln*,Hydroxychloroquine Sulfate
2435,1,bilirubin >five times the uln*,Hydroxychloroquine Sulfate
2436,1,bilirubin >five times the uln*,Chloroquine Sulfate
2437,1,magnesium <1.4 meq/l*,Hydroxychloroquine Sulfate
2438,1,magnesium <1.4 meq/l*,Hydroxychloroquine Sulfate
2439,1,magnesium <1.4 meq/l*,Chloroquine Sulfate
2440,1,calcium <8.4mg/dl >10.6mg/dl*,Hydroxychloroquine Sulfate
2441,1,calcium <8.4mg/dl >10.6mg/dl*,Hydroxychloroquine Sulfate
2442,1,calcium <8.4mg/dl >10.6mg/dl*,Chloroquine Sulfate
2443,1,potassium <3.3 >5.5 meg/l*,Hydroxychloroquine Sulfate
2444,1,potassium <3.3 >5.5 meg/l*,Hydroxychloroquine Sulfate
2445,1,potassium <3.3 >5.5 meg/l*,Chloroquine Sulfate
